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Cancer represents a formidable health burden and was the second leading cause of 
death globally in 2018. In Norway, almost 35000 new cancer cases were reported in 
2019. For colon cancer, the incidence and mortality rates in Norway are among the 
highest in the world. Furthermore, the tumour-node-metastasis (TNM) system used 
today is not optimal for selecting which patients should receive adjuvant therapy or 
not.  
With the implementation of digital pathology in different pathology departments, 
there will be better opportunities for digital image analysis, a tool aimed at giving a 
more reproducible and objective diagnosis than subjective evaluation in a 
microscope. In digital image analysis, a computer programme is used for the 
quantification of different biomarkers. This can improve cancer diagnostics because 
several biases in manual evaluation can be reduced or avoided. One of the challenges 
in pathology is intra-and inter-observer variability of prognostic and predictive 
biomarkers. This especially applies for gastroenteropancreatic neuroendocrine 
neoplasms (GEP-NENs), in which the proliferation marker Ki67 is important for 
grading (1–3), prognosis and treatment of patients. Several studies have shown inter-
and intra-observer variations in the manual evaluation of Ki67 positivity, which can 
be improved with digital image analysis. This is important because the interpretation 
of the immunohistochemical staining of different biomarkers, such as Ki67, often 
influences patient prognosis and treatment.  
The immune system, especially the number of T-cells in and around the tumour, has 
been investigated as a promising biomarker for predicting prognosis and survival in 
colorectal cancer (CRC). The immune system is closely linked to microsatellite 
instability (MSI) in CRC, and MSI-high CRC has been shown to respond well to 
immune therapy. A TNM-immune is suggested based on scoring of the number of T-
cells in the tumour centre and the invasive margin using digital image analysis. 
In this study, we explored the correlation between T-cells in presurgical blood 
samples and T-cells in the invasive margins and the tumour centres in CRC with 
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digital image analysis in a feasibility study and found a correlation. Furthermore, we 
used digital image analysis to calculate the immune score in colon cancer patients 
based on immunohistochemical (IHC) staining of cluster of differentiation (CD)3+ 
and CD8+ T-cells in invasive margins and tumour centres in a prospective cohort. 
This immune score corresponded strongly with known clinicopathological features, 
such as stage and MSI status.  
Also, we evaluated digital image analysis as an objective assessment tool for two 
different proliferation markers in GEP-NENs: Ki67 and Phosphohistone 3 (PHH3). 
We compared manual (visual) evaluation of Ki67 from pathology reports with digital 
image analysis of Ki67 and found excellent agreement, but there is a tendency to 
upgrade cases from grade 1 to grade 2 with digital image analysis. For the digital 
image analysis of PHH3, the measurements were more diverging.  
The data presented show the use of digital image analysis in two settings: developing 
an immune score as a prognostic marker in colon cancer and providing an objective 
and reproducible evaluation of proliferation in neuroendocrine neoplasms. With the 
transition to digital pathology, digital image analysis can be implemented in daily 
diagnostics. This implementation requires more research for the validation of the 
different methods. With time, digital image analysis is expected to be utilized for 
tasks performed by pathologists today. 
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1. Introduction 
This PhD thesis comprises two subprojects. First, a subproject with quantification of 
T-cells in colorectal cancer (CRC). Papers I and II are based on this subproject. The 
second subproject is on quantifying proliferative markers in neuroendocrine 
neoplasms (NENs) of the gastrointestinal tract using digital pathology. Paper III is 
based on this subproject.  
The common denominator for this thesis is using digital image analysis to quantify 
different cell types in cancers of the gastrointestinal tract. For the first subproject, we 
quantified T-cells, and in the second subproject, we quantified proliferative tumour 
cells.  
In Norway, a national project for implementing digital pathology is currently running, 
and all pathology departments in the region of Helse Vest, Norway, are scheduled to 
be fully digitalised in 2021/22. With this transformation, the adaption of existing 
grading systems must be integrated and implemented in digital pathology. With this 
adaptation, software offering digital image analysis can be integrated with 
diagnostics, either as supplementary software or the software used for viewing slides 
for the diagnostics. The benefit of integrating digital image analysis into diagnostics 
is that measurements can be made objectively and reproducibly. However, for this 
integration to occur, research is needed to develop methods, ensure that the methods 
are validated and give prognostic information similar to the manual evaluation 
performed today.  
This thesis developed and explored two different digital image analysis methods. We 
aim to use these methods to give prognostic information to patients after the methods’ 
validation. There is a need for more objective measurements of prognostic markers in 
pathology, and this thesis can contribute to such knowledge. After validation, we aim 
to integrate the methods into the daily diagnostics at pathology departments, as digital 
pathology is introduced in different departments. 
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Since the start of modern pathology, when Rudolf Virchow started describing the 
disease in the microscope, it has been the workhorse for pathologists to investigate 
tissues, understand the disease and give details about biology and formally stage 
disease severity for prognosis. While this is a refined art and a learned process with 
criteria and consensus developed over decades of practice, the current use of the 
human eye and mind is limited by subjective interpretation, leading to inter- and 
intra-observer variabilities. Several attempts have been made to overcome these 
shortcomings in pathology over the decades, such as using standardised criteria to 
grade disease and equipment like grid filters in the microscope when counting cells. 
Due to digital technology advancements in pathology, digital image analyses have 
become a tool to overcome the obstacles of subjective interpretation. Furthermore, 
digital image analysis, if performed correctly, can produce precise and highly 
reproducible results1.  
A virtual slide is a scanned slide image that is an exact copy of a physical slide 
image. However, the scanned slide image is evaluated on a computer screen instead 
of using a light microscope. During the last two decades, virtual microscopy/whole 
slide imaging technology has developed substantially, with several companies 
offering solutions for telepathology/digital pathology imaging systems2.  
Digital pathology requires digital platforms to capture, store, share, analyse and 
report on pathological examination. This includes digitalising the whole laboratory 
process, from registering a specimen to reporting the final diagnosis3. Today, several 
pathology departments worldwide have been digitalised and have used whole slide 
imaging in routine practice4, 5.  
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Digital pathology can be divided into whole slide imaging and digital image analysis. 
Compared to manual observation utilising the human eye alone, digital pathology 
provides opportunities for a more consistent and quantitative evaluation6, 7. Using 
digital image analysis also provides opportunities for different morphometric 
measurements that are not possible with a light microscope8. 
 
1.1.2 Whole slide imaging 
 
Whole slide imaging requires dedicated equipment and an IT infrastructure. The 
technical requirements for whole slide imaging are image acquisition, storage, 
processing and visualisation9. In addition, both trained personnel and specific quality 
control steps are required to ensure that the scans are satisfactory3. Image acquisition 
is both image capture by a digital scanner and image display. For optimal scanning, it 
is important that the tissue section has optimal thickness, and that the tissue is placed 
in the slide’s centre. Artefacts of the microtomy and mounting must be avoided. The 
resolution of a virtual slide should be at least x20 magnification, but, for some types 
of slides, there is a higher diagnostic accuracy with x40 magnification10, which 
unfortunately also increases the scanning time and requires more storage space. The 
pathologist can view the virtual slide on an image-viewing software locally or 
remotely (Figure 1). Most imaging viewing software programmes offer the 
opportunity to annotate on the virtual slide. Some imaging software programmes are 




Figure 1: Whole slide imaging in a digital workflow in a pathology department. 
Created with BioRender.com. 
 
1.1.3 Digital image analysis 
 
Image analysis is a specific discipline that aims to obtain meaningful information 
from images in an objective and reproducible manner1. Analysing images with 
objective tools began as early as the 17th century when Leeuwenhoek developed a 
system to measure microscopic objects11. There has been a development in pathology, 
with a transition from qualitative information to semi-quantitative and quantitative 
evaluation of pathological features and biomarker expression, such as IHC expression 
(Figure 2)12. An example is the percent positivity of the proliferation marker Ki67 of 
tumour cells in neuroendocrine neoplasm (NEN). This development occurs 
independent of digital pathology, but digital image analysis may be a helpful tool and 
may improve quantitative measurements. One of the challenges in pathology is intra-
and inter-observer variability of prognostic and predictive biomarkers13-15, hence the 




Figure 2: Evolution in pathology. Pathology has developed from describing the 
tissue and giving a diagnosis to giving more quantifiable data with grading and then 
using biomarkers such as immunohistochemistry for grading and quantification. 
This example shows the development in diagnosing neuroendocrine neoplasms.  
 
Digital image analysis can be area based, cell based, and measurements pertaining to 
objects in the tissue aside from cells8. Digital image analysis can be used for several 
tasks in pathology, including the measurement of the staining of a protein with IHC 
or the measurement of size or area on a virtual slide. For some IHC markers, there are 
semiquantitative evaluations of staining intensity available, for example, human 
epidermal growth factor 2 in breast cancer, where a trier scoring system from zero to 
3+ in >/< 10% of the tumour cells is used diagnostically. However, difficulties are 
encountered in determining whether the tumour is 1+ or 2+ with manual evaluation16. 
The College of American Pathologists has developed guidelines for quantitative 
image analysis with digital image analysis for human epidermal growth factor 2 IHC 
in breast cancer, which may aid in scoring human epidermal growth factor 217. 
Unfortunately, there is a lack of similar guidelines for other IHC markers analysed by 
quantitative image analysis. By introducing personalised medicine and individualised 
therapies related to IHC assessments, many IHC analyses will likely require digital 
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image analysis for reliable quantitative and more objective measurements in the 
future1.  
An emerging field in digital image analysis is the development of artificial 
intelligence (AI). AI refers to the simulation of the human mind in computer systems 
programmed to think like humans and mimic their actions, such as learning and 
problem-solving18. This is a more complex form of digital image analysis than 
quantitative image analysis, in which the computer programme learns and interprets 
the data based on training. The learning process can be supervised or unsupervised. 
Supervised learning has a defined set of outputs compared to unsupervised learning, 
whose output is not predefined19, 20. AI can be divided into machine learning and deep 
learning. Machine learning is the ability to learn without being directly programmed, 
while deep learning is a subset of machine learning using artificial neural networks, 
in which statistical models are established through input data18, 21. Using deep neural 
networks, these computer algorithms can be used to detect malignant tissue in a 
histological specimen22 or give prognostic information to guide treatment (e.g. 
adjuvant therapy in CRC23). An example from gastrointestinal pathology is the 
development of multiple deep learning algorithms, where the computer could classify 
several types of colorectal polyps, including hyperplastic, sessile serrated, traditional 
serrated, tubular and tubulovillous/villous polyps with an overall accuracy of 93%24. 
Deep learning algorithms like this can help in colorectal screening programmes to 
identify high-risk polyps for further evaluation by a pathologist.  
 
1.1.4 Advantages and disadvantages of digital pathology 
 
A transition to a digital workflow likely provides several advantages, including easier 
sharing of slides for consultation with other pathologists, collaboration with 
interdisciplinary and remote research teams or during routine practice by the 
contribution of pathology in multidisciplinary clinical teams. It can also help to 
standardise teaching1. One of the major benefits of digital pathology is the 
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opportunity of remote consulting. This technology is important, especially in 
countries with a shortage of pathologists25, 26, and in other countries like Norway, 
with long distances and a lack of or limited pathology services at many small 
hospitals27. Furthermore, with the evolving subspecialisation in pathology, there is an 
increasing need for consultation among pathologists. Digital pathology may facilitate 
this28.  
 
Several technical aspects of digital pathology need to be addressed. First, the 
hardware and storage capacity are important. Each scanned slide is currently about 
0.5–4.0 GB, and huge storage capacity, both locally and in a cloud is necessary21. The 
computer must be powerful enough to process the images rapidly and 
upload/download the data to storage. So, both the intranet and the internet capacity 
are critical21, 29. Compared to a traditional glass slide, the scanned slide does not 
break, fade or get lost30. Thus, the organisation of archived digitized slides is easier 
than physical filing 1. Also, there is evidence that digital pathology will increase 
safety with barcode identification and thus improve quality and efficiency3. A study 
by Nakhleh and co-workers in 136 institutions found that the overall mislabelling of 
cases occurred in about 1.1 pr. 100031. The rates for specimens, blocks and slides 
were 1.0, 1.7 and 1.1, respectively. Only 27% of the laboratories in this study had 
barcoding, which dramatically reduced the error rate31. One large study found that 
misidentification errors were reduced by 55% when barcoding was implemented for 
the throughput of an entire laboratory32. Barcoding allows full laboratory tracking, 
which reduces misidentification errors and increases efficiency33.  
A meta-analysis showed that whole slide imaging was discordant in about 4% of the 
cases compared with light microscopy. Most of this discordance was related to 
diagnosing and grading dysplasia (32%) or to the inability to find small objects 
(10%)34. A study that assessed mitosis in breast cancer found a reduction of 20% 
when counting mitosis using whole slide imaging compared with light microscopy35. 
This illustrates the need for automated measurements using digital image analysis. 
Automated measurements of IHC staining can give more precise and reliable results, 
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reducing the under-and overtreatment of patients36. Digital quantification of 
histopathological parameters, such as steatosis or fibrosis, has also been more precise 
and reproducible than manual quantification of the same features37. With digital 
image analysis, data can be extracted in a highly reproducible fashion via specialized 
software, which is a great benefit of this technology8.  
With whole slide imaging, AI and machine learning are facilitated22, and promising 
results using AI in histopathology have been shown in several studies18, 23, 24. 
Algorithms, as delineated in Figure 3, may be helpful in routine diagnostics in the 
future.  
 
Figure 3: Processing of whole slide imaging (WSI). Potential workflow at a given 
department of pathology in the future. Reprinted under CC BY 4.0 with permission 
from38. Copyright © MDPI 2020. 
 
Digital image analysis likely yields more precise and reproducible results, which may 
partly be explained by reducing many biases that influence manual scoring, including 
visual and cognitive traps (Table 1)39. Biases are systematic errors that can affect 
scientific investigations and destroy the validity of a study40, 41. There are several 
visual traps in manual scoring, such as the illusion of size, where the perception of 
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size is influenced by the context in which it is displayed, which is the Ebbinghaus 
illusion (Figure 4)42. Other visual traps are also present in manual scoring, such as 
‘inattentional blindness’, in which one fails to observe salient features when engaged 
in a different task43, 44. For example, in a study of chest X-rays, 60% of radiologists 
failed to observe a missing left medial clavicle45. The perception of colour and hues 
also depends on their context and the individual who does the evaluation42, 46. In 
addition, there are several cognitive traps. Pathologists tend to avoid extreme ranges 
when assigning pathology scores47. Furthermore, measurements tend to be given and 
end at a value of 0 or 5, for example, in blood pressure measurements48, 49. The same 
would probably apply to the manual scoring of percentages in pathology. A 
pathologist may also be influenced by context bias when evaluating a sample50. For 
example, if a disease is prevalent, it is more likely to consider a sample as abnormal 
when viewed together with other samples showing high disease prevalence. One of 
the most important cognitive biases is the predisposition to seek informative support 
for a favourable hypothesis51. The introduction of digital pathology and digital image 
analysis will probably reduce bias, such as the ones mentioned above and enhance the 
accuracy and reproducibility of different biomarkers, such as the interpretation of 
IHC stains1.  
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Visual and cognitive traps where the effect can be diminished by digital image analysis  
Visual traps Brief description 
Illusion of size Perception of an object’s size is influenced by 
the context in which it is displayed 
Inattentional blindness The phenomenon of failing to observe salient 
features or events when engaged in a different 
task 
Perception of colour and hues Perception of colours and hues depends on their 
context 
Checker shadow illusion Perception of a surface’s brightness is 
influenced by our knowledge of how it should 
appear, even if it is covered by a shadow 
Lateral inhibition A tendency for activated neurons to influence 
neighbouring neurons in the visual pathway, 
yielding an increased ability to respond to edges 
of surfaces 
Cognitive traps  
Confirmation bias The predisposition of people to seek 
information supportive of a favoured hypothesis 
Avoidance of extreme ranges Tendency to avoid extremes of ranges when 
assigning pathology scores 
Diagnostic drift The situation in which scoring values vary 
slightly and in a consistent fashion during a 
study 
Number preference Predisposition to assign numerical scores 
ending in 0 or 5 
Context bias Predisposition to consider a sample as abnormal 
when viewed in series with other samples 
showing a high disease prevalence but not when 
the sample is interpreted as part of a group with 
lower disease prevalence 
Gambler’s fallacy Inability to consider individual samples and 
endpoints (e.g. cytoplasmic versus membrane 
staining in IHC) as events independent from 
previous and following slides or scoring events 
Table 1: Visual and cognitive traps that can be reduced with digital image analysis. 





Figure 4: Ebbinghaus illusion. Although the inner circles are the same size, the 
surrounding circles affect how we interpret the size. Reprinted with permission 




Cancer represents a formidable health burden and was the second leading cause of 
death globally in 2018. About 1/6 of deaths are due to cancer53. According to a recent 
report from the Cancer Registry of Norway, over 35 000 new cancer cases (54.1% 
men) were reported annually, and 10981 deaths from cancer were encountered54. 
 
The cancer formation process is called carcinogenesis. In this process, various 
biological events and molecular changes are involved. Several genetic changes lead 
to abnormal cell division and cause normal cells to transform into cancer cells55. For 
cancer to develop, genes that regulate cell growth and differentiation must be altered 
by genetic or epigenetic changes56. An epigenetic change is a phenotype change 
without altering the DNA sequence (e.g. DNA methylation or histone modification)57.  
 
Genetic alterations are usually somatic events and take a long time to accrue (hence, 
the debut of cancer is usually in the age groups 60–70s), but a germline mutation 
predisposes a person to cancer at a much earlier age (usually in their early 30s or 40s) 
56. Driver mutations are causal in the neoplastic process and are positively selected 
during carcinogenesis. They often occur in genes that regulate cell division, apoptosis 
and deoxyribonucleic acid (DNA) repair. Passenger mutations are biologically neutral 
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and provide no advantage to the tumour but are retained by chance during repeated 
cell division and clonal expansion58.  
 
In carcinogenesis, these genetic changes affect two broad categories of genes: proto-
oncogenes and tumour suppressor genes. Proto-oncogenes encode proteins that 
control cell proliferation and or/apoptosis56. These may be normal genes expressed at 
inappropriately high levels or altered genes with novel properties. Tumour suppressor 
genes inhibit cell division, survival or other properties of cancer cells and are often 
disabled by cancer-promoting genetic changes59. An important difference between 
oncogenes and tumour suppressor genes is that oncogenes result from 
the activation (switching on) of proto-oncogenes, whereas tumour suppressor genes 
cause cancer when they are inactivated (switched off)60. 
 
 
1.2.1 Hallmarks of cancer  
 
Our understanding of carcinogenesis involves several other aspects besides genetic 
changes. Several alterations are found in cancer, and these have been called 
Hallmarks of cancer61 in a publication by Hanahan and Weinberg in 2000. The list 
included six functional acquired capabilities: sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, activating invasion and metastasis62. A decade later, two more 




Figure 5: Hallmarks of cancer. Adapted with permission from62. Copyright © 
Elsevier Inc. 2011. 
 
The most fundamental trait of a cancer cell is its ability to sustain continuous 
proliferation. Normally, proliferation is controlled by the release of growth-
promoting signal molecules that regulate the cell cycle to ensure the homeostatic 
maintenance of normal tissue. Cancer cells deregulate these signals. In addition, there 
is resistance to cell death, which adds to the uncontrolled proliferation of cancer 
cells62. Furthermore, cancer cells develop the ability to avoid destruction by the 
immune system, which aids in their resistance to cell death63. For cancer cells to 
survive and metastasis to other organs, angiogenesis and modification of the tumour 
microenvironment are critical to access nutrients. In addition, there is a gain of 
telomerase in cancer cells, which has a life-prolonging effect64.  
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1.3 Colorectal Cancer 
 
1.3.1 Epidemiology and aetiology 
 
Worldwide, CRC represents a formidable health burden, with an estimated 72% 
increase in cases towards 204065. It is the third most common cancer type and the 
second most common cause of death from cancer worldwide (Figure 6)66, 67. Despite 
the improvements in surgical and oncological treatments over the last decade68, about 
half of all patients will develop metastasis and eventually die from disseminated 
disease69, 70. The incidence of CRC varies greatly, and about 60% of all deaths occur 
in countries with a high or very high human development index70.  
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Figure 6: Incidence (A) and mortality rates (B) of colorectal cancer in the world. 
Reprinted with permission from71. Copyright© International Agency for Research on 
Cancer IARC 2020. 
 
In Norway, almost 4500 patients were diagnosed with CRC in 2020. It is the second 
leading cause of cancer death in Norway, following lung cancer. Of CRC, about 2/3 
is colon cancer54. For decades, incidence rates for both colon and rectal cancer have 




since the 1990s, and the mortality rate is about half of what it used to be54. For colon 
cancer, the incidence and mortality rates in Norway are among the highest in the 
world54, 66.  
Incidence rates are influenced by lifestyle factors, such as diet and obesity, while 
mortality rates depend on the stage of the disease at the time of diagnosis and the 
available treatment options72. In many low-income countries, adjuvant therapy is not 
available73. Screening programmes may have contributed to the decrease in mortality 
rates seen in many countries, such as Israel, Japan, the United States74 and several 
European countries75. In Norway, a national screening programme for CRC is 
scheduled to start in 202276.  
Both hereditary and environmental risk factors play a role in development of CRC 
(Figure 7)77. Positive family history is a risk factor for CRC78, but only a subgroup of 
approximately 5–7% is affected by a well-defined hereditary CRC syndrome, such as 
Lynch syndrome or familial adenomatous polyposis79, 80. People with a positive 
family history of CRC, but where the genetic pathway is unknown, will have a 




Figure 7: Risk factors for the development of colorectal cancer. Reprinted with 




Carcinogenesis was first described for CRC in the 1990s and referred to as the 
adenoma–carcinoma sequence (Figure 8)82, 83. Although our understanding of 
carcinogenesis in CRC is more complex today77, this model illustrates the molecular 
events in the most common pathway of CRC leading to precancerous disease 
(adenoma) before developing into invasive carcinoma. The commonest genetic 
changes in this pathway include alterations seen in adenomatous polyposis coli, 
tumour protein 53 and the KRAS (Kirsten rat sarcoma) gene, which are present in 
81%, 60% and 43% of sporadic CRCs, respectively84. About 70-90% of CRC 
develop via this pathway82. The other development pathways are the serrated 





Figure 8: Adenoma-carcinoma sequence. Development of cancer through different 
genetic changes, which promote tumour development. Adapted with permission 
from83 using BioRender.com. Copyright© Cell Press 1990. 
 
 
Figure 9: The three different developmental pathways of colorectal cancer and their 
associated hereditary syndromes and molecular genetic changes. Abbreviations: 
FAP: Familial adenomatous polyposis, APC: adenomatous polyposis coli, TP53: 
tumour protein 53, KRAS: Kirsten rat sarcoma, BRAF: Proto-oncogene B-raf, MMR: 
Mismatch repair, PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
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subunit alpha, MGMT: O(6)-methylguanine-DNA methyltransferase MLH: MutL 
homolog 1, CIMP: CpG island methylator phenotype, MSH: MutS homolog, PSM: 
protein signalling modulator. Adapted with permission from77. Copyright © Elsevier 
Inc. 2019. 
 
1.3.3 Microsatellite instability in colorectal cancer 
 
A microsatellite is a stretch of repetitive DNA, where certain DNA motifs (typically 
1–6 base pairs) are repeated in the genome85. Microsatellites comprise 
mononucleotides, dinucleotides or higher-order nucleotides such as (A)n or (CA)n
86, 
and are present in about 3% of the human genome87. Microsatellites are often referred 
to as short tandem repeats or simple sequence repeats. Due to their repetitive 
structure, microsatellites are particularly prone to replication errors and have a higher 
mutation rate than other segments of DNA88. These errors are normally repaired by 
the mismatch repair (MMR) system86. MSI is a state of genetic hypermutability that 
results from an impaired MMR system. Thus, MSI is phenotypic evidence that the 
MMR system is not functioning normally. Deficient in the MMR system are either 
caused by germline mutation (Lynch syndrome), somatic mutation or epigenetic 
silencing86.   
In 1993, several papers reported the presence of MSI as a frequent molecular 
phenomenon in CRC89-91. MSI was found in Lynch syndrome patients, linked to a 
specific genetic locus (D2S123)89 subsequently identified as one of the MMR genes. 
15–20% of CRCs have MSI. About 2–3% of these have Lynch syndrome, an 
autosomal dominant genetic disorder with defect MMR genes92-95.There is a 
correlation between MSI and tumours in the proximal colon and increased patient 
survival90. MSI is reported in several other tumour types, such as endometrial, 
ovarian and gastric carcinoma96.  
MSI can be detected by polymerase chain reaction (PCR) of specific microsatellite 
repeats or IHC staining of different MMR proteins. In Bethesda in the late 1990s, a 
consensus conference established a panel of microsatellite markers to diagnose MSI 
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in CRC. Microsatellite instability is defined as ‘a change in length due to either 
insertion or deletion of repeating units, in a microsatellite within a tumour when 
compared to normal tissue’96. The guidelines suggest a panel of five microsatellite 
loci to assess instability, known as the Bethesda panel. Originally, it included five 
microsatellite loci, two mononucleotides (BAT25 and BAT26) and three 
dinucleotides (D5S346, D2S123 and D17S250)86, 96. The panel has later been debated 
and revised and now includes five monomorphic repeats, where the dinucleotides 
have been replaced by the mononucleotides NR-21, NR24 and NR27. The Bethesda 
guidelines also describe three different classes of CRC based on MSI status. These 
classes were MSI-high, showing MSI at ≥ 2/5 loci, MSI-low, with instability at 1/5 
loci, and MSS CRCs, where no instable marker was detected out of the suggested 
five96.  
IHC staining for MMR proteins was first successfully performed in 199697. Today, 
the recommended panel includes MLH1, MSH2, MSH6 and PMS298. Normally, 
cancer cells will show nuclear staining for MMR-proteins. Loss of one or more of 
these proteins/negative staining is pathologic and suggests mismatch repair defects, 
either sporadic or inherited (Lynch syndrome)98. In cases of difficult interpretation of 
the IHC stain, a more sensitive method of PCR is recommended99. In general, IHC 
and PCR-based analysis for MSI/MMR show good concordance100, but weak or 
heterogeneous staining of MMR proteins might be difficult to interpret101. 
Testing for MSI and/or examining MMR proteins with IHC is recommended in 
patients with CRC, who at the time of diagnosis are less than 60 years of age, have 
high-risk stadium II or following the Norwegian national guidelines, are eligible for 
adjuvant therapy102. If a patient is MSI-high and/or has lost MMR proteins, further 
PCR analysis to check for proto-oncogene B-raf (BRAF) mutation and/or MLH1 
promoter hyper-methylation is recommended. If these are absent, genetic counselling 





An alternative form of MSI is found in tetranucleotide-based microsatellites and is 
labelled Elevated Microsatellite Alterations at Selected Tetranucleotides or 
EMAST104, 105. While MSI with repetitive mono-and dinucleotides has been 
extensively investigated, less is known about EMAST. Currently, the prognostic 
value, molecular mechanisms and clinical implications of EMAST are unclear. Thus, 
there are no consensus guidelines regarding EMAST. In CRC, EMAST is more often 
found in elderly and female patients and tumours of the proximal colon. It is 
associated with longer recurrence-free survival106.  
 
1.3.4 Diagnosis and treatment  
 
CRC patients present with a wide range of symptoms. The most common symptoms 
are changes in bowel habits, occult or overt rectal bleeding, anaemia and abdominal 
pain. However, many patients are asymptomatic77. In diagnosing CRC, colonoscopy 
is the reference standard107. This examination allows for biopsy or even the removal 
of small lesions. In addition, computer tomography (CT) colonography is done, and 
in cases of rectum cancer, magnetic resonance imaging. CT scans of the liver and 
thorax are also performed following Norwegian national guidelines102. For advanced 
diseases, positron emission tomography (PET) may be performed. Measuring the 
tumour marker carcinoembryonic antigen in blood at the time of diagnosis is 
recommended108. A high level of carcinoembryonic antigen is associated with a 
worse prognosis, and can be useful in monitoring the disease after surgery109.  
Surgical resection is the recommended treatment for patients with non-metastatic 
CRC. Tumour location, depth of invasion and vascular structure in the area determine 
the extent of the resection. For rectal cancer, total mesorectal excision is performed, 
either with or without preoperative radiotherapy. In patients with metastatic disease in 
the liver or lung, curative resection of metastases might be possible. Other options 
include microwave ablation or stereotactic radiotherapy of the metastases. More 
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options are becoming available, notably personalised treatment like immunotherapy 
in patients with MSI-high tumours or epidermal growth factor receptor inhibitors102. 
For patients with non-curative disease, palliative surgery might be an option. 
Depending on the disease stage, patients might be offered radiotherapy or systemic 
chemotherapy following primary surgery or as a primary treatment in a palliative 
setting77, 102. 
 
1.3.5 Histopathology and staging 
 
Pathology staging is done using the tumour-node-metastasis (TNM) system (Figure 
10)110, American Joint Committee on Cancer (AJCC) 8th edition. The TNM system 
compiles information of importance to the patient’s prognosis. A standardised gross 
pathology and microscopic histopathology template is used for reporting relevant 
findings and stages. The pathologist’s evaluation of the resected specimen provides 
information necessary in deciding which patients are eligible for adjuvant treatment, 
as this depends on whether there is metastasis to the lymph nodes or distant 
metastasis110. We used the AJCC 7th edition for Paper I, and for Paper II, we used 
the AJCC 8th edition (Figure 11). Minor changes were made in the TNM 
classification from the 7th to the 8th edition, with an expansion of the M category, as 
M1c was added for peritoneal metastasis111. Peritoneal metastasis was previously 
encompassed in M1b. The AJCC 8th edition offers a personalised approach to 
diagnosing and treating CRC, including the use of molecular markers for somatic and 
germline mutations leading to mismatch repair deficiency or microsatellite instability 
and RAS/RAF pathway mutations, such as KRAS, NRAS and BRAF110, 111. 
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Figure 10: Tumour-node-metastasis (TNM) classification of colorectal cancer. Used 
with permission of the American College of Surgeons, Chicago, Illinois. The source 
of this information is the American Joint Committee on Cancer (AJCC) Cancer 
Staging System (2020)110. Created with BioRender.com. 
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Figure 11: American Joint Committee on Cancer (AJCC) Colorectal Cancer 
Staging, 8th edition110. Used with permission of the American College of Surgeons, 
Chicago and Illinois. The source of this information is the AJCC Cancer Staging 
System (2020). Created with BioRender.com. 
 
According to the latest WHO classification112, several histopathological parameters 
are recommended in the pathology report. These are tumour size and location, 
histological subtype, tumour grade, depth of invasion, presence of lymphatic and/or 
vascular infiltration, perineural growth, lymph node status, tumour budding113, 114, 
resection margins, presence of treatment response if neoadjuvant therapy, MSI-status, 
immune response and presence or absence of relevant mutations112. Figure 12 shows 




Figure 12: A: Cross sections through a colon cancer specimen. B: Haematoxylin 
and eosin staining x11.5 of the same tumour as A, showing an invasive 
adenocarcinoma. In both images, you can see tumour infiltration through the 
muscularis propria and into pericolic tissue. This is classified as a T3 tumour, 
according to the Tumour-Node-Metastasis system. 
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Challenges of the TNM system  
 
The TNM system110 is the most widely used staging system for CRC. It is easy to use 
and allows for a fairly accurate estimation of prognosis115, 116. However, the TNM 
system is imperfect in defining appropriate subgroups of patients and guiding 
treatment beyond surgical resection117. The TNM-system does not permit 
discrimination between ‘good’ and ‘bad’ cancers within the same stage. In fact, up to 
20% of stage II patients may still die of recurrent disease118. For stage III patients, 
about half of the patients are cured by surgery alone, and about 20% benefit from 
adjuvant therapy119. The TNM system largely leaves the decision of adjuvant 
treatment up to lymph node status. Consequently, due to the current guidelines for 
adjuvant chemotherapy, there is a risk of under-and overtreatment of patients120, 121.  
Concerns have been raised regarding updates in the newest editions of the TNM-
system. Critiques claim that existing system elements are not evidence-based and 
question making changes without a basis in systematic empirical investigation122, 123. 
Specifically, they question keeping the subdivision of T4 into T4a (invasion of 
visceral peritoneum) and T4b (invasion of adherent structures and/or organs), as 
studies have not confirmed a difference in outcome between these two124. 
The definition of tumour deposits has been altered several times, as new editions of 
the TNM classification have been published. The reason for this is criticism regarding 
the use of unpublished data and difficulties in understanding the definition125. Thus, 
pathologists use different versions of the TNM-classification126. This reduces validity 
and hampers comparison of results across regions, as patients may be down-/up-
staged according to the variation in definitions. The challenges of the TNM system 
illustrate the need for other prognostic markers to better determine optimal treatment 
of CRC in the future.  
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1.3.6 Prognosis and prediction 
 
Based on figures from the Cancer Registry of Norway, the five-year relative survival 
rate for colon cancer is 69.4% for men and 71.3% for women, and the corresponding 
figures for rectum cancer are 71.4% and 72.4%, respectively54. Thus, during the last 
five years, CRC survival rates have increased slightly for both men and women54. In 
Europe, decreasing mortality rates for CRC has been ascribed to reduced prevalence 
of risk factors and/or improved treatment127. In addition, CRC screening has had an 
effect in some countries74, 128 but has not yet been generally established in Norway.  
In addition to the TNM system and histopathological parameters, there are several 
other predictive biomarkers in CRC, including the ras-genes and BRAF. Mutations in 
the ras-genes (HRAS, NRAS and KRAS) are found in about 30% of human 
cancers129. For primary colon cancer, KRAS is found in about 32%, NRAS in about 
3% and BRAF in about 14% of the cases129. About half of the patients with metastatic 
CRC have mutations in KRAS and NRAS. This excludes them from receiving 
epidermal growth factor receptor directed therapy130. BRAF mutation is found in 
about 7–8% of patients with metastatic CRC130, 131. Mutations in either KRAS or 
BRAF are associated with reduced progression-free survival and overall survival132. 
For NRAS, the data is sparser, but a meta-analysis indicates that NRAS is associated 
with poor overall survival, especially in western countries133. There have been clinical 
trials with BRAF inhibitors, either alone or in combination with other therapies, but 
the results have been quite disappointing134. 
MSI status is another predictive biomarker. About 3–5% of patients with metastatic 
CRC have MSI-high tumour or deficient MMR proteins135. Although MSI-high is a 
marker of less aggressive disease in a primary CRC136, 137, the opposite is the case in 
metastatic CRC, where MSI-high is associated with a worse overall survival138. MSI 
reduces the effect of fluorouracil-based chemotherapy139, 140. In sporadic cases of 
MSI, approximately 40–60% have a BRAF mutation. Lynch syndrome is associated 
with wild type BRAF141. Both MSI and BRAF mutations in metastatic CRC are 
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independent markers of poor prognosis regarding progression-free survival and 
overall survival142. 
The effect of immune check point inhibitors (ICI) in CRC is being investigated in 
several clinical trials, as studies have shown an effect on Programmed cell death 
1/Programmed cell death ligand-1 and cytotoxic T-lymphocyte-associated protein-4 
inhibition in MSI-high CRC135, 143, 144. In Norway, MSI-high CRC can receive ICI as 
part of ongoing clinical trials102. 
 
1.4 Neuroendocrine Neoplasms 
 
1.4.1 Epidemiology and aetiology 
 
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) belong to a 
heterogeneous family of rare epithelial neoplasms originating from the pancreas or 
the gastrointestinal tract. GEP-NENs include both neuroendocrine tumours (NET) 
and neuroendocrine carcinoma (NEC), with detrimental prognoses for most NEC 
patients145. GEP-NENs are characterized by heterogeneous clinical patterns, a 
relatively indolent growth rate and the ability to secrete peptide hormones and 
biogenic amines146-148. GEP-NENs are divided into functional tumours (which secrete 
hormones or peptides, causing clinical symptoms or syndromes) and nonfunctional 
tumours.  
Many patients with well-differentiated NENs, even those with advanced disease at 
the time of diagnosis, can survive for several years149-151. Although rather rare, due to 
the low mortality rates, GEP-NENs are the most prevalent gastrointestinal 
malignancy, second to CRC146. According to the international literature, the incidence 
of GEP-NENs is 2.39 per 100,000 inhabitants/year worldwide, and the prevalence is 
35 per 100,000/year worldwide152. In Norway, the incidence is 5.83 per 100,000 
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inhabitants/year153, which complies with recent reports from different regions, 
suggesting that the incidence is higher and increasing149, 154. Increased awareness by 
clinicians and improved diagnostics, such as IHC and radiological imaging, may in 
part explain this increase155. Five-year survival rates vary between 40–100% 
according to the tumour site and stage of disease156, 157. Gastrointestinal NENs are 
more common in women with a median age of 57 years158. About 13% of 
gastrointestinal NENs have metastasis at the time of diagnosis159. The most common 
site for metastasis is the liver, followed by lung, bone and brain158. 
Most NEN is sporadic160. However, some reports of NEN in the lower 
gastrointestinal tract are associated with hereditary colorectal syndromes, such as 
familial adenomatous polyposis and Lynch syndrome161. Furthermore, NET can be 
seen in the pancreas or gastrointestinal tract as a part of hereditary syndromes, such 
as multiple endocrine neoplasia type 1, von Hippel-Lindau syndrome, 
neurofibromatosis type 1 and tuberous sclerosis complex162. These hereditary 
syndromes usually involve the pancreas, but also the occurrence of NETs outside the 




Neuroendocrine tumours as an entity were described in 1907 by Siegfried 
Oberndorfer (1876–1944). He described them as small tumours of the intestine and 
called them Karzinoide Tumoren, which means ‘cancer-like’. This term was used 
because of its indolent clinical behaviour163. For many years, ‘carcinoid tumours’ has 
been the terminology for these tumours, but this is now outdated and not 
recommended112.  
NENs in the gastrointestinal tract originate from enterochromaffin cells and 
enterochromaffin-like cells164. Pancreatic NENs are thought to develop in the islets of 
Langerhans148, but alternative origins have also been suggested165. NETs are 
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characterised by the high-density expression of somatostatin receptors, which 
modulate proliferation and protein synthesis in addition to hormone secretion. NEC, 
in contrast, have fever somatostatin receptors148.  
The pathogenesis of NENs is not fully understood. The heterogeneity of these 
tumours, from indolent to highly aggressive, suggests that it is multifactorial. In the 
molecular pathogenesis of NET, aberrant activation of signalling by the mammalian 
target of rapamycin (mTOR) is a hallmark, regardless of the primary site148 (Figure 
13). mTOR modulates cell survival, proliferation, angiogenesis and metabolism. 
Mutations in the mTOR pathway are observed in approximately 15% of pancreatic 
NET166, 167. In hereditary syndromes, such as tuberous sclerosis, which is associated 
with pancreatic NET, there are losses of function mutations in two tumour suppressor 
genes (TSC1 and TSC2) that inhibit mTOR168. Phosphatase and tensin homolog 
(PTEN), which regulate mTOR activity through the Akt pathway, and TSC2 are 
downregulated in approximately 75% of pancreatic NETs, and their low expression is 
associated with shorter disease-free and overall survival169. Studies of molecular 
pathways in NENs have shown high expression of proangiogenic molecules, such as 
angiogenic cytokine vascular endothelial growth factor170. Several vascular 
endothelial growth factor inhibitors have shown clinical effects on some NENs, 
particularly in pancreas171, 172. 
 44
 
Figure 13: Schematic representation of the mammalian target of rapamycin (mTOR) 
pathway and associated regulatory circuitries. mTOR exists as two different 
complexes (mTORC1 and mTORC2) that are activated through different signalling 
cascades. Here is depicted the activation of mTORC1 by receptor tyrosine kinases–
triggered signalling. Positive and feedback regulatory loops are also described. 
Abbreviations – PIP2: phosphatidylinositol (4,5)-bisphosphate, ERK: extracellular 
signal-regulated kinase. IGFR: insulin-like growth factor receptor, MEK: MAP–ERK 
kinase, PDGFR: platelet-derived growth factor receptor, PI3K: phosphoinositide 3-
kinase, PIP2: phosphatidylinositol (4,5)-bisphosphate, PIP3: phosphatidylinositol 
(3,4,5)-triphosphate. Republished with permission from168. Copyright© American 
Association for Cancer Research 2013.  
 
 
1.4.3 Diagnosis and treatment 
 
The clinical symptoms depend on the tumour localisation and stage of the disease. In 
some locations (i.e. appendix, rectum and stomach), a NEN is often an incidental 
finding. Patients with GEP-NENs may have general cancer-associated symptoms, 
including loss of appetite, unexpected or unintended weight loss and fatigue. In 
addition, there might be localised symptoms, such as pain or obstruction, depending 
on where in the body the tumour is located. Functional tumours usually lead to 
diarrhoea and facial flushing. The patient might also experience hyper-or 
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hypoglycaemia, gastric ulcers, skin rashes, wheezing, tachycardia or high blood 
pressure, determined by which hormone is produced. The combination of symptoms 
related to the release of serotonin is called carcinoid syndrome173. About ¼ of patients 
with GEP-NENs have hormone hypersecretion symptoms174. NEN in the distal colon 
and rectum or NEC is rarely associated with hormonal syndrome/carcinoid 
syndrome175. 
For diagnosing GEP-NENs, a biopsy of the tumour is recommended. In addition, 
biochemical markers such as serum-chromogranin A (CgA), are measured in blood. 
Serum-CgA is a predictor of outcome176 and correlates with tumour progression or 
regression177. Measuring other markers in blood such as gastrin, insulin, somatostatin 
and other endocrine markers is recommended, depending on tumour location175. 
Several imaging techniques are also used. Multidetector CT and/or magnetic 
resonance imaging with intravenous contrast are usually performed175. PET is 
increasingly used to gain information about functionality in tumours. Several tracers 
can be used for PET evaluations of NEN patients, including F-deoxyglucose (i.e. 
measures glucose metabolism in the tumours) of poorly differentiated NENs and 
Gallium-DOTATOC (i.e. detects one of the somatostatin receptors) in well-
differentiated NENs. Somatostatin receptor imaging is used for tumour staging, 
monitoring tumour recurrence and evaluating eligibility for peptide receptor 
radionuclide therapy178. 
Surgery is the recommended treatment for NEN and should always be considered175. 
While curative surgery is not always possible, even in advanced disease, debulking 
surgery is considered beneficial to ease symptoms from local large tumour masses 
and reduce tumour volumes to alleviate therapy-resistant and debilitating endocrine 
effects179. However, even when surgery with curative intent is employed, several 
patients will eventually present with recurrent disease.  
A better understanding of the biology of this disease and the development of novel 
diagnostic approaches and treatment options have increased the complexity of the 
clinical management of NENs148, 180. Other therapies include chemotherapy in 
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advanced pancreatic NET, GEP-NET grade 3 and NEC175. Somatostatin analogues 
are used as symptomatic and anti-proliferative treatment181. Patients with functional 
tumours might benefit from tryptophan hydroxylase inhibitors. Peptide receptor 
radionuclide therapy is used in inoperable or metastatic NEN with high tumour 
uptake on somatostatin receptor imaging. Several other molecular-targeted therapies 
are being introduced. Examples include an inhibitor of the mTOR pathway 
(Everolimus) and a tyrosine kinase inhibitor (Sunitinib) in pancreatic NEN175. 
 
1.4.4 Histopathology and staging 
 
On histopathological examination, NET is a well-defined cellular tumour with 
uniform round to ovoid cells. The cytoplasm is amphophilic or eosinophilic. Nuclei 
are enlarged, often with a stippled salt-and pepper-type pattern of the chromatin 
(Figure 14A). Tumour cells may have a nested, solid, trabecular or pseudoglandular 
growth pattern182. NECs, however, are poorly differentiated tumours and often show 
bleeding or necrosis and destruction of surrounding normal tissue (Figure 15)182. 
The diagnosis is based on morphological features and a positive IHC staining for 
synaptophysin and/or CgA (Figure 14BC). Synaptophysin is a glycoprotein that 
occurs in the presynaptic vesicles of neurons and the small vesicles of normal and 
neoplastic neuroendocrine cells. CgA is one of several soluble proteins located in the 
matrix of the secretory granules of many neuroendocrine cells183. The proliferation 
marker Ki67 is performed for grading112. Different IHC markers might be used to 
indicate primary tumour sites, such as CDX2, for the gastrointestinal tract. IHC can 
also be used to detect endocrine production, such as gastrin or insulin, in functional 
tumours (Figure 14D). 
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Figure 14: A) Haematoxylin and eosin (HE) staining of primary neuroendocrine 
tumour in pancreas x400. Arrow marks the nest of tumour cells. B) Positive 
immunohistochemical (IHC) staining of synaptophysin in tumour x400. C) Positive 
IHC staining of chromogranin A in tumour x400. D) Positive IHC staining of gastrin 
in tumour x400.  
 
The nomenclature and classification of NENs have changed over the last decades. 
There is no uniform classification of morphology or grading that covers all 
anatomical sites. For example, the nomenclature of GEP-NENs and NEN in the lung 
are different184. NEN was grouped into three categories in the 2000 WHO 
classification: well-differentiated endocrine tumours, well-differentiated endocrine 
carcinomas and poorly-differentiated carcinomas185. In 2006, the European 
Neuroendocrine Tumour Society (ENETS) proposed a new classification of GEP-
NENs based on mitotic count and Ki67 index186. This was adapted and modified in 
the WHO grading system (2019) for GEP-NET, which is in use today112.  
Grading is based on mitotic activity, estimated either by counting mitosis on HE-
stained slides or by calculating the percentage of Ki67-positive cells in a hot spot 
(Table 2)112, 187. In the case of discordance between the two, the highest grade should 
be applied112. It has, however, been shown that the Ki67 index more accurately 
predicts prognosis than mitotic count188. 
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 Grade Mitotic count, per 2 mm2* Ki-67%* 
NET Grade 1 Low 1 < 3 
NET Grade 2 Intermediate 2–20 3–20 
NET Grade 3 High > 20 > 20 
LCNEC High† > 20 > 20 
SCNEC High† > 20 > 20 
MiNEN Variable Variable Variable 
LCNEC: Large‐cell neuroendocrine carcinoma, MiNEN: Mixed neuroendocrine–non‐
neuroendocrine neoplasm, NEC: Neuroendocrine carcinoma, NET: Neuroendocrine tumour, 
and SCNEC: Small‐cell neuroendocrine carcinoma 
* Mitotic rates are expressed as the number of mitoses/2 mm2 as determined by counting in 
50 fields of 0.2 mm2 (i.e. in a total area of 10 mm2); the Ki67 proliferation index value is 
determined by counting at least 500 cells in the regions of highest labelling (hot spots), 
which are identified at scanning magnification. 
† Poorly differentiated NECs are not formally graded but are considered high‐grade by 
definition. 
 
Table 2: Grading of gastroenteropancreatic neuroendocrine neoplasms according 
to World Health Organization (2019)112. 
Figure 15: Neuroendocrine tumour grade 1 (A) and large cell neuroendocrine 
carcinoma grade 3 (B) and immunohistochemical staining of the proliferation 
marker Ki67 in the same tumours (C and D).  
 
NET grade 3 and NEC can be difficult to discriminate from one another, and 
additional analyses may be helpful189. Genetic alterations in tumour protein 53 and/or 
Retinoblastoma protein 1 are frequently seen in poorly differentiated NENs and can 
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be demonstrated by IHC190. Analysis of mutations in BRAF might be an option in 
selected cases when BRAF/MEK inhibitor treatment is considered175.  
Staging is done according to the AJCC 8th edition110. The staging of NET (grades 1 
to 3) depends on the primary organ. NEC and MiNEN are staged as primary 
carcinomas in their respective primary organs110, 112. 
 
Challenges with grading 
 
Grading poses several challenges for the pathologist. Mitotic count is time 
consuming, and it is often difficult to identify mitosis in tumour cells191, 192. In 
addition, it requires 10 mm2 of tumour tissue, which makes it less convenient for 
biopsies74, 112. For Ki67, controversies exist regarding what to count and how to do 
the count193. Several methods have been proposed. A study by Tang and co-workers 
recommended either doing a manual count of 2000 cells or using digital image 
analysis15. Another study recommended counting at a camera captured or printed 
picture14. For Ki67, counting > 500 – 2000 cells is time-consuming, which may lead 
to an eyeball estimate as a shortcut in a busy routine practice15. In addition, the 
identification of a ‘hot spot’ in a section is sometimes difficult13. These difficulties 
may partly explain the reported poor intra-and inter-observer reliability of grading15. 
Furthermore, since the WHO defined NET grade 3 as a distinct entity, the challenge 
of differentiating between NET grade 3 and NEC has presented itself. There is no 
cut-off proliferation value to separate these two entities, as Ki-67 values are 
overlapping. Also, follow-up data on both are sparse194 (Figure 16).  
Tumour heterogeneity and the fact that different locations have different prognoses is 
another challenging issue110, as this makes it difficult to compare grading between 
different organs and to ensure correct treatment for these patients.  
Differences in procedures for fixation and processing of the tissue and IHC of Ki67 
may lead to differences in grading between laboratories195. While automated IHC 
 50
staining is recommended, this option is not available at all laboratories. 
Standardisation of protocols, such as external quality control, may help improve 
staining quality and reproducibility192, 196.  
 
Figure 16: Neuroendocrine neoplasms’ separation according to grade, Ki-67 and 
morphology. The red circle shows the overlap in the Ki-67 index between 
neuroendocrine tumour (NET) grade 3 and neuroendocrine carcinoma (NEC).   
Republished with permission from194. Copyright© Elsevier Science & Technology 
Journals 2018. 
 
1.4.5 Prognosis and predication 
 
There is no national cancer statistics registry specifically for GEP-NENs in Norway. 
Existing statistics are often deficient because only malignant tumours are registered, 
and NEN outside the gastrointestinal tract are registered together with GEP-NENs. A 
Norwegian study, based on data from the period 1993 to 2015 in the Cancer Registry 
of Norway, found that the 5-year relative survival rate in patients with 
low/intermediate aggressive NENs was 64.8% (95% CI, 63.3–66.2). In patients with 
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highly aggressive NENs, the rate was 8.4% (95% CI, 7.8–9.1). In the same study, 
multivariable analysis showed that gender, age and stage at the time of diagnosis and 
primary site were all predictors of outcome, independent of grade. In addition, 
survival improved significantly during the period145. However, the study included all 
organs in the body. The primary location in the lung was the most common tumour 
site. This might hamper the interpretation of the results.  
A recent study based on data from the Southwestern region of Norway showed a 
median overall survival of 183 months for GEP-NENs, with 5-and 10-year survival 
rates of 66% and 57%, respectively. The significant determinants of overall survival 
were age, WHO tumour grade and surgery as primary treatment197. The same study 
found that the occurrence of different WHO grades varied between different organs. 
For example, grade 3 tumours were more commonly found in the stomach, pancreas, 
colon and rectum. Other population-based studies have demonstrated that sex, tumour 
differentiation, stage and primary site were independent predictors of overall 
survival149, 150, but these studies also included tumour locations outside of the 
gastrointestinal-pancreatic area. 
Since prognosis depends on grade and location, survival data vary significantly 
between organs. The five-year survival of GEP-NET is directly related to the 
restriction of the disease (i.e. primary tumour) and the occurrence of (distant) 
metastases: 96% (localised), 77% (nodal), 73% (liver) and 50% (extrahepatic 
metastases)198. For the appendix, most tumours are grade 1 and < 1 cm in size. In this 
group, the 5-year survival rate is close to 100%, while for patients with metastatic 
NEC, it is less than 10%175. 
The prognostic relevance of tumour grading was first proposed in Europe199 and 
eventually embraced by clinicians worldwide200-202. Tumour grade may also serve as 
a predictive factor in selecting GEP-NEN patients for chemotherapy202, particularly in 
cases with a well-differentiated morphology despite a high Ki67 index (>55%)203. 
NET does not progress to NEC182, but NET can have a NEC component190.  
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As mentioned, serum CgA is an important prognostic marker and marker of tumour 
progression. It may also be a predictive indicator of progression-free survival and 
overall survival204. However, serum CgA is only elevated in about 50–70% of NEN 
patients, and there are few prospective studies on serum CgA in NEN patients205.  
The role of other emerging biomarkers is not determined, including the tumour 
mutational burden or programmed cell death ligand 1 expression in exploring the 
possibilities for immunotherapy206, 207 or treatment options targeting different somatic 
and germline mutations, especially in the mTOR pathway166. Biomarker panels in 
liquid biopsies, such as NETestTM, are another interesting emerging possibility208. 
 
1.5 Cancer and the immune system 
 
In 1863, Rudolf Virchow deducted leucocytes in neoplastic tissues and connected 
inflammation and cancer. Virchow suggested that the ‘lymphoreticular infiltrate’ 
reflected the origin of cancer at sites of chronic inflammation209.We now know that 
cancer-related inflammation plays a key role as a contributor to cancer progression, 
both in the tumour microenvironment and the induction of genetic instability and has 
been described as the seventh hallmark of cancer210. Inflammation is now included in 
the ‘Next generation of Hallmarks of cancer’62. 
 
Globally, about 1/4 of cancers are related to infection and chronic inflammation211. 
Out of these, it is estimated that 1/8 are directly caused by infection and the resulting 
inflammation212. Examples are Helicobacter pylori as a cause of gastric cancer and 
the human papillomavirus in developing cervical cancer209. The rest are due to other 
causes of chronic inflammation, such as chemical, physical or autoimmune disease213, 
214.  
 
The immune system comprises two parts: the innate and the adaptive or acquired 
immune system. The innate immune system is ‘what we are born with’ and is at the 
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front line of defence. Evolutionary, this is an older defence mechanism than the 
adaptive immune system, which is more specialised. However, both systems 
contribute to the destruction of pathogens using both humoral immunity components 
and cell-mediated immunity (Figure 17). 
 
The innate immune system uses toll-like receptors to recognise pathogens. Most of 
the cells in the innate immune system are derived from multipotent stem cells in the 
bone marrow and perform phagocytosis. These cells express ‘self-proteins’ on their 
surface, along with major histocompatibility complex (MHC) class I, thus helping 
other components of the immune system discriminate ‘self’ from ‘not-self’. The 
innate immune system also has antigen-presenting cells with MHC class I or II, 
presenting protein antigens to adaptive immune cells. In addition, some antigen-
presenting cells, such as dendritic and B-cells, contain MHC classes I and II on their 
cell surface63.  
 
The adaptive immune system relies on the recognition of antigens and the activation 
of T-cells or B-cell production of antibodies215. T-cells enable the immune system to 
recognize foreign antigens through an interaction between their T-cell receptors and 
peptide epitopes presented by MHC class I molecules on cancer cells. This activation 
requires the co-stimulation of a CD28216. B-cells modulate immune response and 
inflammation through antibody production and promote T-cell activation and 
proliferation through antigen presentation217. B-cells also produce different pro-
inflammatory cytokines and promote co-stimulation and the activation of other types 
of immune cells218.  
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Figure 17. Innate and Adaptive Immune Systems. The innate immune system 
provides a nonspecific response against invading pathogens. This response is 
mediated by various immune cells (granulocytes, monocytes, macrophages, 
dendritic cells, neutrophils, basophils and natural killer cells, and active molecules 
as proteins of the complement cascade) through the recognition of pathogens. The 
innate immune response shapes adaptive immunity, resulting in the production of 
antigen-specific T and B lymphocytes. Abbreviations – APCs: antigen-presenting 
cells, CD: cluster of differentiation, CLRs: C-type lectin receptors, CTL: cytotoxic 
lymphocytes, ICOS: inducible T-cell costimulatory, MHC: major histocompatibility 
complex, NKT: natural killer T-cells, NLRs: nucleotide-binding, oligomerization 
domain (NOD)-like receptors, TCR: T-cell receptor, TLRs: Toll-like 
receptors. Adapted with permission from219. Copyright© Cell Press 2017. 
 
The immune system protects the organism from harmful endogenous and exogenous 
events. For instance, inflammation is a normal response to infection and is also part 
of the wound-healing process after an injury. The inflammatory process releases 
different chemical mediators, such as cytokines, to recruit immune cells and growth 
factors, stimulating tissue growth and neovascularisation. This is something cancer 
cells take advantage of220. The inflammatory cells are part of the tumour 
microenvironment, which surrounds the tumour cells. The tumour microenvironment 
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harbours different components, such as extracellular matrix, blood and lymphatic 
vessels and several cell types, including fibroblasts and immune cells, such as 
neutrophils, lymphocytes, natural killer cells, tumour-associated macrophages and 
dendritic (antigen-presenting) cells221. Thus, there is a complex interaction between 
immune cells and cancer cells in the tumour microenvironment, and tumour 
microenvironment-associated cells play an important part in tumour development and 




Figure 18: Cells in the tumour microenvironment. Reprinted with permission from 62 
Copyright © 2011 Elsevier Inc. 
 
The immune system can work as both an agonist and an antagonist in cancer 
development and progression (Figure 19). First, the immune system recognises 
tumour antigens on the surface of cancer cells or from antigen-presenting cells. This 
initiates an immune response. Tumour-promoting inflammatory cells include 
macrophages (several subtypes), mast cells, neutrophils and T- and B-cells. These 
cell types produce several signal molecules that mediate their tumour-promoting 
effects, such as tumour growth factor, angiogenic growth factor, chemokines and 
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cytokines. Tumour-promoting inflammatory cells also produce proangiogenic and/or 
proinvasive matrix-degrading enzymes, which may help the cancer cells to 
proliferate, invade normal tissue and metastasise62. On the antagonist side, the innate 
immune system induces antibody-induced complement-mediated lysis222. The 
adaptive immune system induces an anti-tumour response, activating both cytotoxic 
T-cells that can kill the cancer cells and B-cells, producing antibodies directed against 
the cancer cells. Tumour-associated macrophages can have antagonistic and agonistic 
effects. They can kill tumour cells but may also produce growth factors and protease 





Figure 19: A model of innate and adaptive immune cell functions during 
inflammation-associated cancer development. Antigens that are present in early 
neoplastic tissues are transported to lymphoid organs by dendritic cells (DCs) that 
activate adaptive immune responses, resulting in both tumour-promoting and anti-
tumour effects. The pathways that regulate DC trafficking during early cancer 
development and the exact nature of the antigen(s) remain to be established. 
Activation of B cells and humoral immune responses results in chronic activation of 
innate immune cells in neoplastic tissues. Activated innate immune cells, such as 
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mast cells, granulocytes and macrophages, promote tumour development by the 
release of potent pro-survival soluble molecules that modulate gene-expression 
programmes in initiated neoplastic cells, culminating in altered cell-cycle 
progression and increased survival. Inflammatory cells positively influence tissue 
remodelling and the development of the angiogenic vasculature by producing 
proangiogenic mediators and extracellular proteases. Tissues in which these 
pathways are chronically engaged exhibit an increased risk of tumour development. 
In contrast, activation of adaptive immunity also elicits anti-tumour responses 
through T-cell-mediated toxicity (by induction of FAS, perforin and/or cytokine 
pathways) in addition to antibody-dependent cell-mediated cytotoxicity and 
antibody-induced complement-mediated lysis. Adapted with permission from222. 
Copyright© Springer Nature 2006. 
 
1.5.1 The immune system in colorectal cancer 
 
Over the last few decades, great efforts have been made to investigate how immune 
response affects progression and prognosis in CRC. Pronounced lymphocytic or 
inflammatory cell infiltrate in and around the tumour is associated with an improved 
prognosis in primary resectable CRC223, 224 and reduces disease progression and 
metastatic potential225. Especially, the T-cell response plays a significant role in this 
respect226, 227. For example, Galon and co-workers showed that CRC patients with a 
high number of CD3+ cells (T-cells) and CD45RO+ (Memory T-cells) in tumours 
had a better prognosis compared to patients with a low number, independent of TNM 
stage226. In contrast, chronic inflammation and the presence of anti-inflammatory 
macrophages favour tumour growth and the spreading of cancer228. Another study 
found that low densities of CD68+ (macrophage linage) and CD57+ (T-cells/natural 
killer cells) were independent prognostic markers, regardless of stage (stage II–III), in 
patients with CRC229.  
 
MSI-high cancers have a better prognosis. However, they also have a distinct 
histopathological growth pattern and prominent inflammation, with tumour-
infiltrating lymphocytes (Figure 20)230. The mechanism for this is believed to be 
mutations in mismatch repair (MMR) genes, leading to high levels of MSI. This 
results in a higher mutational burden, which correlates with increased expression of 





Figure 20: Various morphologic features associated with microsatellite instable 
cancer (MSI-high). A) Medullary-type carcinoma showing nests and cords of cells 
with pink cytoplasm, vesicular nuclei, and prominent nucleoli (note apparent tumour 
infiltrating lymphocytes). B) Mucinous carcinoma with abundant extracellular mucin 
and free-floating carcinoma cells. C) Signet-ring cells. D) Histologic heterogeneity 
with a distinct mucinous component abutting a poorly differentiated carcinoma 
component. Republished with permission from230. Copyright© Wolters Kluwer 




Figure 21. The immune landscape of microsatellite instable (MSI) and microsatellite 
stable (MSS) cancer. The DNA mismatch repair (MMR) system relies on key genes, 
such as MLH1, MSH2, MSH6, PMS2 or MSH3, that correct mismatched or wrongly 
inserted or deleted bases in the DNA. If this machinery fails due to defects in one or 
more repair genes, these errors are free to be integrated into the DNA permanently, 
forming microsatellites. Thus, deficient MMR/MSI-high tumours have a defect in 
one of the major DNA repair genes, resulting in high levels of microsatellites (MSI-
high). However, tumours with a functional MMR system result in low or stable levels 
of microsatellites (MSS). The result of this damaged repair system in deficient 
MMR/MSI-high tumours is a higher mutational burden, which correlates with a 
higher expression of neoantigens on MHC-I molecules. Adapted with permission 





Immunotherapy, particularly ICI, has revolutionized cancer treatment232. Although 
the response rate to ICI is only about 10–20% in different cancers, those who respond 
usually have an enduring response233. ICI inhibits negative regulatory receptors on T-
cells, such as cytotoxic T lymphocyte antigen 4 and programmed cell death 1. This 
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results in a boosting of anti-tumour immune responses216. Several factors influence 
tumour response to immune checkpoint inhibitors, for example, mutational load, 
MHC, tumour infiltrating lymphocytes and regulatory checkpoint receptors231. 
Tumours with high mutational burdens, such as non-small cell lung cancer and 
melanomas, respond better to ICI. For stage IV CRC, patients with MSI-high tumours 
have been shown to benefit from immunotherapy. These cancers have a high 
mutational burden and respond to ICI231. Thus, so far, not many CRC patients have 
been eligible for this treatment234. Although MSS CRC generally does not respond to 
ICI, some patients may still respond to this therapy235. Studies have shown that MSS 
CRC with a high T-cell infiltrate in tumours has a better prognosis236, 237. Further 





In exploring the role of T-cells in CRC as a diagnostic tool for evaluating immune 
reactions, the Immunoscore was developed by Galon and coworkers238. Two 
populations of lymphocytes (either CD3/CD45RO, CD3/CD8 or CD8/CD45RO), in 
the core of the tumour and at the invasive margin, are visualised using IHC. The 
slides were analysed by digital pathology. Based on the number of positive cells, a 
score between 0 and 4 was calculated (Figure 22). A high score (I4) equals a strong 
immune reaction238. They found that CRC patients with high densities of CD8+ and 
CD45RO+ T-cells (high Immunoscore) in tumours had a 5-year survival rate of 
86.2%. Those with low densities had a 5-year survival rate of only 27.5%239. The 
method has been validated for colon cancer in an international consortium (14 centres 
in 13 different countries), which found that the Immunoscore association with time to 
recurrence was independent of existing prognostic factors and patient age, sex, T- and 
N-stage and MSI status237. Immunoscore is not validated for rectal cancer, but it 
might be a prognostic tool in patients with rectal cancer treated with primary 
surgery236. It has been suggested to implement the Immunoscore in a TNM-Immune 
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classification system for CRC237, 240. Initially, there was a scoring system of five 
categories, but in the validation study, this was reduced to three: low, intermediate 
and high237. The prognostic value of the Immunoscore might also be relevant in other 
types of cancer241, 242. The method has been patented and is now commercially 
available as Immunoscore® (HalioDx, Marseille, France)237. A validated, non-
commercial, method for scoring immune response is therefore lacking.
 
Figure 22: (A) A section of colonic cancer immunostained for CD3, showing the 
regions of interest (the tumour and the invasive margin). (B) An enlargement 
showing CD3+ cells (stained brown) in the stroma and within the tumour glands 
(original magnification ×300). (C) The tumour (shown in red) and the invasive 
margin (shown in brown) were selected to determine the Immunoscore. (D) The 
Immunoscore is based on the numeration of CD3+ and CD8+ cells in the tumour 
and the invasive margin. The densities of the stained cells were determined using 
an image analysis workstation. According to a predetermined cut-off value, the 
immune densities are categorized as Hi (high) or Lo (low) in each tumour region. 
Patients are stratified according to a score ranging from I0 to I4, depending on the 
total number of high densities observed (the two markers CD3 and CD8 are 
assessed in the tumour, and the two markers are assessed in the invasive margin). 
Abbreviations: CD: Cluster of differentiation. Reprinted with permission from243. 
Copyright© Oxford University Press 2016.  
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1.6 Proliferation in cancer cells 
 
Proliferation is the most essential feature of cancer development. The ability of 
cancer cells to sustain proliferative signalling, evade growth suppressors, resist cell 
death and enable replicative immortality is evident in the Hallmarks of cancer, as 
mentioned above61, 62. Cell proliferation is a complex and carefully regulated process 
with an intrinsic quality control system244, dependant on interaction with the 
surrounding cells/environment and stimulation of growth factors. When this process 
gets out of control, cells avoid the intrinsic control system in the body, and cancer 
may develop. Cancer cells often establish autocrine proliferation stimulation as 
well62. 
Cell proliferation occurs in a multistep process called the cell cycle, which comprises 
several phases. The cells’ resting phase are called G0. The active part of the cell cycle 
starts with G1, where the cells grow and prepare for DNA synthesis. The S-phase is 
when the DNA replication occurs. The S-phase is followed by the G2-phase, where 
the cells continue to grow and prepare for mitosis, with DNA maintained at double 
copies. The final phase is mitosis, the M-phase, where the division into two cells 
occurs. The M-phase is divided into several sub-stages, see Figure 23. Together, G1, 




Figure 23: The different phases of the cell cycle. From G0 (resting phase) to 
mitosis. The phases in preparation for mitosis are called the G1, S and G2, while 
mitosis (M-phase) is divided into several sub-stages, from prophase to mitosis 
abscission. Created with BioRender.com. 
 
Proliferation is a prognostic marker in several types of cancer, such as breast cancer, 
malignant lymphomas, gastrointestinal stromal tumour and NEN246, 247.  
 
1.6.1 Mitotic activity 
 
Tumour growth correlates with mitotic activity, which is one of the main prognostic 
factors in several types of cancer192. Mitotic activity can be visualised and counted in 
the microscope with haematoxylin and eosin (HE) – staining. This is, however, time-
consuming. In some cases, it is also difficult to determine whether a cell is mitotic, 
especially to distinguish it from an apoptotic body (Figure 24)191. There are different 
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ways to determine and score mitotic activity, depending on the cancer type. For NEN, 
the mitotic count is reported as the number of mitosis pr. 2 mm2, counting in a tumour 
area of 10 mm2, which is 50 high-power fields at x40. This usually requires a surgical 
specimen to ensure enough tumour tissue for evaluation112.  
 
Figure 24: Haematoxylin and eosin (HE) and phosphohistone H3 (PHH3) staining of 
different sub-stages of mitosis. The examples include cells in prophase, 
metaphase, anaphase and telophase. Reprinted with permission from191. Copyright 




Ki67 is a nuclear DNA-binding protein expressed in proliferating cells247. Its function 
has been unclear, but it has been shown to play a role in controlling and timing of cell 
division248. To visualise Ki67 in pathological specimens, IHC staining with the MIB-
1 antibody is the most commonly used and recommended assay249. However, the 
method has been criticised because of difficulties in standardising Ki67 staining, 
which affects reliability and reproducibility250, 251. Ki67 can be expressed in apoptotic 
bodies252, which may overestimate the number of positive cells in a specimen. 
However, Ki67 correlates with a mitotic count, even though more cells than those in 
actual mitosis are labelled, and Ki67 is easier to quantify compared to the mitotic 
count in an HE stain193. Consequently, Ki67 is used as a prognostic biomarker in 
several types of cancers, such as GEP-NENs192. However, its role as a predictive 
marker is not yet well established253. 
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1.6.3 Phosphohistone H3 
 
Histone H3 is a nuclear core histone protein of DNA chromatin with an important 
role in chromosome condensation and cell cycle progression during mitosis. 
Phosphorylation occurs between late G2 and early prophase, while dephosphorylation 
occurs slowly from late anaphase to early telophase. Therefore, histone H3 is always 
heavily phosphorylated in the metaphase and positive for phospho-histone H3 
(PHH3) IHC. In the interphase, there is no or minimal expression of PHH3, which 
allows PHH3 to stain only mitotically active cells. Hence, PHH3 is regarded as 
proliferation-specific and a promising marker of mitotic activity254. In addition, it is a 
validated prognostic marker in several types of cancer255 and has been identified as a 
promising marker for predicting disease-free survival and disease-specific survival in 
pancreatic NEN256, 257. However, its role in GEP-NENs has yet to be determined. 
As already mentioned, counting mitosis in an HE stain is challenging because 
apoptotic bodies can be misinterpreted as mitotic figures191, 252. In contrast to Ki67, 
which is present in all proliferative phases of the cell cycle and can also be expressed 
in apoptotic bodies, PHH3 only stains M-phase cells, see Figure 25. Thus, with 
PHH3, mitotic activity can be specifically determined258, and PHH3 may be a better 
biomarker for mitosis252. Several studies have shown good concordance between the 
number of mitoses and PHH3259, 260. PHH3 is suggested as an alternative to the Ki67 
index in pancreatic NEN252 and is regarded as promising for assessing grading in 
GEP-NENs in general. 
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Figure 25: Expression of Ki67 (A) and phosphohistone H3 (PHH3) (B) in the cell 
cycle. The arrows indicate which phase the immunohistochemical markers are 




2. Aims of the study 
Prognostic and predictive factors are important for treatment decisions in 
gastrointestinal cancer. In addition, the reproducibility and accuracy of the methods 
used in the diagnostics are crucial for the optimal clinical management of patients.  
The aims of our study were as follows: 
 To establish a method for evaluating the immune response in CRC tumours 
(Papers I and II); 
 To compare the serologic immune response with the immune response in CRC 
tumours (Paper I); 
 To calculate an immune score for colon cancer and see how it corresponds 
with known histopathological parameters (Paper II); 
 To improve the prognostic assessment regarding which patients with colon 
cancer may benefit from additional treatment (Paper II);  
 To improve the prognostic value of grading using digital image analysis of Ki-
67 in GEP-NENs compared to manual evaluation with a light microscope 
(Paper III); and 
 To evaluate the proliferation marker phosphohistone-H3 (PHH3) in GEP-
NENs to improve prognostic assessment and evaluate the potential advantages 




3.1 Study population 
 
This thesis involved two different study populations. The patients recruited for the 
Papers I and II were from the ACROBATICC cohort261 (clinicaltrials.gov identifier: 
NCT01762813). This is an ongoing prospective clinical-molecular biomarker 
outcomes study. ACROBATICC is an abbreviation for ‘Assessment of clinically 
related outcomes and biomarker analysis for translational integration in colorectal 
cancer’. The study was approved by the Norwegian Regional Committees for 
Medical and Health Research Ethics (REK-Vest, #2012/742) and conducted 
according to national legislation. Written informed consent was obtained from all 
participants before inclusion in the ACROBATICC project.  
Twenty-one patients were recruited for an early pilot feasibility study, resulting in 
Paper I. These patients were recruited for the ACROBATICC cohort between 
February 2015 and May 2015. Eighteen of them had stage I–III invasive CRC and 
were included in the analysis. Three patients were excluded due to a final diagnosis 
of adenoma without an invasive tumour. The second study, culminating in Paper II, 
encompassed a sub-cohort of patients with stage I–III colon cancer that did not 
undergo neoadjuvant treatment from the initial cohort recruited between January 
2013 and May 2014106.  
The second study population, for Paper III, was all consecutive patients diagnosed 
with GEP-NENs and treated at Stavanger University Hospital from 2003 to 2013. 
This hospital serves as the only hospital for a well-defined Norwegian population of 
approximately 380,000 people153. The study was approved by the Norwegian 
Regional Committees for Medical and Health Research Ethics (REK -Vest, 
#2016/1622) and conducted following national legislations. Written informed consent 
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was obtained from all living participants before they were included in the study. Out 
of 204 consecutive patients, 35 did not respond or declined their participation.  




ACROBATICC is a translational cancer research project led by the Department of 
Gastrointestinal Surgery at Stavanger University Hospital. The prospective 
registration includes all patients with CRC, either primary or metastatic disease261. 
Collaboration between departments and institutions is key to the project. By 
inclusion, the patients received a unique identifier number in the project. Blood 
samples were taken before surgery and at follow-up, which is normally about one 
month after surgery. From the surgical specimen, fresh frozen tissue was sampled 
from the normal mucosa and the tumour tissue and stored at –80ºC. In addition, 
routine samples were selected for diagnostics as formalin-fixed paraffin-embedded 
(FFPE) tissue. Minimum three FFPE blocs were sampled from the primary tumour 
from each patient. The section with the deepest infiltration was used in this study. 
The same procedures were performed with patients who developed metastatic 
disease. The database was handled and protected according to the hospital’s 
regulations and current legislation.  
 
3.2.2 GEP-NENs cohort 
 
The GEP-NENs cohort was obtained from the Department of Gastrointestinal 
Surgery at Stavanger University Hospital, and this department led the inclusion of 
patients. In addition, FFPE sections were retrieved from archives at the Department 
of Pathology. All tumours were confirmed as NENs by positive IHC staining for 
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synaptophysin and/or chromogranin A. NEC was included as grade 3 (high grade). 
MiNENs were excluded. A patient was excluded due to possible primary pulmonary 
NEC. Nine patients were excluded due to a lack of tissue for analysis. Thus, 159 
(77.9%) patients were included in the study. The material comprised 63 (39.6%) 
biopsies and 96 (60.4%) surgical specimens. For some patients, there was not enough 
material to perform IHC for PHH3. In these cases, only IHC for Ki67 was analysed.  
Routine evaluation of patients encompassed clinical examination, blood tests, 
including tumour marker detection (i.e. CgA), and standard oncologic imaging, as 
recommended in available guidelines155, 262-264. PET imaging was not routinely 
performed. Transthoracic echocardiography was performed in cases of suspected 
carcinoid heart disease. Endoscopy, including endoscopic ultrasound (EUS) and 
video capsule endoscopy, was available if indicated. If a GEP-NEN was incidentally 
discovered during an unrelated surgery, a clinical evaluation was performed 
postoperatively. 
 
3.2.3 Enhancing the quality and transparency of health research 
 
The ACROBATICC cohort study is reported according to the STROBE 
(strengthening of the reporting of observational studies in epidemiology)265 and the 
REMARK (REporting recommendations of tumour MARKer prognostic studies)266 
guidelines for biomarker studies. STROBE is a checklist to improve reports of 
observational studies developed by methodologists, researchers and journal editors to 
ensure transparency and good reporting of observational studies267. The checklist is 
used for both cohort, case-control and cross-sectional studies268.The REMARK 
guidelines are used to provide relevant information about the study design, 
preplanned hypotheses, patient and specimen characteristics, assay methods and 
statistical analysis methods. These guidelines were developed jointly by the US 
National Cancer Institute (NCI) and the European Organisation for Research and 
Treatment of Cancer (EORTC)269. The goal of these guidelines is to encourage 
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transparent and complete reporting so that relevant information is available to 
others in tumour marker studies269.  
 
3.3 Statistical analysis 
 
IBM SPSS Statistics for Windows, Version 23 or 26.0 (IBM Corporation, Armonk, 
NY, USA), was used for the statistical calculations.  
In Paper I, correlation analyses were performed using the non-parametric test 
Spearman’s rank correlation coefficient (rho; ρ), assuming a non-Gaussian 
distribution of variables. In Paper II, associations between categorical variables were 
tested with Chi-square. In addition, Mann–Whitney U test was used to compare 
differences in continuous or ordinal variables between groups. All tests were two-
tailed, and a p-value <0.050 was determined as statistically significant.  
In Paper III, quadratically weighted kappa was used to measure the agreement 
between ordinal variables270 and calculations were aided using VasserStats271. The 
interclass correlation coefficient (ICC) was used to measure the agreement between 
continuous variables (single rater, absolute agreement). All agreement estimates are 
presented with 95% confidence intervals (CIs). Values less than 0.50, between 0.50 
and 0.75, between 0.75 and 0.90 and greater than 0.90 indicated poor, moderate, good 
and excellent reliability, respectively272. To plot the difference in pathology Ki67 and 
digital image analysis Ki67 measurements against the average value, we used a 







3.4.1 Flow cytometry 
 
 
Flow cytometry enables the rapid analysis of numerous cells at a single cell level. 
Physical characteristics of each cell are registered as it flows in suspension through a 
detector based on scatter made from laser excitation. Targeted antibodies with 
fluorescent markers can be used to label whole cells or cellular components, such as 
organelles, nuclei, DNA, ribonucleic acid (RNA), chromosomes, cytokines, hormone 
receptors or protein content274. This allows flow cytometry to be used for many 
purposes, such as antigen detection. 
The main principle of this technique is based on the scattering of light and the 
emission of fluorescence, which occurs when light from an excitation source, usually 
a laser beam, hits the cells moving in a directed fluid stream274, 275. A flow cytometer 
comprises several components for the different analytical steps. First, there is a 
fluidic system that contains the material to be analysed, such as white blood cells. 
Second, the fluidic system aligns the cells to flow at the same speed and axis through 
the light source. The light source is usually one or several lasers that focus on the 
cells. The resulting light scatter is detected through a forward scatter and a side 
scatter. Forward scatter is proportional to the cell surface area or size and is suitable 
for detecting particles greater than a given size. Side scatter is a measurement of 
refracted and reflected light collected at approximately 90° of the laser beam. It is an 
expression of the granularity/complexity of the cell. Forward scatter and side scatter 
combined are commonly used for immunophenotyping, as different blood cells are 
easily separated by size and granularity274.To study specific biomarkers or the 
complexity of cells, cell components are detected using antibodies with different 
fluorescent markers and lasers emitting light at different wavelengths. The light 
signals are converted to voltage by a detection system that comprises photodiodes or 
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photomultiplier tubes. The photodiodes detect the strong signals sent by forward 
scatter, while photomultiplier tubes detect the weaker signal generated by side scatter 
and fluorescence. A converter transforms analogue signals from detectors into digital 
signals, which are then sent to a computer. The software usually displays the results 
as a scatter plot or histogram, which can then be analysed (Figure 26). Finally, the 
waste products end up in a collecting waste container to be disposed of275.  
  
  
Figure 26: The signalling process of flow cytometry. The fluidics contain particles 
that go through the light detection system. Here, two types of light scatter occur: 
forward scatter (FSC) and side scatter (SSC). The light signals are converted to 
voltage by detectors. There are two types of detectors: photodiodes (FSC) and 
photomultiplier tubes (PMT). The photodiodes detect signals sent by FSC, while 
PMT detects signals generated by SSC and fluorescence. The signals from the 
detectors go to a computer that analyses and displays the results. Adapted with 
permission from274. Copyright© Taylor & Francis 2017.  
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In present work, blood samples were run using a two-laser flow cytometer (BD 
Accuri C6 and Cytoflex, Beckman-Coulter, USA). The flow cytometer was equipped 
with a blue (588 nm) and red laser (640 nm), two light scatter detectors (forward 
scatter and side scatter) and four fluorescence detectors. The fluorescence detectors 
were equipped with optical filters optimized for the detection of fluorescence from 
fluorescein isothiocyanate (FITC 588/30 nm), phycoerythrin (PE 585/40 nm), 
peridinin chlorophyll (PER-CP 670 nm) and allophycocyanin (APC 675/25 nm). As 
described in our paper, we used an antibody kit from BD Biosciences (NJ, USA). 
White blood cells were marked with CD45+ conjugated to Per-CP, all T-cells were 
marked with CD3+ linked to FITC and cytotoxic T-cells with CD8 PE. In addition, 
CD4+ positive T-cells were marked with APC-conjugated antibodies for staining. 
Using the corresponding software, we calculated the absolute numbers of the 
different T-cell populations per ml blood276.  
 
3.4.2 Multiplex polymerase chain reaction and fragment analysis 
 
 
PCR is a method used to examine small segments of DNA or RNA. PCR can be used 
to detect gene mutations, but it is widely used in forensic medicine277. The method is 
based on the amplification of small segments of DNA278.  
PCR is performed in several stages. First, a DNA template is made. To do this, the 
tissue of interest is mixed with a buffer before primers, DNA polymerase and 
nucleotides are added. A primer is a short stretch of DNA, usually 20–30 base pairs, 
which complement the DNA region to be examined. At least two primers are used. 
These are forward and reverse primers and ensure that the DNA strands can be read 
upstream and downstream directions in the region of interest. DNA polymerase is the 




The DNA template was placed in a PCR machine. The machine can change 
temperature very quickly, and a rapid temperature change is one of the key factors of 
the method. The process comprises three steps (Figure 27). Step 1 is the denaturation 
of DNA, in which the DNA strands are separated. For this to take place, a high 
temperature is required. Step 2 involves annealing when the primers bind to the 
separated DNA strands. Step 3 is elongation, as the primers synthesise DNA strands. 
These steps were repeated several times, with the resulting amplification of the DNA 
segments. The process requires specific temperatures at each step.279 When 
amplification is completed, the product is analysed with electrophoresis. In modern 
PCR techniques, the fluorescent labelling of primers makes detection by laser 
possible. In multiplex PCR, several primers are used so that several genes can be 
examined simultaneously280.  
 
 
Figure 27: Steps in the polymerase chain reaction. Green = primer. Purple = 
nucleotides. Red and blue: DNA template strands. Created with BioRender.com 
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In our case, tissue was extracted from sections of FFPE blocs. Five primers were used 
for both MSI and EMAST, and two independent multiplex PCR reactions were 
performed. Detailed descriptions of the procedure and interpretation of the results are 




IHC is used to detect specific proteins in FFPE tissue and has revolutionised 
diagnostics in pathology281. When performing IHC, enzyme-linked antibodies are 
used to detect tissue antigens. The basic principles of IHC are described in Figure 28. 
The first step is sectioning tissue from the FFPE block onto a slide. Next, the slide is 
heated in a buffer to unmask the antigen, a process called antigen retrieval. After 
incubation with the primary antibody, a secondary antibody with a polymer complex 
(polymer with horseradish peroxidase) binds to the primary antibody. The peroxidase 
enzymes convert a chromogen substrate solution called 3,3 Diaminobenzidine into a 
brown precipitate. This occurs close to the location of the antigen and is used to 
visualise the antibody. Endogenous enzymes are blocked, so they will not interfere 
with the detection system. Between each step of the procedure, unbound reagents are 
washed off. The final step is to counterstain the slide with haematoxylin and apply a 





Figure 28: Basic principles of immunohistochemistry. Abbreviations: HPR: 
horseradish peroxidase, DAB: 3.3 diaminobenzidines, CD: cluster of differentiation. 
Created with BioRender.com 
  
Over the years, the different steps of IHC have been standardised and automated281. 
This improved the method. However, international standardisation remains 
insufficient, hampering reproducibility282. Several studies have shown poor intra-and 
inter-observer reliability15, 283. Numerous factors affect the results: pre-analytical, 
such as fixation time; analytical, such as detection system; and post-analytical, such 
as interpretation of results282. Therefore, every step of IHC has to be optimised for the 
method to be reliable284.  
All the IHC stains used in our studies were performed in routine diagnostics at the 
Department of Pathology, Stavanger University Hospital. The laboratory participates 
in Nordic immunohistochemical quality control (NordiCQ), a scientific organisation 
that standardises and recommences protocols for IHC196. Hence, the method was 
optimised before our studies. The specific methods for the different IHC antibodies 
are described in each paper. An automated slide stainer was used, with positive and 
negative controls in each run.  
 
 
3.4.4 Digital image analysis 
 
Digital image analysis involves several variables that must be optimised for a 
successful result. These can be divided into pre-processing, classification and post-
processing variables. Pre-processing variables include laboratory routines for 
fixation, preparation and staining of the surgical specimen or biopsy. The section you 
want to scan has to be evenly cut and stained. Artefacts from suboptimal processing 
or staining can hamper the results. Furthermore, the slide has to be clean, without air 
bubbles or dust under the glass.  
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The first step in digital image analysis is scanning the sections. Photos taken with a 
camera can also be used, but usually, a scanner is preferred. The scanner is calibrated 
and adjusted for focus, white balance, light source, exposure time and colour. To 
sustain details in the image, scanning at x40 is favourable. The more details you 
want, the more storage is required. The scanned image is compressed into a digital 
image file. File format varies depending on the scanner and programme used. 
Examples of formats are tagged image file format (TIFF) and joint photographic 
expert group (JPEG). TIFF preserves more details in the image, whereas JPEG is 
more compressed and results in a smaller file size with less detail. The Leica scanner 
used in our studies uses scenario (SCN) format, which is comparable to TIFF.  
 
For classification, there are three categories of digital image analysis measuring 
algorithms8: 
- Area-based measurements 
o Pixel-based assessment, where the algorithm quantifies the colour (or 
intensity of staining) in each pixel 
- Cell-based measurements 
o Morphometry-based assessment where pixels are grouped based on 
similarity defines structure (e.g. cells or nuclei) profiles that meet 
certain preselected criteria (e.g. size and shape).  
- Object-based counting or assessment of ‘events’  
o Specialised algorithms are designed to serve a particular need, often the 
automated identification and/or enumeration of non-cell structures. 
 
Classification, in applications used for digital image analysis, requires a classifier. A 
classifier aims to create a contrast between the structures you want to examine in the 
image and other image segments. One aim could be to separate positively stained 
nuclei from negatively stained nuclei in an image. Several types of classifiers are 
available, and some will be mentioned here. The simplest classifier is ‘Threshold’. 
This classifier marks areas of and above a defined pixel value to separate objects 
from the background285. Although ‘Threshold’ is used in some image analysis 
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software286, it is not very sensitive to variation in staining intensity, and the optimal 
‘Threshold’ might vary from one image to another. More sophisticated classifiers 
include ‘Bayes classification’ and ‘K-means clustering’285. These can be 
unsupervised (K-means clustering) or supervised (Bayes classification), depending on 
whether pixels relevant for the classification are set or not21. K-means clustering does 
not need a training set to be used for digital image analysis287, while Bayes 
classification is a probabilistic model that uses training data to find the most probable 
prediction288. If you teach the classifier to recognise one or several colour pixels in a 
training set, the classifier will use this knowledge to recognise the same colours in 
different virtual slides that have not been presented to the classifier before. This 
knowledge is used to develop an application for digital image analysis. Applications 
that use more sophisticated classifiers can be trained to group several colour pixel 
intensities into the same category287. For example, a nucleus positive for 3.3 
diaminobenzidine staining can be light brown or dark brown, and the application can 
be trained to include different shades of brown in the positive category. For 
haematoxylin (blue) staining, the same applies. This feature is important when the 
same application is used for several scanned sections, as there will always be some 
differences between scanned slides from different patients. Lezoray and Cardot found 
that Bayes classification gave a better segmentation of colour pixels than K-means 
clustering287. Bayes classification can also be used to assign objects to different 
groups, depending on the size and shape in a segmentation285. This can be used to 
separate tumour cells from stroma and lymphocytes in digital image analysis. An 




Figure 29: Bayes classification of Ki67 immunohistochemical staining in a 
neuroendocrine neoplasm. The green dotted line outlines the region of interest. The 
classifier has separated tumour from stroma (blue line). It has also identified 
positive tumour cells (green) and negative tumour cells (blue) based on nuclei 
staining. The red areas are cytoplasm/background, which was excluded from the 
calculation. The different classified areas are exemplified by the green, blue and red 
arrows. 
 
An important step in digital image analysis is selecting the region of interest on a 
virtual slide. The region of interest can be manually selected, or digital image 
analysis can be used to do this. For example, digital image analysis can identify the 
region of interest using a heat map that selects a hot spot based on threshold, 
clustering or other criteria285, 289. The benefit of automation is avoiding selection bias. 
However, manual selection might be better to avoid tissue that you do not want to 
include in the analysis. If a technician selects a region of interest, it should always be 
controlled by a pathologist8. Several regions of interest can be selected, and 
measurements can be performed on several areas simultaneously.  
 
Post-processing involves manual control and adjustment of the image. Examples 
include the removal of artefacts or the separation of overlapping objects1. This 
usually requires some knowledge of histopathology. Digital image analysis measures 
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pixels, and this must be translated into understandable variables that can be 
interpreted. This is done by applying definitions to output data. A spreadsheet or 
other type of software is usually used in this process. 
 
In our studies, we used Bayes classification to develop the different classifiers 
utilised in applications for digital image analysis. The applications used for digital 
image analysis were developed based on knowledge from similar studies13, 191. 
Region of interest and applications used were defined differently in the different 
papers. In Paper I, we used two different applications. The first counted T-cells 
(CD3 and CD8) in a manually defined region of interest in the tumour centre and the 
invasive margin. The second separated the epithelium and stroma into a 2 mm circle 
in the tumour centre and the invasive margin before quantifying the same T-cell 
populations. In Paper II, we used the first application from Paper I. In Paper III, a 
manually defined region of interest for hotspot Ki67 was used. 500–2000 cells in the 
region of interest were counted based on the mean nuclear size. Stroma was excluded 
from the region of interest if present. The percentage of Ki67-positive nuclei was 
calculated based on positive and negative nuclei staining. For PHH3, depending on 
the area available, we had 1 to 4 different manually selected regions of interest in 
hotspots where the number of PHH3-positive cells was counted in an area of 2mm2. 
Further details and photos are provided in the corresponding papers276, 290, 291. All the 
annotations of the region of interest, analysis and post-processing were done by a 
certified pathologist (DL). To avoid selection bias, measurements were done without 
information about clinicopathological data, such as the stage of the disease or the 




In Paper I, (Hagland, Lea et al., Anticancer Research, 2017), the relationship 
between circulating T-cells in blood and intratumoural T-cells in CRC was 
investigated in a feasibility study. Eighteen patients with stage I–III CRC were 
included. Using flow cytometry, pre-surgical blood samples were analysed for T-cell 
type (CD3+, CD4+ and CD8+) and count. Intratumoural T-cells were stained with 
CD3 and CD8 using IHC and quantified in the invasive margin and tumour centre by 
digital image analysis, using an automated image analysis software, Visiopharm® 
(Hoersholm, Denmark). We found that the number of CD3+ and CD4+ T-cells in pre-
surgical blood samples correlated with the number of CD3+ T-cells found in the 
invasive margin (Spearman ϱ = 0.558, p < 0.05 and 0.598, p < 0.01, respectively) and 
with CD3+ T-cells in the tumour centre (ϱ = 0.496, p < 0.05, and ϱ = 0.637, p < 0.01, 
respectively). There was a strong correlation between CD4+ T-cells in blood and 
CD8+ T-cells in the tumour centre and the invasive margin (ϱ = 0.602 and ϱ = 0.591, 
p<0.01). The correlation was strongest for analysis on whole section scans, compared 
to 2 mm circles in the tumour centre and invasive margin. 
 
In Paper II (Lea, Watson et al., Cancer Immunology Immunotherapy, 2021), we 
developed an objective quantification method for T-cells to calculate an immune 
score for colon cancer. The method was based on one of the digital image analysis 
applications used in Paper I and used automated image analysis software, 
Visiopharm® (Hoersholm, Denmark). CD3 and CD8 T-cells at the invasive margin 
and in the tumour centre were quantified. An algorithm template for whole slide 
assessment generated cell counts per square millimetres (cells/mm2), from which the 
immune score was calculated using distribution volumes. To confirm its relevance, 
the immune score was juxtaposed with the clinical and histopathological 
characteristics. Based on the number of T-cells calculated by digital image analysis, 
patients were classified into low (n = 83, 69.7%), intermediate (n = 14, 11.8%) and 
high (n = 22, 18.5%) immune score groups. A high immune score was associated 
with stage I–II tumours (p = 0.017) and a higher prevalence of MSI-high tumours (p 
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= 0.030). MSI-high tumours had significantly higher numbers of CD3+ T-cells in the 
invasive margin and significantly higher numbers of CD8+ T-cells in both the tumour 
centre and the invasive margin than MSS tumours. Our digital template to quantify T-
cells is an easy-to-use immune score, corresponding with known clinicopathological 
features such as stage and MSI in colon cancer.  
 
In Paper III (Lea, Gudlaugsson et al., Applied Immunohistochemistry & Molecular 
Morphology, 2021), we evaluated the use of digital image analysis as an objective 
assessment of proliferation markers in GEP-NENs. The study included 159 patients 
(57% male) in a consecutive cohort of 204 patients. Automated digital image analysis 
measurements of Ki67 (digital image analysis Ki67) and PHH3 (digital image 
analysis PHH3) on IHC slides were analysed using Visiopharm® image analysis 
software (Hoersholm, Denmark). The results were compared with the Ki67 index 
recorded in the corresponding routine pathology reports (pathology Ki67). The 
median pathology Ki67 was 2.0%. Median digital image analysis Ki67 was 4.1%. 
The interclass correlation coefficient of the digital image analysis Ki67 compared 
with the pathology Ki67 showed an excellent agreement of 0.96 (95% confidence 
interval [CI]: 0.94–0.96). When comparing grades based on the same methods, the 
observed kappa value was 0.86 (95% CI: 0.81–0.91). PHH3 was measured in 145 
(91.2%) tumours. The observed kappa value was 0.74 (95% CI: 0.65–0.83) when 
comparing grades based on the digital image analysis PHH3 and the pathology Ki67. 
In conclusion, there was excellent agreement between digital image analysis Ki67 
and pathology Ki67. However, digital image analysis Ki67 tended to upgrade cases 
from grade 1 to grade 2. The digital image analysis PHH3 measurements were more 






There is an ongoing paradigm shift in pathology, where laboratories are going digital 
and the microscope will eventually become obsolete. There are many benefits to 
digitalisation, especially concerning patient safety and logistics in the pathology 
departments. However, one challenge in pathology today is the subjectivity in 
evaluating and interpreting IHC staining, especially in the quantification of 
prognostic markers. This leads to intra-and inter-observer variations. By introducing 
new diagnostic methods, including digital image analysis, some of these obstacles 
might be solved. In addition, novel prognostic parameters (e.g. a score for immune 
response) not routinely used today might be introduced. 
5.1 Determine immune status in colorectal patients 
 
We aimed to investigate the correlation between T-cells in the blood and T-cells in 
tumour tissue from patients with CRC (Paper 1). Although this was a feasibility 
study with only 18 patients, we found an interesting relationship between the two. 
Unfortunately, these findings are not explored further in the cohort at this time. To 
our knowledge, no other studies with the same methodology have been conducted for 
CRC. However, a study by Chirca et al. found different levels of CD4+ and CD8+ in 
peripheral blood compared with tumours, using flow cytometry for both analyses292. 
A study by Won et al. found a lower number of circulating mucosal-associated 
invariant T-cells in mucosa-associated cancers (including colon cancer) compared to 
healthy controls293. Sun et al. found that several immune-related genes were 
upregulated in blood samples from CRC patients compared with healthy controls. 
Furthermore, the gene protein phosphatase 3 regulatory subunits Bα (PPP3R1) was 
especially associated with poor prognosis294. In this latter study, the CRC patients 
were significantly older than the healthy controls, which may have influenced the 
results. The beneficial effect of a local cancer-specific immune reaction in CRC is 
well documented and has been shown to be related to a better outcome. However, a 
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lower immune response is associated with a worse prognosis226, 237, 295, 296. Liquid 
biopsies, especially in the blood, are evolving in other fields of cancer diagnostics for 
the early detection and tracking of biomarkers297. The role of liquid biopsies for 
immune cells as prognostic markers in CRC remains unsettled. 
5.2 Immune score for colon cancer 
 
In Papers I and II, we developed a method for quantifying T-cells in CRC. In Paper 
I, two different digital image analysis methods to quantify T-cells in the tumour were 
explored. We found that analysis of whole-section scans gave the highest correlation 
with T-cells in the corresponding blood samples. The method emanates from the 
constructed principle of Immunoscore® (HalioDx, Marseille, France), which has 
been validated in a large international cohort series237. Over the years, there has been 
a shift in methodology for calculating iImmunoscore, from analysis on tissue micro 
arrays to analysis on whole section scans226, 237. In addition, the classification of 
Immunoscore® (HalioDx, Marseille, France) has been changed from five to three 
categories237, 240. The calculations, including the cut-off values, are largely under 
wraps237, complicating the method’s reproducibility. In addition, the commercially 
available Immunoscore® (HalioDx, Marseille, France) is adapted to certain 
manufacturers of antibodies and autostainer237, and this may prevent pathology 
departments from setting up the method with equipment available in their laboratory. 
Others have developed deep learning methods to analyse tumour-infiltrating 
lymphocytes in CRC and have found an association with survival23, 298. 
Our method for immune score (Paper II) may represent an alternative that is 
adaptable, easy to implement, affordable and objective and provides transparency for 
reproduction. The latest guidelines from the European Society for Medical Oncology 
recommend that Immunoscore® (HalioDx, Marseille, France) be considered in 
conjunction with TNM to refine the estimate of prognosis for early colon cancer 
patients and assist chemotherapy decision making in stage II and low-risk stage III 
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patients299. This highlights the necessity of this parameter in clinical practice. 
However, pathology departments must be able to determine immune scores using the 
available equipment. Integration with digital software must also be possible, as 
pathology departments are transitioning to digital pathology. The necessity of an 
immune score is also highlighted as an indication for immunotherapy becomes more 
available. Chalabi et al. showed that neoadjuvant immunotherapy decreased primary 
tumours in MSI–high colon cancer patients. In several cases, the tumour disappeared 
completely. Some patients with MSS tumours also responded to immunotherapy300, 
and an immune score might be a tool for selecting these patients231. 
5.3 Digital image analysis of proliferation markers in 
neuroendocrine neoplasms 
 
In Paper III, we quantified two different proliferation markers in GEP-NENs, where 
one of the markers, Ki67, is currently used in diagnostics. Previous studies have 
shown that digital image analysis or counting on a camera captured/printed image 
gave the best results for evaluating Ki67 in GEP-NENs14, 15. The same studies found 
that eyeball estimation had the lowest agreement and reproducibility. In this study 
(Paper III), we found more grade 2 tumours when digital image analysis calculated 
the Ki67, but when we compared the percentage of digital image analysis Ki67 with 
the pathology Ki67, we found excellent agreement. We think that an explanation for 
this finding is that many of these cases had a percentage between 2% and 4%, which 
is around the cut-off value to separate WHO grade 1 and grade 2 tumours. Another 
explanation might be that eyeball estimations of Ki67 tend to downgrade more NETs 
to grade 1 than evaluations by digital image analysis, as found by Kroneman et al.301. 
A study by Owens et al. found that digital image analysis overestimated the Ki67 
percentage compared with manual counting, but increasing the hot spot size reduced 
the difference302. One can discuss whether manual evaluation should be the reference 
standard303, 304 since we believe that many of the diagnostic cases have been evaluated 
with eyeball estimation, while others have been counted properly. A study by 
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Hacking et al. did not manage to establish a good concordance between digital image 
analysis and manual counting, and an explanation might be the program/software 
used for digital image analysis in their study305. In our routine practice today, we 
always use quantitative counting if there are Ki67-positive cells in the tumour. This 
was not the case when the cohort was established. We have not yet established a 
routine for digital image analysis Ki67, but hopefully, we will get more experience 
with the method when digital pathology is established in our department.  
In Paper III, we explored PHH3 as a marker in GEP-NENs. The results for PHH3 
varied, and agreement with WHO grade was worse than for the digital image analysis 
Ki67. This parallels the results of others257, 305, 306. Villani et al. found this marker to 
be of prognostic value in pancreatic NEN256 and seven mitosis pr. 10 high power 
fields differentiated between low-and high-risk patients. We did not explore whether 
this marker or Ki67 gives prognostic information about disease-free survival or 
overall survival in this study. The challenge with these comparisons is the limited 
number of patients in this study and the prognosis varies depending on tumour 
localisation175. 
  
5.4 Methodological considerations and limitations 
 
5.4.1 Study population 
 
Two different study populations were included in this study. Paper I is a feasibility 
study with a limited number of patients. The aim of that study was merely to test the 
hypothesis that there is an association between blood and tumour T-cell count, which 
we could confirm. In Paper II, the total number of patients was 119, which is quite 
low for analysing disease-free survival and overall survival. In addition, there is no 
validation cohort. Validation is necessary to demonstrate any predictive or prognostic 
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impact of our immune score method. However, the ACROBATICC cohort is 
consecutive and thus should not have an inherent referral bias. This makes our results 
more robust.  
In Paper III, 159 patients were included. For GEP-NENs, this is quite a large cohort. 
In addition, the cohort includes quite an even distribution of WHO grade 1–3. 
Compared with similar studies, the number of included patients with grade 2 and 3 
tumours were high14, 15, 252, 303-305. Like with the ACROBATICC cohort, we lack a 
validation cohort for the GEP-NENs. A validation of our findings in another cohort 
will be necessary, with data for disease-free survival and overall survival, to 
demonstrate the predictive and prognostic impact of digital image analysis methods. 
A drawback of Paper III is that almost 40% of the tumour samples were from 
biopsies. Therefore, the material was more fragmented, and the sample size was 
smaller compared to surgical specimens. However, this parallels current routine 
practice at many centres, as surgical specimens are not achievable for all patients, 
especially patients with advanced disease197. A study by Yang et al. showed that the 
Ki67 staining of core biopsies was reliable for the prognosis of metastatic NETs to 
the liver, despite tumour heterogeneity307. The same biopsies were compared using 
different methods in this study; therefore, a small sample size should not affect the 
comparison. However, PHH3 was omitted for some of the samples.  
  
5.4.2 Reference standard 
 
In Paper II, we did not compare our method with the patented Immunoscore® 
(HalioDx, Marseille, France). Immunoscore® (HalioDx, Marseille, France) is the 
closest resemblance to a reference standard, but the calculations in this method are 
different, using intervals of 0%–25%, > 25%–70% and > 70%–100% for mean 
percentiles237. However, it would be interesting to see whether our method for an 
immune score gave similar results. Unfortunately, since our laboratory used different 
equipment and our immune stains were done with different antibodies/laboratory 
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equipment, we could not have sent our IHC slides for evaluation either, but we had to 
send the tumour blocs for an evaluation. This was quite expensive and was not done.  
In Paper III, the digital image analysis of Ki67 was compared with manual counting 
from the corresponding pathology report. Several pathologists have been involved in 
diagnostics, and there might be differences in how they count and grade these 
tumours. These data are subjective histopathological scores39 and reflect routine 
practice in different pathology departments. Tumours were graded and staged, and 
patients underwent follow-up based on these evaluations. Discussions are ongoing 
regarding whether digital image analysis of Ki67 versus manual counting should be 
the reference standard15, 303, 304. Digital image analysis is more objective and 
reproducible than manual counting due to several known cognitive and visual biases 
hampering human visual evaluation of tissue39. This favours digital image analysis. 
For breast cancer, several studies have shown superior prognostic information from 
digital image analysis308, 309. For GEP-NENs, Tang and co-workers demonstrated the 
best agreement with the digital image analysis of Ki6715. The same is true for similar 
studies14, 305, but none of these studies compared their results with disease-free 
survival or overall survival.  
 
5.4.3 Digital image analysis 
 
Digital image analysis was used in all of our papers to evaluate prognostic and 
predictive markers. The biggest challenge with digital image analysis in Papers I and 
II was that the same analysis was performed on two different slides. Although slides 
for IHC CD3 and CD8 were cut immediately following each other, there were small 
differences between one image and the next. In addition, the orientation of the 
sectioned tissue was of significance. In Paper I, we used two different applications 
for digital image analysis of the same scanned images. For one of the applications in 
Paper I, tissue orientation on the CD3 and CD8 slides did not matter, as the region of 
interest was circular. For the other method, using a whole-section scan, the 
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orientation of the tissue was important for us to mark the same region of interest on 
both slides. In all of our papers, the region of interest was manually annotated in the 
scanned images. This process might be biased compared with an automated 
annotation of the region of interest. For the region of interest shaped as 2 mm circles 
in Paper I, the circles were placed in the centre of the tumour and at the deepest 
infiltration of the invasive margin. For the whole section scans, a larger region of 
interest was employed for the analyses, largely avoiding selection bias.  
Manual scoring of IHC slides has the inherent possibility of several biases and errors 
compared to digital image analysis, wherein visual traps/optical illusions are 
avoided39. With manual scoring, the region of interest was selected by the pathologist. 
So, although selection bias might be present using digital image analysis with manual 
annotation, the same bias is present in manual scoring.  
Not only does the method used for digital image analysis matter, but the work 
beforehand must also be optimal and standardised. Several preanalytical variables 
may affect the results of digital image analysis, such as tissue collection, fixation 
time, section thickness, morphologic criteria for assessment and the staining 
processes310. In our laboratory, we have procedures for handling the tissue, fixation 
time, section thickness, etc. to avoid bias from such variables. The same technician 
was also used to section the samples for the different studies. Furthermore, digital 
image analysis can be hampered by poor slide quality and a lack of consistency in 
slide preparation. In addition, the digital image analysis results can be greatly affected 
by the quality of IHC6. As mentioned in the method, our laboratory participates in 
Nordic immunohistochemical Quality Control (NordiCQ) to ensure standardised and 
recommended protocols for IHC196. 
In Papers I and II, we analysed the number of cells in an area given as n cells/mm2. 
The mean nuclear area of the lymphocyte was the basis for the algorithm. As the 
image analysis software measured area rather than register entities, the IHC staining 
intensity of positive cells was important. Although CD3 and CD8 staining of T-cells 
are similar, there are differences in staining intensity between the slides and from 
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patient to patient. Therefore, it is of great significance that the algorithm for digital 
image analysis is trained to recognize different staining intensities to make it more 
robust285. In our study, we used the Bayes classifier to ensure that the application of 
digital image analysis could handle different staining intensities. Since we 
programmed the applications ourselves, we could adjust the different applications 
until we found the results satisfying to perform digital image analysis. 
In Papers I and III, we used segmentation to distinguish the stroma from the 
epithelium and identify negative IHC-stained nuclei (Paper III). This process is often 
difficult in the presence of adjacent or overlapping cells, which can lead to under-
segmentation or over-segmentation285. There are several ways to adjust the 
application for digital image analysis to avoid these issues311. When developing 
algorithms for digital image analysis, it is often necessary to prioritise between 
sensitivity (how likely the algorithm is to capture a weakly stained nucleus or cell), 
specificity (how well the algorithm rejects artefacts) and contour accuracy (how well 
the algorithm can approximate the exact shape of the nucleus or cell)1.  
In all our papers, we used a software called Visiopharm® (Hoersholm, Denmark). 
This is licenced commercial software. The alternative would be an open-source 
software312. Options for adaptions and adjustments are often better in commercial 
software compared to open-source software1. The Visiopharm® (Hoersholm, 
Denmark) offers CE-IVD applications for use in the diagnostic workflow, which 
means that the programme is approved according to the requirements of the European 
Union for in vitro diagnostic medical devices313. We did not use these applications in 
diagnostics but programmed and adjusted the applications according to what we 
wanted to examine in our studies. To our knowledge, no CE-IVD applications are 
available for either scoring immune cells or measuring proliferation in NEN. There 
are, however, applications for CE-IVD Ki67 in breast cancer314.  
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6. Conclusion and future perspectives 
 
We developed a whole slide digital pathology template to quantify immune cells 
(Papers I and II) in CRC using imaging software. In Paper II, we established an 
immune score based on the distribution volumes of CD3 and CD8. We found that 
immune scores correlate with known clinicopathological parameters, such as MSI 
status and stage of the disease. In Paper I, we found an association between T-cells 
in the blood and T-cells in the tumour, but this association was not investigated 
further. Thus, there is a need for large-scale internal and external validation to 
demonstrate the robustness and adaptability of the immune score for clinical use in 
CRC. We initiated such validation with a follow-up study encompassing a larger 
cohort of ACROBATICC patients. We hope that this will provide further information 
about the predictive and prognostic value of the immune scores we developed. 
In Paper III, we successfully developed a digital image analysis for grading GEP-
NENs based on Ki67 IHC. The method can be integrated with routine diagnostics in 
pathology departments that are digital. However, because of the heterogeneity of the 
disease, it is difficult to obtain reliable data regarding disease-free survival and 
overall survival. Survival rates need to be further evaluated in subsequent studies to 
gain more information about this method’s predictive and prognostic value. PPH3 
needs to be further evaluated in a larger cohort to determine whether it can be of any 
predictive or prognostic value in GEP-NENs patients. It might be of prognostic value 
in subpopulations of GEP-NENs, such as NET grade 3 versus NEC grade 3 or large-
cell or small-cell NEC.  
With the implementation of digital pathology, there is a need for validation of both 
equipment and whole slide imaging, including methods for digital image analysis315, 
316, to ensure that the developed methods can be safely used at different laboratories. 
This requires both national and international collaboration. In Norway, the National 
Department of Health has appointed a national forum to address equipment issues. 
This forum will also establish guidelines for standardisation for handling 
tissue/surgical specimens, macroscopic examination and reporting of results317. It is 
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difficult to predict how this will be implemented and what the ramifications will be. 
Hopefully, it will enhance quality control and provide results based on more robust 
and comparable diagnostics across pathology departments. It would be interesting to 
perform a similar analysis for digital image analysis to what we conducted with open-
source software tools. It would be a great advantage if the method could be used in 
platforms available to pathology departments free of cost. We hope to evaluate 
immune score on other digital image analysis platforms in close collaboration with 
researchers within our network. 
 94
7. References 
1. Aeffner F, Zarella MD, Buchbinder N, et al. Introduction to Digital Image 
Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology 
Association. J Pathol Inform 2019; 10:9. 
2. Weinstein RS, Graham AR, Lian F, et al. Reconciliation of diverse 
telepathology system designs. Historic issues and implications for emerging 
markets and new applications. Apmis 2012; 120(4):256-75. 
3. Griffin J, Treanor D. Digital pathology in clinical use: where are we now and 
what is holding us back? Histopathology 2017; 70(1):134-145. 
4. Cheng CL, Azhar R, Sng SH, et al. Enabling digital pathology in the 
diagnostic setting: navigating through the implementation journey in an 
academic medical centre. J Clin Pathol 2016; 69(9):784-92. 
5. Stathonikos N, Veta M, Huisman A, et al. Going fully digital: Perspective of a 
Dutch academic pathology lab. J Pathol Inform 2013; 4:15. 
6. Webster JD, Dunstan RW. Whole-slide imaging and automated image 
analysis: considerations and opportunities in the practice of pathology. Vet 
Pathol 2014; 51(1):211-23. 
7. Diller RB, Kellar RS. Validating whole slide digital morphometric analysis as 
a microscopy tool. Microsc Microanal 2015; 21(1):249-55. 
8. Aeffner F, Wilson K, Bolon B, et al. Commentary: Roles for Pathologists in a 
High-throughput Image Analysis Team. Toxicol Pathol 2016; 44(6):825-34. 
9. Kumar N, Gupta R, Gupta S. Whole Slide Imaging (WSI) in Pathology: 
Current Perspectives and Future Directions. J Digit Imaging 2020; 33(4):1034-
1040. 
10. Wright AM, Smith D, Dhurandhar B, et al. Digital slide imaging in 
cervicovaginal cytology: a pilot study. Arch Pathol Lab Med 2013; 
137(5):618-24. 
11. Meijer GA, Beliën JA, van Diest PJ, et al. Origins of ... image analysis in 
clinical pathology. J Clin Pathol 1997; 50(5):365-70. 
12. Laurinavicius A, Laurinaviciene A, Dasevicius D, et al. Digital image analysis 
in pathology: benefits and obligation. Anal Cell Pathol (Amst) 2012; 35(2):75-
8. 
13. Gudlaugsson E, Skaland I, Janssen EA, et al. Comparison of the effect of 
different techniques for measurement of Ki67 proliferation on reproducibility 
and prognosis prediction accuracy in breast cancer. Histopathology 2012; 
61(6):1134-44. 
14. Reid MD, Bagci P, Ohike N, et al. Calculation of the Ki67 index in pancreatic 
neuroendocrine tumors: a comparative analysis of four counting 
methodologies. Mod Pathol 2015; 28(5):686-94. 
15. Tang LH, Gonen M, Hedvat C, et al. Objective quantification of the Ki67 
proliferative index in neuroendocrine tumors of the gastroenteropancreatic 
system: a comparison of digital image analysis with manual methods. Am J 
Surg Pathol 2012; 36(12):1761-70. 
16. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth 
Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical 
 95 
Oncology/College of American Pathologists Clinical Practice Guideline 
Focused Update. Arch Pathol Lab Med 2018; 142(11):1364-1382. 
17. Bui MM, Riben MW, Allison KH, et al. Quantitative Image Analysis of 
Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for 
Breast Cancer: Guideline From the College of American Pathologists. Arch 
Pathol Lab Med 2019; 143(10):1180-1195. 
18. Cui M, Zhang DY. Artificial intelligence and computational pathology. 
Laboratory Investigation 2021; 101(4):412-422. 
19. Bini SA. Artificial Intelligence, Machine Learning, Deep Learning, and 
Cognitive Computing: What Do These Terms Mean and How Will They 
Impact Health Care? J Arthroplasty 2018; 33(8):2358-2361. 
20. Komura D, Ishikawa S. Machine Learning Methods for Histopathological 
Image Analysis. Comput Struct Biotechnol J 2018; 16:34-42. 
21. Abels E, Pantanowitz L, Aeffner F, et al. Computational pathology definitions, 
best practices, and recommendations for regulatory guidance: a white paper 
from the Digital Pathology Association. J Pathol 2019; 249(3):286-294. 
22. Levine AB, Schlosser C, Grewal J, et al. Rise of the Machines: Advances in 
Deep Learning for Cancer Diagnosis. Trends Cancer 2019; 5(3):157-169. 
23. Skrede OJ, De Raedt S, Kleppe A, et al. Deep learning for prediction of 
colorectal cancer outcome: a discovery and validation study. Lancet 2020; 
395(10221):350-360. 
24. Korbar B, Olofson AM, Miraflor AP, et al. Deep Learning for Classification of 
Colorectal Polyps on Whole-slide Images. J Pathol Inform 2017; 8:30. 
25. Pagni F, Bono F, Di Bella C, et al. Virtual surgical pathology in 
underdeveloped countries: The Zambia Project. Arch Pathol Lab Med 2011; 
135(2):215-9. 
26. Hitchcock CL. The future of telepathology for the developing world. Arch 
Pathol Lab Med 2011; 135(2):211-4. 
27. Nordrum I, Engum B, Rinde E, et al. Remote frozen section service: a 
telepathology project in northern Norway. Hum Pathol 1991; 22(6):514-8. 
28. Graham AR, Bhattacharyya AK, Scott KM, et al. Virtual slide telepathology 
for an academic teaching hospital surgical pathology quality assurance 
program. Hum Pathol 2009; 40(8):1129-36. 
29. Chan HP, Samala RK, Hadjiiski LM, et al. Deep Learning in Medical Image 
Analysis. Adv Exp Med Biol 2020; 1213:3-21. 
30. Jara-Lazaro AR, Thamboo TP, Teh M, et al. Digital pathology: exploring its 
applications in diagnostic surgical pathology practice. Pathology 2010; 
42(6):512-8. 
31. Nakhleh RE, Idowu MO, Souers RJ, et al. Mislabeling of cases, specimens, 
blocks, and slides: a college of american pathologists study of 136 institutions. 
Arch Pathol Lab Med 2011; 135(8):969-74. 
32. Zarbo RJ, D'Angelo R. The Henry ford production system: effective reduction 
of process defects and waste in surgical pathology. Am J Clin Pathol 2007; 
128(6):1015-22. 
33. Nakhleh RE. Role of Informatics in Patient Safety and Quality Assurance. 
Surg Pathol Clin 2015; 8(2):301-7. 
 96
34. Williams BJ, DaCosta P, Goacher E, et al. A Systematic Analysis of 
Discordant Diagnoses in Digital Pathology Compared With Light Microscopy. 
Arch Pathol Lab Med 2017; 141(12):1712-1718. 
35. Lashen A, Ibrahim A, Katayama A, et al. Visual assessment of mitotic figures 
in breast cancer: a comparative study between light microscopy and whole 
slide images. Histopathology 2021. 
36. Tomić S, Mrklić I, Razumović JJ, et al. Inter-laboratory comparison of Ki-67 
proliferating index detected by visual assessment and automated digital image 
analysis. Breast Dis 2019; 38(2):73-79. 
37. Rawlins SR, El-Zammar O, Zinkievich JM, et al. Digital quantification is 
more precise than traditional semiquantitation of hepatic steatosis: correlation 
with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. Dig Dis 
Sci 2010; 55(7):2049-57. 
38. Jahn SW, Plass M, Moinfar F. Digital Pathology: Advantages, Limitations and 
Emerging Perspectives. Journal of Clinical Medicine 2020; 9(11):3697. 
39. Aeffner F, Wilson K, Martin NT, et al. The Gold Standard Paradox in Digital 
Image Analysis: Manual Versus Automated Scoring as Ground Truth. Arch 
Pathol Lab Med 2017; 141(9):1267-1275. 
40. Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast 
Reconstr Surg 2010; 126(2):619-625. 
41. Whiting P, Rutjes AW, Reitsma JB, et al. Sources of variation and bias in 
studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004; 
140(3):189-202. 
42. Conway C, Dobson L, O'Grady A, et al. Virtual microscopy as an enabler of 
automated/quantitative assessment of protein expression in TMAs. Histochem 
Cell Biol 2008; 130(3):447-63. 
43. Raffone A, Srinivasan N, van Leeuwen C. The interplay of attention and 
consciousness in visual search, attentional blink and working memory 
consolidation. Philos Trans R Soc Lond B Biol Sci 2014; 369(1641):20130215. 
44. Memmert D. The effects of eye movements, age, and expertise on inattentional 
blindness. Conscious Cogn 2006; 15(3):620-7. 
45. Potchen EJ. Measuring observer performance in chest radiology: some 
experiences. J Am Coll Radiol 2006; 3(6):423-32. 
46. Perales E, Martínez-Verdú FM, Linhares JM, et al. Number of discernible 
colors for color-deficient observers estimated from the MacAdam limits. J Opt 
Soc Am A Opt Image Sci Vis 2010; 27(10):2106-14. 
47. Kay EW, O'Dowd J, Thomas R, et al. Mild abnormalities in liver histology 
associated with chronic hepatitis: distinction from normal liver histology. J 
Clin Pathol 1997; 50(11):929-31. 
48. Thavarajah S, White WB, Mansoor GA. Terminal digit bias in a specialty 
hypertension faculty practice. J Hum Hypertens 2003; 17(12):819-22. 
49. Wen SW, Kramer MS, Hoey J, et al. Terminal digit preference, random error, 
and bias in routine clinical measurement of blood pressure. J Clin Epidemiol 
1993; 46(10):1187-93. 
 97 
50. Berbaum KS, Schartz KM, Caldwell RT, et al. Satisfaction of search from 
detection of pulmonary nodules in computed tomography of the chest. Acad 
Radiol 2013; 20(2):194-201. 
51. Nickerson RS. Confirmation Bias: A Ubiquitous Phenomenon in Many 
Guises. Review of General Psychology 1998; 2(2):175-220. 
52. Witt JK. Awareness Is Not a Necessary Characteristic of a Perceptual Effect: 
Commentary on Firestone (2013). Perspect Psychol Sci 2015; 10(6):865-72. 
53. Cancer 2018, 12. September. Available at: https://www.who.int/news-
room/fact-sheets/detail/cancer.  
54. Cancer in Norway 2020. Cancer Registry of Norway, Institute of Population-
based Cancer Research 2021. 
55. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 
1(2):157-62. 
56. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358(5):502-11. 
57. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and 
clinical perspective. Seminars in reproductive medicine 2009; 27(5):351-357. 
58. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in 
human cancer genomes. Nature 2007; 446(7132):153-8. 
59. Sun W, Yang J. Functional mechanisms for human tumor suppressors. J 
Cancer 2010; 1:136-40. 
60. Wang LH, Wu CF, Rajasekaran N, et al. Loss of Tumor Suppressor Gene 
Function in Human Cancer: An Overview. Cell Physiol Biochem 2018; 
51(6):2647-2693. 
61. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70. 
62. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
2011; 144(5):646-74. 
63. Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape 
Immune Destruction and Mechanisms of Action for the New Significantly 
Active Immune Therapies: Helping Nonimmunologists Decipher Recent 
Advances. Oncologist 2016; 21(2):233-43. 
64. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. 
Carcinogenesis 2010; 31(1):9-18. 
65. Gunter MJ, Alhomoud S, Arnold M, et al. Meeting report from the joint 
IARC-NCI international cancer seminar series: a focus on colorectal cancer. 
Ann Oncol 2019; 30(4):510-519. 
66. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers 
in 185 countries. CA Cancer J Clin 2018; 68(6):394-424. 
67. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 
2020; 70(4):313. 
68. Nedrebø BS, Søreide K, Eriksen MT, et al. Survival effect of implementing 
national treatment strategies for curatively resected colonic and rectal cancer. 
Br J Surg 2011; 98(5):716-23. 
69. The global, regional, and national burden of colorectal cancer and its 
attributable risk factors in 195 countries and territories, 1990-2017: a 
 98
systematic analysis for the Global Burden of Disease Study 2017. Lancet 
Gastroenterol Hepatol 2019; 4(12):913-933. 
70. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J 
Cancer 2015; 136(5):E359-86. 








ent=0&rotate=%255B10%252C0%255D. Accessed 2021, 5. February.  
72. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in 
colorectal cancer incidence and mortality. Gut 2017; 66(4):683-691. 
73. Kingham TP, Alatise OI, Vanderpuye V, et al. Treatment of cancer in sub-
Saharan Africa. Lancet Oncol 2013; 14(4):e158-67. 
74. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a 
global overview of existing programmes. Gut 2015; 64(10):1637-49. 
75. Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and 
stage distribution in European countries in the colorectal cancer screening era: 
an international population-based study. Lancet Oncol 2021. 
76. Kreftregisteret. Tarmscreening blir tilbud til alle 55- åringer. Available at: 
https://kreftforeningen.no/forebygging/screening-og-
masseundersokelser/tarmscreeningprogrammet/. Accessed 18. September, 
2021.  
77. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet 2019; 
394(10207):1467-1480. 
78. Schoen RE, Razzak A, Yu KJ, et al. Incidence and mortality of colorectal 
cancer in individuals with a family history of colorectal cancer. 
Gastroenterology 2015; 149(6):1438-1445.e1. 
79. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing 
and management of hereditary gastrointestinal cancer syndromes. Am J 
Gastroenterol 2015; 110(2):223-62; quiz 263. 
80. Lung MS, Trainer AH, Campbell I, et al. Familial colorectal cancer. Intern 
Med J 2015; 45(5):482-91. 
81. Baglietto L, Jenkins MA, Severi G, et al. Measures of familial aggregation 
depend on definition of family history: meta-analysis for colorectal cancer. J 
Clin Epidemiol 2006; 59(2):114-24. 
82. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during 
colorectal-tumor development. N Engl J Med 1988; 319(9):525-32. 
83. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 
1990; 61(5):759-67. 
 99 
84. Robles AI, Traverso G, Zhang M, et al. Whole-Exome Sequencing Analyses 
of Inflammatory Bowel Disease−Associated Colorectal Cancers. 
Gastroenterology 2016; 150(4):931-943. 
85. Richard GF, Kerrest A, Dujon B. Comparative genomics and molecular 
dynamics of DNA repeats in eukaryotes. Microbiol Mol Biol Rev 2008; 
72(4):686-727. 
86. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable 
evidence. Nat Rev Clin Oncol 2010; 7(3):153-62. 
87. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the 
human genome. Nature 2001; 409(6822):860-921. 
88. Brinkmann B, Klintschar M, Neuhuber F, et al. Mutation rate in human 
microsatellites: influence of the structure and length of the tandem repeat. Am 
J Hum Genet 1998; 62(6):1408-15. 
89. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of 
familial colorectal cancer. Science 1993; 260(5109):812-6. 
90. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the 
proximal colon. Science 1993; 260(5109):816-9. 
91. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in 
simple repeated sequences reveal a new mechanism for colonic 
carcinogenesis. Nature 1993; 363(6429):558-61. 
92. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome 
(hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 
352(18):1851-60. 
93. Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as 
a marker of prognosis and response to therapy: a meta-analysis of colorectal 
cancer survival data. Eur J Cancer 2010; 46(15):2788-98. 
94. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary 
nonpolyposis colorectal cancer and the feasibility of molecular screening for 
the disease. N Engl J Med 1998; 338(21):1481-7. 
95. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection 
of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18(11):2193-
200. 
96. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute 
Workshop on Microsatellite Instability for cancer detection and familial 
predisposition: development of international criteria for the determination of 
microsatellite instability in colorectal cancer. Cancer Res 1998; 58(22):5248-
57. 
97. Leach FS, Polyak K, Burrell M, et al. Expression of the human mismatch 
repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 1996; 
56(2):235-40. 
98. Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry 
and microsatellite instability testing of colorectal tumors for Lynch syndrome 
among US cancer programs and follow-up of abnormal results. J Clin Oncol 
2012; 30(10):1058-63. 
99. Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on 
microsatellite instability testing for immunotherapy in cancer, and its 
 100
relationship with PD-1/PD-L1 expression and tumour mutational burden: a 
systematic review-based approach. Ann Oncol 2019; 30(8):1232-1243. 
100. Loughrey MB, McGrath J, Coleman HG, et al. Identifying mismatch repair-
deficient colon cancer: near-perfect concordance between 
immunohistochemistry and microsatellite instability testing in a large, 
population-based series. Histopathology 2021; 78(3):401-413. 
101. McCarthy AJ, Capo-Chichi JM, Spence T, et al. Heterogenous loss of 
mismatch repair (MMR) protein expression: a challenge for 
immunohistochemical interpretation and microsatellite instability (MSI) 
evaluation. J Pathol Clin Res 2019; 5(2):115-129. 
102. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og 




103. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical 
management of Lynch syndrome (HNPCC): recommendations by a group of 
European experts. Gut 2013; 62(6):812-23. 
104. Watson MM, Berg M, Soreide K. Prevalence and implications of elevated 
microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer 
2014; 111(5):823-7. 
105. Koi M, Tseng-Rogenski SS, Carethers JM. Inflammation-associated 
microsatellite alterations: Mechanisms and significance in the prognosis of 
patients with colorectal cancer. World Journal of Gastrointestinal Oncology 
2018; 10(1):1-14. 
106. Watson MM, Kanani A, Lea D, et al. Elevated Microsatellite Alterations at 
Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with 
an Elderly, Frail Phenotype and Improved Recurrence-Free Survival. Ann Surg 
Oncol 2020; 27(4):1058-1067. 
107. Hazewinkel Y, Dekker E. Colonoscopy: basic principles and novel techniques. 
Nature Reviews Gastroenterology & Hepatology 2011; 8(10):554-564. 
108. Becerra AZ, Probst CP, Tejani MA, et al. Evaluating the Prognostic Role of 
Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer 
Patients: Results from the National Cancer Database. Ann Surg Oncol 2016; 
23(5):1554-61. 
109. Körner H, Söreide K, Stokkeland PJ, et al. Diagnostic Accuracy of Serum-
Carcinoembryonic Antigen in Recurrent Colorectal Cancer: A Receiver 
Operating Characteristic Curve Analysis. Annals of Surgical Oncology 2007; 
14(2):417-423. 
110. AJCC Cancer Staging Manual. 8 ed. Cham, Switzerland: Springer 
International Publishing AG, 2017. 
111. Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol 2018; 
25(6):1454-1455. 
112. WHO Classification of Tumours, Digestive System Tumours. 5 ed. Vol. 1: 
IARC Publications, 2019. 
 101 
113. Cho SJ, Kakar S. Tumor Budding in Colorectal Carcinoma: Translating a 
Morphologic Score Into Clinically Meaningful Results. Arch Pathol Lab Med 
2018; 142(8):952-957. 
114. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor 
budding in colorectal cancer based on the International Tumor Budding 
Consensus Conference (ITBCC) 2016. Mod Pathol 2017; 30(9):1299-1311. 
115. Williams ST, Beart RW, Jr. Staging of colorectal cancer. Semin Surg Oncol 
1992; 8(2):89-93. 
116. Hashiguchi Y, Hase K, Kotake K, et al. Evaluation of the seventh edition of 
the tumour, node, metastasis (TNM) classification for colon cancer in two 
nationwide registries of the United States and Japan. Colorectal Dis 2012; 
14(9):1065-74. 
117. Lea D, Haland S, Hagland HR, et al. Accuracy of TNM staging in colorectal 
cancer: a review of current culprits, the modern role of morphology and 
stepping-stones for improvements in the molecular era. Scand J Gastroenterol 
2014; 49(10):1153-63. 
118. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial 
growth factor can predict event-free survival in stage II colon cancer. Clin 
Cancer Res 2000; 6(7):2803-7. 
119. Auclin E, Zaanan A, Vernerey D, et al. Subgroups and prognostication in stage 
III colon cancer: future perspectives for adjuvant therapy. Ann Oncol 2017; 
28(5):958-968. 
120. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for 
colorectal cancer improved care? Nat Rev Clin Oncol 2012; 9(2):119-23. 
121. Puppa G, Sonzogni A, Colombari R, et al. TNM staging system of colorectal 
carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 
2010; 134(6):837-52. 
122. Lin Y, Chappell R, Gonen M. A systematic selection method for the 
development of cancer staging systems. Stat Methods Med Res 2013. 
123. Nagtegaal ID, Tot T, Jayne DG, et al. Lymph nodes, tumor deposits, and 
TNM: are we getting better? J Clin Oncol 2011; 29(18):2487-92. 
124. Lan YT, Yang SH, Chang SC, et al. Analysis of the seventh edition of 
American Joint Committee on colon cancer staging. Int J Colorectal Dis 2012; 
27(5):657-63. 
125. Quirke P, Cuvelier C, Ensari A, et al. Evidence-based medicine: the time has 
come to set standards for staging. J Pathol 2010; 221(4):357-60. 
126. Ueno H, Mochizuki H, Akagi Y, et al. Optimal colorectal cancer staging 
criteria in TNM classification. J Clin Oncol 2012; 30(13):1519-26. 
127. Bosetti C, Levi F, Rosato V, et al. Recent trends in colorectal cancer mortality 
in Europe. Int J Cancer 2011; 129(1):180-91. 
128. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the 
status of cancer, 1975-2006, featuring colorectal cancer trends and impact of 
interventions (risk factors, screening, and treatment) to reduce future rates. 
Cancer 2010; 116(3):544-73. 
129. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental 
disorders and cancer. Nat Rev Cancer 2007; 7(4):295-308. 
 102
130. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment 
and RAS mutations in colorectal cancer. N Engl J Med 2013; 369(11):1023-
34. 
131. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab 
versus FOLFIRI plus bevacizumab as first-line treatment of patients with 
metastatic colorectal cancer: updated overall survival and molecular subgroup 
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 
16(13):1306-15. 
132. Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, 
NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled 
analysis of five randomized trials in metastatic colorectal cancer by the AIO 
colorectal cancer study group. Ann Oncol 2016; 27(9):1746-53. 
133. Hu Y, Tao SY, Deng JM, et al. Prognostic Value of NRAS Gene for Survival 
of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Asian 
Pac J Cancer Prev 2018; 19(11):3001-3008. 
134. Ducreux M, Chamseddine A, Laurent-Puig P, et al. Molecular targeted therapy 
of BRAF-mutant colorectal cancer. Ther Adv Med Oncol 2019; 
11:1758835919856494. 
135. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-
Repair Deficiency. N Engl J Med 2015; 372(26):2509-20. 
136. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite 
instability and colorectal cancer prognosis. J Clin Oncol 2005; 23(3):609-18. 
137. Dudley JC, Lin MT, Le DT, et al. Microsatellite Instability as a Biomarker for 
PD-1 Blockade. Clin Cancer Res 2016; 22(4):813-20. 
138. Kim CG, Ahn JB, Jung M, et al. Effects of microsatellite instability on 
recurrence patterns and outcomes in colorectal cancers. Br J Cancer 2016; 
115(1):25-33. 
139. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in 
vitro response to 5-fluorouracil. Gastroenterology 1999; 117(1):123-31. 
140. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of 
high-degree microsatellite instability in colon cancer: a National Cancer 
Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative 
Study. J Clin Oncol 2007; 25(7):767-72. 
141. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in 
sporadic colorectal cancer with methylated hMLH1, but not in hereditary 
nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10(1 Pt 1):191-5. 
142. Aasebø K, Dragomir A, Sundström M, et al. Consequences of a high incidence 
of microsatellite instability and BRAF-mutated tumors: A population-based 
cohort of metastatic colorectal cancer patients. Cancer Med 2019; 8(7):3623-
3635. 
143. Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/ PD-L1 blockade as a novel 
treatment for colorectal cancer. Biomed Pharmacother 2019; 110:312-318. 
144. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With 
Nivolumab Plus Ipilimumab in DNA Mismatch Repair-
Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin 
Oncol 2018; 36(8):773-779. 
 103 
145. Boyar Cetinkaya R, Aagnes B, Myklebust T, et al. Survival in neuroendocrine 
neoplasms; A report from a large Norwegian population-based study. Int J 
Cancer 2018; 142(6):1139-1147. 
146. Schimmack S, Svejda B, Lawrence B, et al. The diversity and commonalities 
of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 
2011; 396(3):273-98. 
147. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and 
treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 
2011; 61(2):113-32. 
148. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA 
Cancer J Clin 2018; 68(6):471-487. 
149. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and 
Survival Outcomes in Patients With Neuroendocrine Tumors in the United 
States. JAMA Oncol 2017; 3(10):1335-1342. 
150. Boyar Cetinkaya R, Aagnes B, Myklebust TA, et al. Survival in 
neuroendocrine neoplasms; A report from a large Norwegian population-based 
study. Int J Cancer 2018; 142(6):1139-1147. 
151. Zhong Q, Chen QY, Xie JW, et al. Incidence trend and conditional survival 
estimates of gastroenteropancreatic neuroendocrine tumors: A large 
population-based study. Cancer Med 2018. 
152. Merola E, Rinzivillo M, Cicchese N, et al. Digestive neuroendocrine 
neoplasms: A 2016 overview. Dig Liver Dis 2016. 
153. Sandvik OM, Søreide K, Gudlaugsson E, et al. Epidemiology and 
classification of gastroenteropancreatic neuroendocrine neoplasms using 
current coding criteria. Br J Surg 2016; 103(3):226-32. 
154. Lee MR, Harris C, Baeg KJ, et al. Incidence Trends of Gastroenteropancreatic 
Neuroendocrine Tumors in the United States. Clin Gastroenterol Hepatol 
2019; 17(11):2212-2217 e1. 
155. Janson ET, Sørbye H, Welin S, et al. Nordic Guidelines 2010 for diagnosis 
and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 
2010; 49(6):740-56. 
156. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid 
tumors. Cancer 2003; 97(4):934-59. 
157. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of 
carcinoid tumors. Ann Surg 2004; 240(1):117-22. 
158. Zheng Z, Chen C, Jiang L, et al. Incidence and risk factors of gastrointestinal 
neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A 
population-based study. Cancer Med 2019; 8(17):7288-7298. 
159. Cai W, Tan Y, Ge W, et al. Pattern and risk factors for distant metastases in 
gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer 
Med 2018; 7(6):2699-2709. 
160. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine 
tumours. Lancet Oncol 2008; 9(1):61-72. 
161. Kidambi TD, Pedley C, Blanco A, et al. Lower gastrointestinal neuroendocrine 
neoplasms associated with hereditary cancer syndromes: a case series. Fam 
Cancer 2017; 16(4):537-543. 
 104
162. Lewis MA. Hereditary Syndromes in Neuroendocrine Tumors. Curr Treat 
Options Oncol 2020; 21(6):50. 
163. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and 
perspectives of carcinoid tumors. Hum Pathol 2004; 35(12):1440-51. 
164. Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr 
Gastroenterol Rep 2019; 21(4):13. 
165. Vortmeyer AO, Huang S, Lubensky I, et al. Non-islet origin of pancreatic islet 
cell tumors. J Clin Endocrinol Metab 2004; 89(4):1934-8. 
166. Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic 
neuroendocrine tumours. Nature 2017; 543(7643):65-71. 
167. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway 
genes are frequently altered in pancreatic neuroendocrine tumors. Science 
2011; 331(6021):1199-203. 
168. Oberg K, Casanovas O, Castaño JP, et al. Molecular pathogenesis of 
neuroendocrine tumors: implications for current and future therapeutic 
approaches. Clin Cancer Res 2013; 19(11):2842-9. 
169. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression 
profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 
28(2):245-55. 
170. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial 
growth factor in digestive neuroendocrine tumours. Histopathology 1998; 
32(2):133-8. 
171. Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine 
tumors: updated progression-free survival and final overall survival from a 
phase III randomized study. Annals of Oncology 2017; 28(2):339-343. 
172. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib Malate for the Treatment of 
Pancreatic Neuroendocrine Tumors. New England Journal of Medicine 2011; 
364(6):501-513. 
173. Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, 
Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020; 
2020:8341426. 
174. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns 
of care and prognostic factors for outcome of gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs): results from the National Cancer 
Registry of Spain (RGETNE). Ann Oncol 2010; 21(9):1794-1803. 
175. Janson ET, Knigge U, Dam G, et al. Nordic guidelines 2021 for diagnosis and 
treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 
2021:1-11. 
176. Papantoniou D, Grönberg M, Landerholm K, et al. Assessment of hormonal 
levels as prognostic markers and of their optimal cut-offs in small intestinal 
neuroendocrine tumours grade 2. Endocrine 2021; 72(3):893-904. 
177. Jensen KH, Hilsted L, Jensen C, et al. Chromogranin A is a sensitive marker 
of progression or regression in ileo-cecal neuroendocrine tumors. Scand J 
Gastroenterol 2013; 48(1):70-7. 
178. Pollard J, McNeely P, Menda Y. Nuclear Imaging of Neuroendocrine Tumors. 
Surg Oncol Clin N Am 2020; 29(2):209-221. 
 105 
179. Putzer D, Schullian P, Jaschke W, et al. NEN: Advancement in Diagnosis and 
Minimally Invasive Therapy. Rofo 2020; 192(5):422-430. 
180. Mohamed A, Strosberg JR. Medical Management of Gastroenteropancreatic 
Neuroendocrine Tumors: Current Strategies and Future Advances. J Nucl Med 
2019; 60(6):721-727. 
181. Hu Y, Ye Z, Wang F, et al. Role of Somatostatin Receptor in Pancreatic 
Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front 
Endocrinol (Lausanne) 2021; 12:679000. 
182. Patel N, Barbieri A, Gibson J. Neuroendocrine Tumors of the Gastrointestinal 
Tract and Pancreas. Surg Pathol Clin 2019; 12(4):1021-1044. 
183. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. 
Best Pract Res Clin Endocrinol Metab 2007; 21(1):15-31. 
184. Saeger W, Schnabel PA, Komminoth P. [Grading of neuroendocrine tumors]. 
Pathologe 2016; 37(4):304-13. 
185. Pathology and Genetics of Tumours of the Digestive System 3ed. Vol. 2: 
IARC Publications, 2000. 
186. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut 
(neuro)endocrine tumors: a consensus proposal including a grading system. 
Virchows Arch 2006; 449(4):395-401. 
187. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of 
tumours of the digestive system. Histopathology 2020; 76(2):182-188. 
188. McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated 
pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 
proliferative index and mitotic rate. Am J Surg Pathol 2013; 37(11):1671-7. 
189. Elvebakken H, Perren A, Scoazec JY, et al. A consensus developed 
morphological re-evaluation of 196 high-grade gastroenteropancreatic 
neuroendocrine neoplasms and its clinical correlations. Neuroendocrinology 
2020. 
190. Tang LH, Basturk O, Sue JJ, et al. A Practical Approach to the Classification 
of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) 
and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the 
Pancreas. Am J Surg Pathol 2016; 40(9):1192-202. 
191. Skaland I, Janssen EA, Gudlaugsson E, et al. Validating the prognostic value 
of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph 
node-negative breast cancer patients less than 71 years of age. Breast Cancer 
Res Treat 2009; 114(1):39-45. 
192. Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in 
gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 2018; 
472(3):341-349. 
193. Guadagno E, D'Avella E, Cappabianca P, et al. Ki67 in endocrine neoplasms: 
to count or not to count, this is the question! A systematic review from the 
English language literature. J Endocrinol Invest 2020; 43(10):1429-1445. 
194. Sorbye H, Baudin E, Perren A. The Problem of High-Grade 
Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated 
Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. 
Endocrinol Metab Clin North Am 2018; 47(3):683-698. 
 106
195. Blank A, Wehweck L, Marinoni I, et al. Interlaboratory variability of MIB1 
staining in well-differentiated pancreatic neuroendocrine tumors. Virchows 
Arch 2015; 467(5):543-50. 
196. NordiCQ 2021. Available at: https://www.nordiqc.org/index.php. Accessed 
22. June, 2021.  
197. Søreide JA, Kvaløy JT, Lea D, et al. The overriding role of surgery and tumor 
grade for long-term survival in patients with gastroenteropancreatic 
neuroendocrine neoplasms: A population-based cohort study. Cancer Rep 
(Hoboken) 2021:e1462. 
198. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in 
endocrine tumor patients: comparison between gastrointestinal and pancreatic 
localization. Endocr Relat Cancer 2005; 12(4):1083-92. 
199. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut 
(neuro) endocrine tumors: a consensus proposal including a grading system. 
Virchows Arch 2007; 451(4):757-62. 
200. Frilling A, Åkerström G, Falconi M, et al. Neuroendocrine tumor disease: an 
evolving landscape. Endocr Relat Cancer 2012; 19(5):R163-85. 
201. Sakin A, Tambas M, Secmeler S, et al. Factors Affecting Survival in 
Neuroendocrine Tumors: A 15-Year Single Center Experience. Asian Pac J 
Cancer Prev 2018; 19(12):3597-3603. 
202. Zhai H, Li D, Feng Q, et al. Pancreatic neuroendocrine tumours: Grade is 
superior to T, N, or M status in predicting outcome and selecting patients for 
chemotherapy:A retrospective cohort study in the SEER database. Int J Surg 
2019; 66:103-109. 
203. Coriat R, Walter T, Terris B, et al. Gastroenteropancreatic Well-Differentiated 
Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 
2016; 21(10):1191-1199. 
204. Fuksiewicz M, Kowalska M, Kolasińska-Ćwikła A, et al. Prognostic value of 
chromogranin A in patients with GET/NEN in the pancreas and the small 
intestine. Endocr Connect 2018; 7(6):803-810. 
205. Marotta V, Zatelli MC, Sciammarella C, et al. Chromogranin A as circulating 
marker for diagnosis and management of neuroendocrine neoplasms: more 
flaws than fame. Endocr Relat Cancer 2018; 25(1):R11-r29. 
206. Ali AS, Langer SW, Federspiel B, et al. PD-L1 expression in 
gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS One 2020; 
15(12):e0243900. 
207. Shao C, Li G, Huang L, et al. Prevalence of High Tumor Mutational Burden 
and Association With Survival in Patients With Less Common Solid Tumors. 
JAMA Netw Open 2020; 3(10):e2025109. 
208. Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a 
multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 
2020; 65(1):18-29. 
209. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 
2001; 357(9255):539-45. 
 107 
210. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh 
hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 
30(7):1073-81. 
211. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel 
potentials. Int J Cancer 2007; 121(11):2373-80. 
212. de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to 
infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020; 
8(2):e180-e190. 
213. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. 
A population-based study. N Engl J Med 1990; 323(18):1228-33. 
214. Gulumian M. The role of oxidative stress in diseases caused by mineral dusts 
and fibres: current status and future of prophylaxis and treatment. Mol Cell 
Biochem 1999; 196(1-2):69-77. 
215. Miller JF. Immunological function of the thymus. Lancet 1961; 2(7205):748-9. 
216. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 
2015; 348(6230):56-61. 
217. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. 
Blood 2008; 112(5):1570-80. 
218. Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-
tumor immunity. Cell Mol Immunol 2017; 14(8):662-674. 
219. Bonam SR, Partidos CD, Halmuthur SKM, et al. An Overview of Novel 
Adjuvants Designed for Improving Vaccine Efficacy. Trends Pharmacol Sci 
2017; 38(9):771-793. 
220. Foster DS, Jones RE, Ransom RC, et al. The evolving relationship of wound 
healing and tumor stroma. JCI Insight 2018; 3(18). 
221. Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates 
Cancer Progression. Cancer Res 2019; 79(18):4557-4566. 
222. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune 
system during cancer development. Nat Rev Cancer 2006; 6(1):24-37. 
223. Di Caro G, Bergomas F, Grizzi F, et al. Occurrence of tertiary lymphoid tissue 
is associated with T-cell infiltration and predicts better prognosis in early-stage 
colorectal cancers. Clin Cancer Res 2014; 20(8):2147-58. 
224. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory 
response in predicting recurrence and survival in patients with primary 
operable colorectal cancer. Cancer treatment reviews 2012; 38(5):451-66. 
225. Curtis NJ, Primrose JN, Thomas GJ, et al. The adaptive immune response to 
colorectal cancer: from the laboratory to clinical practice. European journal of 
surgical oncology : the journal of the European Society of Surgical Oncology 
and the British Association of Surgical Oncology 2012; 38(10):889-96. 
226. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of 
immune cells within human colorectal tumors predict clinical outcome. 
Science 2006; 313(5795):1960-4. 
227. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic 
factors of colorectal cancers are associated with the state of the local immune 
reaction. J Clin Oncol 2011; 29(6):610-8. 
 108
228. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 
2008; 454(7203):436-44. 
229. Chaput N, Svrcek M, Auperin A, et al. Tumour-infiltrating CD68+ and CD57+ 
cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer 
2013; 109(4):1013-22. 
230. Shia J, Ellis NA, Paty PB, et al. Value of histopathology in predicting 
microsatellite instability in hereditary nonpolyposis colorectal cancer and 
sporadic colorectal cancer. Am J Surg Pathol 2003; 27(11):1407-17. 
231. Lichtenstern CR, Ngu RK, Shalapour S, et al. Immunotherapy, Inflammation 
and Colorectal Cancer. Cells 2020; 9(3):618. 
232. Couzin-Frankel J. Cancer Immunotherapy. Science 2013; 342(6165):1432-
1433. 
233. Zugazagoitia J, Guedes C, Ponce S, et al. Current Challenges in Cancer 
Treatment. Clin Ther 2016; 38(7):1551-66. 
234. Franke AJ, Skelton WP, Starr JS, et al. Immunotherapy for Colorectal Cancer: 
A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst 
2019; 111(11):1131-1141. 
235. André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-
Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 
383(23):2207-2218. 
236. Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of 
the immunoscore in patients with rectal cancer. Clin Cancer Res 2014; 
20(7):1891-9. 
237. Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus 
Immunoscore for the classification of colon cancer: a prognostic and accuracy 
study. Lancet 2018; 391(10135):2128-2139. 
238. Galon J, Franck P, Marincola FM, et al. Cancer classification using the 
Immunoscore: a worldwide task force. Journal of translational medicine 2012; 
10(1):205. 
239. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells 
predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 
2009; 27(35):5944-51. 
240. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 
'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 
232(2):199-209. 
241. Selvi I, Demirci U, Bozdogan N, et al. The prognostic effect of immunoscore 
in patients with clear cell renal cell carcinoma: preliminary results. Int Urol 
Nephrol 2020; 52(1):21-34. 
242. Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool 
for hepatocellular carcinoma. J Immunother Cancer 2016; 4:71. 
243. Kirilovsky A, Marliot F, El Sissy C, et al. Rational bases for the use of the 
Immunoscore in routine clinical settings as a prognostic and predictive 
biomarker in cancer patients. Int Immunol 2016; 28(8):373-82. 
244. Sclafani RA, Holzen TM. Cell cycle regulation of DNA replication. Annu Rev 
Genet 2007; 41:237-80. 
 109 
245. Mercadante AA, Kasi A. Genetics, Cancer Cell Cycle Phases.  StatPearls. 
Treasure Island (FL): StatPearls Publishing LLC. Copyright © 2021.; 2021. 
246. Menon SS, Guruvayoorappan C, Sakthivel KM, et al. Ki-67 protein as a 
tumour proliferation marker. Clin Chim Acta 2019; 491:39-45. 
247. Sobecki M, Mrouj K, Colinge J, et al. Cell-Cycle Regulation Accounts for 
Variability in Ki-67 Expression Levels. Cancer Res 2017; 77(10):2722-2734. 
248. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma 
2018; 127(2):175-186. 
249. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine 
neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol 2020; 31(7):844-860. 
250. Raap M, Ließem S, Rüschoff J, et al. Quality assurance trials for Ki67 
assessment in pathology. Virchows Arch 2017; 471(4):501-508. 
251. Polley MY, Leung SC, McShane LM, et al. An international Ki67 
reproducibility study. J Natl Cancer Inst 2013; 105(24):1897-906. 
252. Tracht J, Zhang K, Peker D. Grading and Prognostication of Neuroendocrine 
Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3. J 
Histochem Cytochem 2017; 65(7):399-405. 
253. Chan DL, Clarke SJ, Diakos CI, et al. Prognostic and predictive biomarkers in 
neuroendocrine tumours. Crit Rev Oncol Hematol 2017; 113:268-282. 
254. Lee LH, Yang H, Bigras G. Current breast cancer proliferative markers 
correlate variably based on decoupled duration of cell cycle phases. Sci Rep 
2014; 4:5122. 
255. Kim JY, Jeong HS, Chung T, et al. The value of phosphohistone H3 as a 
proliferation marker for evaluating invasive breast cancers: A comparative 
study with Ki67. Oncotarget 2017; 8(39):65064-65076. 
256. Villani V, Mahadevan KK, Ligorio M, et al. Phosphorylated Histone H3 
(PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic 
Neuroendocrine Tumors. Ann Surg Oncol 2016; 23(Suppl 5):609-617. 
257. Ozturk Sari S, Taskin OC, Gundogdu G, et al. The Impact of Phosphohistone-
H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor 
Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic 
Neuroendocrine Tumors. Endocr Pathol 2016; 27(2):162-70. 
258. Sun A, Zhou W, Lunceford J, et al. Level of phosphohistone H3 among 
various types of human cancers. BMJ Open 2012; 2(5). 
259. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 labelling for 
histoprognostic grading of breast adenocarcinomas and computer-assisted 
determination of mitotic index. J Clin Pathol 2006; 59(7):706-10. 
260. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody 
anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of 
meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004; 
28(11):1532-6. 
261. Soreide K, Watson MM, Lea D, et al. Assessment of clinically related 
outcomes and biomarker analysis for translational integration in colorectal 
cancer (ACROBATICC): study protocol for a population-based, consecutive 
 110
cohort of surgically treated colorectal cancers and resected colorectal liver 
metastasis. J Transl Med 2016; 14(1):192. 
262. Åkerström G, Falconi M, Kianmanesh R, et al. ENETS Consensus Guidelines 
for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative 
therapy in patients with neuroendocrine tumors. Neuroendocrinology 2009; 
90(2):203-8. 
263. Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for 
the Standards of Care in Neuroendocrine Tumors: radiological examinations. 
Neuroendocrinology 2009; 90(2):167-83. 
264. Collaborative. Neuroendokrine tumorer. En veiledning til diagnostikk og 
behandling(in Norwegian). Norwegian Neuroendocrine Tumor Group – 2003. 
265. Elm Ev, Altman DG, Egger M, et al. Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: guidelines for 
reporting observational studies. BMJ (Clinical research ed.) 2007; 
335(7624):806–808. 
266. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations 
for tumour MARKer prognostic studies (REMARK). British journal of cancer 
2005; 93(4):387-391. 
267. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: guidelines for 
reporting observational studies. Bmj 2007; 335(7624):806-8. 
268. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: guidelines for 
reporting observational studies. J Clin Epidemiol 2008; 61(4):344-9. 
269. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations 
for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 
93(4):387-91. 
270. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled 
disagreement or partial credit. Psychol Bull 1968; 70(4):213-20. 
271. Lowry R. Kappa as a Measure of Concordance in Categorical Sorting 2021. 
Available at: http://vassarstats.net/kappa.html. Accessed 18. September, 2021.  
272. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass 
Correlation Coefficients for Reliability Research. J Chiropr Med 2016; 
15(2):155-63. 
273. Bland JM, Altman DG. Comparing methods of measurement: why plotting 
difference against standard method is misleading. Lancet 1995; 
346(8982):1085-7. 
274. Adan A, Alizada G, Kiraz Y, et al. Flow cytometry: basic principles and 
applications. Crit Rev Biotechnol 2017; 37(2):163-176. 
275. Wilkerson MJ. Principles and applications of flow cytometry and cell sorting 
in companion animal medicine. Vet Clin North Am Small Anim Pract 2012; 
42(1):53-71. 
276. Hagland HR, Lea D, Watson MM, et al. Correlation of Blood T-Cells to 
Intratumoural Density and Location of CD3(+) and CD8(+) T-Cells in 
Colorectal Cancer. Anticancer Res 2017; 37(2):675-683. 
 111 
277. Decorte R, Cassiman JJ. Forensic medicine and the polymerase chain reaction 
technique. J Med Genet 1993; 30(8):625-33. 
278. Templeton NS. The polymerase chain reaction. History, methods, and 
applications. Diagn Mol Pathol 1992; 1(1):58-72. 
279. Green MR, Sambrook J. Polymerase Chain Reaction. Cold Spring Harb 
Protoc 2019; 2019(6). 
280. Arya M, Shergill IS, Williamson M, et al. Basic principles of real-time 
quantitative PCR. Expert Review of Molecular Diagnostics 2005; 5(2):209-
219. 
281. Prichard JW. Overview of automated immunohistochemistry. Arch Pathol Lab 
Med 2014; 138(12):1578-82. 
282. Leong AS, Leong TY. Standardization in immunohistology. Methods Mol Biol 
2011; 724:37-68. 
283. Zlobec I, Steele R, Michel RP, et al. Scoring of p53, VEGF, Bcl-2 and APAF-
1 immunohistochemistry and interobserver reliability in colorectal cancer. 
Modern Pathology 2006; 19(9):1236-1242. 
284. True LD. Methodological requirements for valid tissue-based biomarker 
studies that can be used in clinical practice. Virchows Arch 2014; 464(3):257-
63. 
285. Irshad H, Veillard A, Roux L, et al. Methods for nuclei detection, 
segmentation, and classification in digital histopathology: a review-current 
status and future potential. IEEE Rev Biomed Eng 2014; 7:97-114. 
286. Sertel O, Catalyurek UV, Shimada H, et al. Computer-aided prognosis of 
neuroblastoma: detection of mitosis and karyorrhexis cells in digitized 
histological images. Annu Int Conf IEEE Eng Med Biol Soc 2009; 2009:1433-
6. 
287. Lezoray O, Cardot H. Cooperation of color pixel classification schemes and 
color watershed: A study for microscopic images. IEEE transactions on image 
processing : a publication of the IEEE Signal Processing Society 2002; 
11:783-9. 
288. Bayes T. An Essay towards solving a Problem in the Doctrine of Chances. 
Philosophical Transactions 1763; 53:370-418. 
289. Watson MM, Lea D, Hagland HR, et al. Elevated Microsatellite Alterations at 
Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage 
I-III Colon cancer: An Automated, Digitalized Assessment by 
Immunohistochemistry of Whole Slides and Hot Spots. Transl Oncol 2019; 
12(12):1583-1588. 
290. Lea D, Gudlaugsson EG, Skaland I, et al. Digital Image Analysis of the 
Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic 
Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine 
Manual Hot Spot Evaluation of the Ki67 Index. Appl Immunohistochem Mol 
Morphol 2021. 
291. Lea D, Watson M, Skaland I, et al. A template to quantify the location and 
density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by 
digital pathology on whole slides for an objective, standardized immune score 
assessment. Cancer Immunol Immunother 2021; 70(7):2049-2057. 
 112
292. Chirica M, Le Bourhis L, Lehmann-Che J, et al. Phenotypic analysis of T cells 
infiltrating colon cancers: Correlations with oncogenetic status. 
Oncoimmunology 2015; 4(8):e1016698. 
293. Won EJ, Ju JK, Cho YN, et al. Clinical relevance of circulating mucosal-
associated invariant T cell levels and their anti-cancer activity in patients with 
mucosal-associated cancer. Oncotarget 2016; 7(46):76274-76290. 
294. Sun Z, Xia W, Lyu Y, et al. Immune-related gene expression signatures in 
colorectal cancer. Oncol Lett 2021; 22(1):543. 
295. Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and 
Immunoscore are critical determinants of dissemination to distant metastasis. 
Sci Transl Med 2016; 8(327):327ra26. 
296. Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals 
genetic determinants associated with in situ lymphocyte proliferation and 
survival of cancer patients. Sci Transl Med 2014; 6(228):228ra37. 
297. Herrera M, Galindo-Pumariño C, García-Barberán V, et al. A Snapshot of The 
Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy. Int J Mol 
Sci 2019; 20(23). 
298. Saltz J, Gupta R, Hou L, et al. Spatial Organization and Molecular Correlation 
of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology 
Images. Cell Rep 2018; 23(1):181-193.e7. 
299. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 
2020; 31(10):1291-1305. 
300. Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads 
to pathological responses in MMR-proficient and MMR-deficient early-stage 
colon cancers. Nature Medicine 2020; 26(4):566-576. 
301. Kroneman TN, Voss JS, Lohse CM, et al. Comparison of Three Ki-67 Index 
Quantification Methods and Clinical Significance in Pancreatic 
Neuroendocrine Tumors. Endocr Pathol 2015; 26(3):255-62. 
302. Owens R, Gilmore E, Bingham V, et al. Comparison of different anti-Ki67 
antibody clones and hot-spot sizes for assessing proliferative index and 
grading in pancreatic neuroendocrine tumours using manual and image 
analysis. Histopathology 2020; 77(4):646-658. 
303. Dhall D, Mertens R, Bresee C, et al. Ki-67 proliferative index predicts 
progression-free survival of patients with well-differentiated ileal 
neuroendocrine tumors. Hum Pathol 2012; 43(4):489-95. 
304. Goodell PP, Krasinskas AM, Davison JM, et al. Comparison of methods for 
proliferative index analysis for grading pancreatic well-differentiated 
neuroendocrine tumors. Am J Clin Pathol 2012; 137(4):576-82. 
305. Hacking SM, Sajjan S, Lee L, et al. Potential Pitfalls in Diagnostic Digital 
Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal 
Neuroendocrine Tumors. Pathol Res Pract 2020; 216(3):152753. 
306. Kim MJ, Kwon MJ, Kang HS, et al. Identification of Phosphohistone H3 
Cutoff Values Corresponding to Original WHO Grades but Distinguishable in 
Well-Differentiated Gastrointestinal Neuroendocrine Tumors. Biomed Res Int 
2018; 2018:1013640. 
 113 
307. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the 
assessment of Ki67 labeling index in well-differentiated neuroendocrine 
tumors metastatic to the liver: implications for prognostic stratification. Am J 
Surg Pathol 2011; 35(6):853-60. 
308. Stålhammar G, Robertson S, Wedlund L, et al. Digital image analysis of Ki67 
in hot spots is superior to both manual Ki67 and mitotic counts in breast 
cancer. Histopathology 2018; 72(6):974-989. 
309. Klauschen F, Wienert S, Schmitt WD, et al. Standardized Ki67 Diagnostics 
Using Automated Scoring—Clinical Validation in the GeparTrio Breast 
Cancer Study. Clinical Cancer Research 2015; 21(16):3651-3657. 
310. Dunstan RW, Wharton KA, Jr., Quigley C, et al. The use of 
immunohistochemistry for biomarker assessment--can it compete with other 
technologies? Toxicol Pathol 2011; 39(6):988-1002. 
311. Qi X, Xing F, Foran DJ, et al. Robust segmentation of overlapping cells in 
histopathology specimens using parallel seed detection and repulsive level set. 
IEEE Trans Biomed Eng 2012; 59(3):754-65. 
312. Varghese F, Bukhari AB, Malhotra R, et al. IHC Profiler: an open source 
plugin for the quantitative evaluation and automated scoring of 
immunohistochemistry images of human tissue samples. PLoS One 2014; 
9(5):e96801. 
313. CE IVD 2021. Available at: https://www.gpc.center/ce_ivd_/585. Accessed 7. 
July, 2021.  
314. APPsolute image analysis 2021. Available at: https://visiopharm.com/app-
center/?cat=40. Accessed 7. July, 2021.  
315. Pantanowitz L, Sinard JH, Henricks WH, et al. Validating whole slide imaging 
for diagnostic purposes in pathology: guideline from the College of American 
Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 
2013; 137(12):1710-22. 
316. Thrall MJ, Wimmer JL, Schwartz MR. Validation of multiple whole slide 
imaging scanners based on the guideline from the College of American 
Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 
2015; 139(5):656-64. 
317. Nasjonalt forum for digital patologi 2020. Available at: 
https://spesialisthelsetjenesten.no/seksjon/ikt/Sider/Nasjonalt-forum-for-
digital-patologi.aspx. Accessed 7. july, 2021.  
 
 114
8. Figure credits 
Figure 1: The figure was made by D. Lea. 
Figure 2: The figure was made by D. Lea. 
Figure 3: Reprinted with permission from MDPI. Journal of Clinical Medicine 
2020;9(11):3697. Digital Pathology: Advantages, Limitations and Emerging 
Perspectives by Jahn SW et al. ©2020. 
Figure 4: Reprinted with permission from Sage. Philosophical Transactions of the 
Royal Society B London Biological Sciences 2014;369(1641):20130215. The 
interplay of attention and consciousness in visual search, attentional blink and 
working memory consolidation by Raffone A et al. ©2015.  
Figure 5: Adapted with permission from Elsevier Inc. Cell 2011;144(5):646-74. 
Hallmarks of cancer: the next generation by Hanahan D and Weinberg RA. ©2011. 
Figure 6: Reprinted with permission from the International Agency for Research on 
Cancer IARC. ©2020. 
Figure 7: Reprinted with permission from Elsevier Ltd. Lancet 
2019;394(10207):1467-1480. Colorectal cancer by Dekker E et al. ©2019 
Figure 8: Adapted with permission from Cell Press. Cell 1990;61(5):759-67. Genetic 
model for colorectal tumorigenesis by Fearon ER and Vogelstein B. ©1990. The 
figure was created using BioRender.com with publication licence.  
Figure 9: Reprinted with permission from Elsevier Ltd. Lancet 
2019;394(10207):1467-1480. Colorectal cancer by Dekker E et al. ©2019 
Figure 10: Used with permission of the American College of Surgeons, Chicago, 
Illinois. The original source for this information is the AJCC Cancer Staging System 
(2020). ©2020. The figure was created with BioRender.com with publication licence.  
 115 
Figure 11: Used with permission of the American College of Surgeons, Chicago, 
Illinois. The original source for this information is the AJCC Cancer Staging System 
(2020). ©2020. The figure was created with BioRender.com with publication licence.  
Figure 12: The figure was made by D. Lea 
Figure 13: Republished with permission from American Association for Cancer 
Research. Clinical Cancer Research 2013;19(11):2842-9. Molecular pathogenesis of 
neuroendocrine tumors: implications for current and future therapeutic approaches by 
Oberg K et al. ©2013. 
Figure 14: The figure was made by D. Lea. 
Figure 15: The figure was made by D. Lea 
Figure 16: Republished with permission from Elsevier Science & Technology 
Journals. Endocrinology and Metabolism Clinics of North America 2018;47(3):683-
698. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine 
Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine 
Carcinomas, and Beyond by Sorbye et al. ©2018. 
Figure 17: Adapted with permission from Cell Press. Trends in Pharmacological 
Sciences 2017;38(9):771-793. An Overview of Novel Adjuvants Designed for 
Improving Vaccine Efficacy by Bonam et al. ©2017  
Figure 18: Adapted with permission from Elsevier Inc. Cell 2011;144(5):646-74. 
Hallmarks of cancer: the next generation by Hanahan D and Weinberg RA. ©2011. 
Figure 19: Adapted with permission from Springer Nature. Nature Reviews Cancer 
2006;6(1):24-37. Paradoxical roles of the immune system during cancer development 
by de Visser KE et al. ©2006.  
Figure 20: Republished with permission from Wolters Kluwer Health, Inc. American 
Journal of Surgical Pathology 2003;27(11):1407-17. Value of histopathology in 
 116
predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and 
sporadic colorectal cancer by Shia J et al. ©2003. 
Figure 21: Adapted with permission from MDPI under Creative Commons 
Attribution (CC BY 4.0) license. Cells 2020:9(3):618. Immunotherapy, Inflammation 
and CRC by Lichtenstern CR et al. ©2020. 
Figure 22: Reprinted with permission from Oxford University Press. International 
Immunology 2016;28(8):373-82. Rational bases for the use of the Immunoscore in 
routine clinical settings as a prognostic and predictive biomarker in cancer patients by 
Kirilovsky A et al. ©2016.  
Figure 23: The figure was created using BioRender.com with publication licence.  
Figure 24: Reprinted with permission from Springer. Breast Cancer Research and 
Treatment 2009;114(1):39-45. Validating the prognostic value of proliferation 
measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast 
cancer patients less than 71 years of age by Skaland I et al. ©2009. 
Figure 25: The figure was created using BioRender.com with publication licence. 
Figure 26: Adapted with permission from Taylor & Francis. Critical Reviews 
Biotechnology 2017;37(2):163-176. Flow cytometry: basic principles and 
applications by Adan A ©2017  
Figure 27: The figure was created using BioRender.com with publication licence. 
Figure 28: The figure was created using BioRender.com with publication licence. 




In Paper I, the terminology ‘invasive front’ is used in the published paper. The 
terminology has changed to ‘invasive margin’ in the international literature, so 
‘invasive margin’ is used as terminology in the PhD thesis.   
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Abstract
Background In colon cancer, the location and density of tumor-infiltrating lymphocytes (TILs) can classify patients into low 
and high-risk groups for prognostication. While a commercially available ‘Immunoscore®’ exists, the incurred expenses and 
copyrights may prevent universal use. The aim of this study was to develop a robust and objective quantification method of 
TILs in colon cancer.
Methods A consecutive, unselected series of specimens from patients with colon cancer were available for immunohisto-
chemistry and assessment of TILs by automated digital pathology. CD3 + and CD8 + cells at the invasive margin and in tumor 
center were assessed on consecutive sections using automated digital pathology and image analysis software  (Visiopharm®). 
An algorithm template for whole slide assessment, generated cell counts per square millimeters (cells/mm2), from which 
the immune score was calculated using distribution volumes. Furthermore, immune score was compared with clinical and 
histopathological characteristics to confirm its relevance.
Results Based on the quantified TILs numbers by digital image analyses, patients were classified into low (n = 83, 69.7%), 
intermediate (n = 14, 11.8%) and high (n = 22, 18.5%) immune score groups. High immune score was associated with stage 
I–II tumors (p = 0.017) and a higher prevalence of microsatellite instable (MSI) tumors (p = 0.030). MSI tumors had a sig-
nificantly higher numbers of CD3 + TILs in the invasive margin and CD8 + TILs in both tumor center and invasive margin, 
compared to microsatellite stable (MSS) tumors.
Conclusion A digital template to quantify an easy-to-use immune score corresponds with clinicopathological features and 
MSI in colon cancer.
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Introduction
Colorectal cancer (CRC) is a leading cause to the cancer bur-
den and cancer deaths worldwide. Despite improvements in 
surgical and oncological management over the last decade [1], 
about half of all patients will develop metastasis and eventually 
die from disseminated disease [2]. The Tumor–node–metasta-
ses system (TNM classification) used for staging and prognos-
tication is imperfect in its ability to correctly guide treatment 
and define appropriate subgroups beyond surgical treatment 
[3]. The TNM system largely dependent on using the node sta-
tus to guide further adjuvant treatment, and as a consequence 
there is ongoing risk for under- and overtreatment of patients, 
based on the current guidelines for adjuvant chemotherapy 
[4, 5].
Of note, emerging data suggest the role of molecular sub-
types with distinct features and associated outcomes [6, 7]. 
Among the suggested consensus molecular subtypes is the 
“immunogenic” type, which is associated with hypermuta-
tion, microsatellite instability (MSI) and a favorable prog-
nosis. Abundant immune cells are found in the vicinity of 
such tumors and the type, density and location of the immune 
cells within tumor samples strongly influence the evolution 
of CRCs [8, 9] with impact on prognosis reported in large, 
multicenter studies [10–12]. This adaptive immune response 
of T-cells in tumor has been quantified as a measure called 
“Immunoscore®” (HalioDx, Marseille, France) [11, 13], and 
is available commercially as a test [14]. However, the costs 
implied with the commercially available assay may be pro-
hibitive in a public health care setting and/or may currently 
not be reimbursed for clinical routine use. More widespread 
use of immune scoring could be available if easy, accessible 
and low-cost methods would allow for stratification of immu-
nogenic tumors. Moreover, manual and subjective assessment 
such as counting cells, is increasingly being replaced by digi-
tal pathology in routine practice in departments of pathology 
[15, 16]. The benefits of digital pathology include objective 
measurement on regular slides [17] with a quantitative read of 
how many cells of interest are present in an area using immu-
nostained sample slides. The highly objectivity and quantita-
tive approach makes it easier to compare high number of tissue 
slides from patients and correlate to disease outcome.
The aim of this study was to establish an objective and 
highly reproducible quantification method for tumor-infil-
trating lymphocytes (TILs) in colon cancer and to correlate 




Patients were recruited from an ongoing prospective, clin-
ical-molecular biomarker outcomes study, the ACROBAT-
ICC project [18] (clinicaltrials.gov ID: NCT01762813). 
This cohort study is reported according to the STROBE 
[19] and the REMARK [20] guidelines for biomarker 
studies.
Compliance with ethical standards
The study is conducted in accordance to national regulations 
and approved by the Norwegian Regional Ethics Committee 
(REK Helse Vest, #2012/742). All procedures performed 
in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical standards.
Informed consent
Written informed consent was obtained from all partici-
pants prior to inclusion in the study.
Study population
All patients were diagnosed, managed and followed-up 
at Stavanger University Hospital (SUH), a public-funded 
university hospital within the universal health care sys-
tem of Norway. The protocol [18] and study cohort have 
been described in further detail elsewhere [21, 22]. The 
current study is based on patients with stage I–III colon 
cancer from the initial cohort recruited between January 
2013 and May 2014 [21] that did not undergo neoadju-
vant treatment. Of 132 consecutive stage I–III colon can-
cers, 119 were included in the study. Patients with two or 
more invasive colon carcinomas at time of surgery were 
excluded from the study, as these tumors might have a 
different biology [23]. When multiple tumor blocks were 
present, the tumor block that included invasive margin and 
most immune cells was selected for analysis [24].
Histopathology
All specimens were staged (AJCC 8th edition) [25, 26] 
by board certified pathologists using a standardized gross 
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pathology and microscopic histopathology template for 
reporting.
Immunohistochemistry
Antigen retrieval and antibody dilution were optimized prior 
to the study onset. Adjacent to the hematoxylin–eosin (H&E) 
stained sections, consecutive 2 µm paraffin sections were cut 
and mounted onto Superfrost Plus slides (Menzel, Braun-
schweig, Germany), along the principles suggest previously 
[27]. The CD3 and CD8 slides were incubated at 60 °C for 
1 h and then placed in the autostainer (Dako Omnis), where 
they were subject to an automated protocol as per manufac-
turer instructions, with a pretreatment at 97 °C in 30 min. 
CD3 (Dako Clone F7.2.38) was diluted with Dako Antibody 
diluent by 1:75 and CD8 (Dako Clone C8/144B) by 1:50. A 
peroxidase detection kit (Envision substrate working solu-
tion, Dako, Glostrup, Denmark) visualized the immune com-
plex for all the antibodies. Sections were then counterstained 
with hematoxylin in the Dako Omnis stainer. Afterwards, the 
slides were dehydrated and mounted manually.
Digital pathology assessment
CD3- and CD8-stained slides were scanned at 40 × mag-
nification using Leica SCN400 slide scanner (Leica 
Microsystems, Wetzlar, Germany) and uploaded to image 
analysis software,  Visiopharm® (Hoersholm, Denmark). 
The region of tumor center (TC) and invasive margin (IM) 
were marked manually on whole slides in  Visiopharm® 
Fig. 1  a Hematoxylin–eosin staining of tumor. b Immunohisto-
chemical staining of CD3 (brown) in the same tumor with marking 
of tumor center/TC (blue) and invasive margin/IM (green). c Digital 
image analysis measured the CD3 + tumor-infiltrating lymphocytes 
(TILs) in TC and IM. The number of positive TILs was calculated pr. 
 mm2. The same tumor area was analyzed for CD3 and CD8 for each 
patient. d Close-up view that shows positive TILs marked with green. 
Negative nuclei are marked blue and surrounding stroma is marked 
red
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and these regions (region of interest, ROI) were used for 
CD3 + and CD8 + cell quantification (Fig. 1).  Visiopharm® 
identified and measured the area of positive cells (µm) 
using digital image analysis (DIA). After DIA, the area 
of positive cells were transformed into number of positive 
TILs based on the estimation of mean area of a lympho-
cyte (60 µm2). The number of positive CD3 + and  CD8+ 
TILs was calculated per square millimeters (n cells/mm2) 
[28], further represented as density of cells.
Unspecified stains and artefacts were removed manu-
ally using the image software. Application in the image 
software was adjusted for detection of different immune 
stain intensity.
Immune response was calculated based on mean den-
sities of CD3 + and CD8 + in TC and IM in all of the 
patients in the study. The calculated mean density was 
used to divide the individual cases into “high” or “low” 
immune response. Cases with mean density ≥ 75-percen-
tile were regarded as “high” immune response. Patients 
were stratified from I0 to I4 according to the “Immu-
noscore®”, based on the total number of observed high 
densities  (CD3+ TILs and  CD8+ TILs in TC and IM) [11, 
13]. The final immune score was categorized based on 
mean percentiles for all four markers, and divided into 
immune score “low”, “intermediate” and “high” based on 
the number of markers (0–4) ≥ 75th percentile (Fig. 2).
Histopathological parameters
Histopathological parameters were registered from the 
pathology report including mucinous component, lympho-
vascular infiltration and lymph node status. In addition, 
tumor budding was registered in the HE section with deepest 
infiltration according to recommended guidelines [29, 30].
Analysis of microsatellite instability
Analysis of MSI has been described previously [31, 32]. 
Briefly, FFPE blocks were selected by an experienced 
pathologist (DL) and 4 × 10  μm sections were cut at a 
microtome. Automated DNA extraction was carried out 
using AllPrep DNA/RNA FFPE kit (Qiagen, Hilden, Ger-
many) on a QiaCUBE instrument (Qiagen) according to 
manufacturer’s instructions. Nucleic acid concentration and 
purity were measured on a NanoDrop 2000 (ThermoFischer 
scientific, Waltham, USA). Multiplex PCR reactions (one for 
each MSI) were set up for tumor and normal DNA in each 
patient. TypeIT microsatellite (Qiagen) master mix, together 
with a blending of 5 × 5′-fluorescently labelled primer pairs 
was used for each reaction. PCR conditions were as follows: 
5′ at 95 °C (initial denaturation and enzyme activation), fol-
lowed by 37 cycles of 30″ at 95 °C (denaturation), 90″ at 
55 (MSI) and 30″ at 72 °C (extension). A final extension 
step for 30′ at 60 °C. The primers for MSI were specific for 
Fig. 2  Flowchart for calculating immune response based on mean densities of CD3 + and CD8 + in tumor center (TC) and invasive margin (IM)
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BAT-25, BAT-26, NR-21, NR-24 and NR-27 [33, 34], which 
are all quasimonomorphic mononucleotide repeats with a 
high fidelity to high-frequency MSI, as shown previously 
[32]. To define a tumor as MSI, at least 2/5 markers needed 
to be unstable in their panels.
Statistics
IBM SPSS Statistics for Windows, Version 26.0 (IBM Cor-
poration, Armonk, NY, USA) was used for statistical analy-
sis. Associations between categorical variables were tested 
with Chi-square. Mann–Whitney U test was used to com-
pare differences in continuous or ordinal variables between 
groups. All tests were two-tailed and a p value < 0.050 was 
determined as statistically significant.
Results
The study cohort included 119 stage I–III colon cancer 
patients that underwent surgery with curative intent. Patient 
characteristics is presented in Supplement Table 1. Accord-
ing to the TNM classification, the distribution between stage 
I–III were approximately equal (31%, 36% and 32%, respec-
tively). Slightly more women were noted in the cohort, oth-
erwise the distributions were as expected for a consecutive 
cohort of colon cancer, with lymph node status, tumor size, 
histological type and grade, and overall age.
Distribution of the number of CD3 + and CD8 + TILs 
in TC and IM is presented in Fig. 3. The number of TILs 
was higher in IM compared with TC, both for CD3 + and 
CD8 + cells. Percentiles for evaluating immune response 
based on density (cells/mm2) of CD3 and CD8 is presented 
in Table 1. The total numbers of cells/mm2 counted in 
the upper range (75th percentile) were almost double in 
the invasive margin compared to tumor center, for both 
CD3 + and CD8 + cells, respectively. Table 2 shows dis-
tribution of cases with high immune response (≥ 75th 
percentile) in the different regions. These results were 
summarized to calculate immune score, which is pre-
sented in Table 3. According to the immune score set up 
(Table 3), there number of patients in the immune score 
groups of low, intermediate and high was 83 (69.7%), 14 
(11.8%) and 22 (18.5%), respectively. Hence, two-thirds 
of the colon cancers were deemed immune-low, with the 
immune-high cases split even between a three of four and 
four of four regions marked as immune high.
Fig. 3  Distribution of number of CD3 + and CD8 + TILs in tumor center (TC) and invasive margin (IM)
Table 1  Density (cells/mm2) cut-off values based on highest quartiles 
(75th percentile)
Tumor center Invasive margin
CD3 + CD8 + CD3 + CD8 + 
cells/mm2 cells/mm2 cells/mm2 cells/mm2
Median 393 220 858 513
Percentiles 25th 187 112 452 277
50th 393 220 858 513
75th 760 466 1390 896
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Higher immune scores were associated with a higher 
frequency of stage I–II tumors (p = 0.017) and a higher 
prevalence of MSI tumors (p = 0.030), compared with 
tumors from intermediate and low immune score. Three of 
22 patients with high immune score had stage III disease, 
whereas for stage I and II the number was 12 and 7, respec-
tively. For patients with low immune score, 19 were stage 
I, 34 stage II and 30 stage III. For intermediate immune 
score, the corresponding number of patients were 6 stage I, 
2 stage II and 6 stage III. Twelve of 42 MSI tumors (28.6%) 
had high immune score and 10 of 77 microsatellite stabile 
(MSS) tumors (13.0%) had a high immune score, respond-
ing to twofold increase of immune-high cases in the MSI 
colon cancers.
Tumors with MSI had a significantly higher number 
of CD3 + TILs in IM and CD8 + TILs in both TC and IM 
(Fig. 4). There was no significant association between high 
immune score and sex, median age, localization, grade, 
tumor size, N-status, tumor budding, lymphovascular or 
perineural infiltration.
Discussion
In this study, we present an objective automated, digital 
quantification method of CD3 + and CD8 + lymphocytes at 
IM and in TC in colon cancer. The resultant immune score 
is strongly associated with TNM stage and microsatellite 
instability, two well-documented and very strong prognostic 
factors in colon cancer. The immune score allowed to stratify 
patients into low, intermediate and high immune response 
groups. The quantification should be easy to use by other 
digital pathology laboratories and represent a robust and 
objective approach to immune cell quantification in colon 
cancer specimens.
The method is based on the construct principle of the 
“Immunoscore”, which has been validated in a large interna-
tional cohort series [11]. However, this commercially avail-
able  Immunoscore® (HalioDx, Marseille, France) is adapted 
to certain manufactures of antibodies and autostainer [11], 
and may prevents laboratories from setting up the method 
with available equipment in the laboratory. Widespread eval-
uation and dissemination may thus be hampered. Hence, the 
current quantification may represent an alternative measure-
ment that is adoptable, easy to implement, affordable and 
objective, yet provides transparency for reproduction.
We found that the number of TILs is significantly higher 
at the IM than in TC, corresponding to a previously reported 
study [35]. Furthermore, our study showed that patients with 
high immune score were associated with an earlier stage of 
the disease, which might explain why high immune score is 
associated with better prognosis. Several studies show that 
TILs play a significant role for prognosis in colon cancer. 
Mlecnik et al. found that a high density of CD8 + TILs is 
associated with reduced risk of relapse [35], whereas Angell 
and co-workers [36] found that tumors with reduced num-
bers of CD8 + had a higher risk of metastasis. A recent meta-
analysis of 22 studies including 5108 patients by Zhao and 
co-workers, found that high CD3 + infiltrates in colon can-
cer correlated with improved cancer-specific survival and 
overall survival. Furthermore, the same study found that 
high density of CD3 + in IM indicated increased disease-
free survival (DFS) and high CD8 + in TC was associated 
with improved DFS [37]. The abovementioned studies all 
support that scoring TILs in colon cancer can give valuable 
prognostic information.
In the NICHE study [38], the investigators explored the 
safety and efficiency of neoadjuvant immunotherapy (ipili-
mumab and nivolumab) in operable colon cancers. Despite 
being a small phase I/II study with over half being MSI 
cancer, a remarkable response was found (pathological 
response in 20/20 MSI patients; 19 had major pathological 
Table 2  Distribution of patients 
(n) with high immune response 
(≥ 75th percentile) in different 
regions
Tumor center Invasive margin
CD3 Low CD3 High CD8 Low CD8 High CD3 Low CD3 High CD8 Low CD8 High
0 of 4 69 0 69 0 69 0 69 0
1 of 4 13 1 12 2 9 5 8 6
2 of 4 5 9 5 9 8 6 10 4
3 of 4 3 8 3 8 3 8 2 9
4 of 4 0 11 0 11 0 11 0 11
Total 90 29 89 30 89 30 89 30
Table 3  Immune score based on high tumor density of CD3 and CD8 
in different regions
Number of regions Patients (n) Means of markers
0 of 4 69 Low
1 of 4 14
2 of 4 14 Intermediate
3 of 4 11 High
4 of 4 11
Total 119
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response and 12 had complete pathological response. Even 
in tumors with MSS, 4 of 15 had response [38]. As density 
of immune cells were related to response, a pre-treatment 
biopsy may become important. While not investigated in 
the NICHE study, the current template for immune score by 
digital pathology may become essential to select the patients 
who would benefit from such treatment in the future. Of 
note, half the patients in the NICHE study had MSI tumors, 
suggesting a selection of the included patients. The current 
rate of 35% MSI is high, but reflect that only colon (and no 
rectal) cancers were selected for the cohort and, is in line 
with previously reported data for such cohorts [39].
So far, and to the best of our knowledge, no biomark-
ers based on digital image analysis (DIA), has been used 
in pathological classification of colon cancer [24], despite 
digital pathology now being steadily introduced in routine 
diagnostic practice at several pathology departments. While 
there is a lack of consensus biomarkers for use, the imple-
mentation and spread in use makes it easier to use DIA in 
diagnostic setting and to perform prognostic scoring. For 
immune score to become an international recognized stand-
ard, it is important that it is available through affordable soft-
ware and that the method is transparent. Others have applied 
deep learning methods to analyze TILs in HE sections [40, 
41] and have found association with survival.
The added time and cost to stain and score relies on a 
couple of assumptions. One, a digital platform needs to be 
in place. We recognize that not all pathology labs may have 
this readily available, but increasingly this is being rolled 
out as the way forward to standardize scoring in quantitative 
pathology. Second, the time taken for a technician or bioen-
gineer to cut slides and prepare counts from the template is 
time efficient. If standardized and introduced into the routine 
pathway of clinical work, the estimated extra time for a bio-
engineer to cut, stain and prep for digital analysis would be 
in the range of 15–20 min; the pathologist’s time to mark the 
area for digital analyses would be part of the routine clini-
cal work and add a maximum of 30 min, but probably less. 
Hence, the use of this score should not be labor intensive nor 
require extensive human hours of labor.
The cost implied (given that digital pathology instruments 
are available in a given pathology lab) amounts to reagents 
for immunohistochemistry markers. These are usually avail-
able already in most labs, and in general inexpensive (esti-
mated at around 10 Euros per slide), but with variable costs 
between countries. Taken together, we believe that the tem-
plate for an automated immune score presented here would 
be both time efficient and cost containing.
Our study has some limitations to address, with one 
being the size of the cohort. A larger cohort size might have 
Fig. 4  Comparison of number of CD3 + and CD8 + tumor-infiltrating lymphocytes (TILs) of MSS and MSI tumors in tumor center (TC) and 
invasive margin (IM). Extreme values > 4000 cells is not shown in figure
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demonstrated more differences between the clinicopatho-
logical parameters in the patients to the high immune score 
versus the patients with intermediate and low immune score. 
Furthermore, the DIA method is not validated against manual 
pathology evaluation using a microscope and counting cells. 
This is near impossible (from a time and labour perspective 
implied) due to the high number of positive cells found in each 
tissue slide. However, the less time-consuming and labour-
efficient results obtained by DIA exemplifies the strength of 
using automated digital pathology to this extent. The interna-
tional effort of validating the “Immunoscore®” as a prognostic 
marker demonstrated value of the commercial test [11]. Future 
studies using easy-to-use, available, objective and reproduc-
ible methods to assess TILs in colon cancer may facilitate its 
wider dissemination and clinical implementation. With further 
validation, internally and externally, the role of the current 
template-based immune score should arrive at clinically rel-
evant use and be able to designate appropriate subgroups of 
patients stratified to their relevant therapy decisions.
Conclusion
A whole slide, digital pathology template using imaging 
software was developed to quantify immune score. Known 
clinicopathological features like MSI status correlated with 
a higher immune infiltrate, exemplified by a greater immune 
score. Large-scale internal and external validation to dem-
onstrate robustness and generalizability for clinical use is 
ongoing.
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Digital Image Analysis of the Proliferation Markers Ki67
and Phosphohistone H3 in Gastroenteropancreatic
Neuroendocrine Neoplasms: Accuracy of Grading
Compared With Routine Manual Hot Spot Evaluation
of the Ki67 Index
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Abstract: Gastroenteropancreatic neuroendocrine neoplasms
(GEP-NENs) are rare epithelial neoplasms. Grading is based on
mitotic activity or the percentage of Ki67-positive cells in a hot
spot. Routine methods have poor intraobserver and interob-
server consistency, and objective measurements are lacking. This
study aimed to evaluate digital image analysis (DIA) as an ob-
jective assessment of proliferation markers in GEP-NENs. A
consecutive cohort of patients with automated DIA measure-
ment of Ki67 (DIA Ki67) and phosphohistone H3 (DIA PHH3)
on immunohistochemical slides was analyzed using Visiopharm
image analysis software (Hoersholm, Denmark). The results
were compared with the Ki67 index from routine pathology re-
ports (pathology Ki67). The study included 159 patients (57%
males). The median pathology Ki67 was 2.0% and DIA Ki67
was 4.1%. The interclass correlation coefficient of the DIA Ki67
compared with the pathology Ki67 showed an excellent agree-
ment of 0.96 [95% confidence interval (CI): 0.94-0.96]. The ob-
served kappa value was 0.86 (95% CI: 0.81-0.91) when
comparing grades based on the same methods. PHH3 was
measured in 145 (91.2%) cases. The observed kappa value was
0.74. (95% CI: 0.65-0.83) when comparing grade based on the
DIA PHH3 and the pathology Ki67. The DIA Ki67 shows ex-
cellent agreement with the pathology Ki67. The DIA PHH3
measurements were more varied and cannot replace other
methods for grading GEP-NENs.
Key Words: neuroendocrine tumor, neuroendocrine carcinoma,
proliferation, digital image analysis, immunohistochemistry
(Appl Immunohistochem Mol Morphol 2021;29:499–505)
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) comprise a heterogeneous group of rare, benign,
or malignant epithelial tumors (carcinoids) originating from
the pancreas (PNENs) or gastrointestinal tract (GI-NETs).
The reported annual incidence varies between 2.39 and
5.83 per 100,000 inhabitants according to international
literature,1,2 with an estimated prevalence of 35 per 100,000
because of the long survival times. The 5-year survival rates
vary between 40% and 100% and are associated with the
primary tumor site, tumor grade, and stage of disease at the
time of diagnosis.3–5 Moreover, GEP-NENs classified as
functional tumors (which secrete hormones or peptides to
cause clinical symptoms or syndromes) show a different bio-
logical behavior from those classified as nonfunctional GEP-
NENs,6 and tumor behavior is also associated with the his-
topathologic pattern, including the features of an
adenocarcinoma.7 The diagnostic criteria of neuroendocrine
tumors are based on morphology and the positive staining of
the neuroendocrine markers synaptophysin and/or chromog-
ranin A by immunohistochemistry (IHC).8
According to the World Health Organization (WHO)
criteria, the grading of GEP-NENs is based on the evalua-
tion of mitotic activity, either by counting mitosis, the so-
called “mitotic activity index” (MAI), on hematoxylin and
eosin (HE)-stained slides or by calculating the percentage of
Ki67-positive cells in a hot spot (Table 1).9,10 The highest
grade should apply if any discordance between the MAI and
Ki67 index assessment occurs.10 The Ki67 index predicts
prognosis better than MAI.11
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One of the challenges related to the current routine
grading procedure is the time-consuming counting of >500
cells by a pathologist, which may lead to an eyeball esti-
mation as a short-cut in a busy routine practice. Moreover,
the identification of “hot spots” in a section may be
difficult,12 which may partly explain the reported poor in-
traobserver and interobserver reliability.13 Consequently,
objective measurements, including digital image analysis
(DIA), are warranted for accurate grade reporting.
The heterogeneous biological behavior of GEP-NENs
has encouraged a search for better prognostic markers. Phos-
phohistone H3 (PHH3) has been identified as a promising
marker for the prediction of disease-free survival and disease-
specific survival in PNENs.14,15 In contrast to Ki67, which is
present in cell nuclei in the G1, S, G2, and M phases of the cell
cycle, PHH3 stains mitotic cells (M phase). Thus, with PHH3,
mitotic activity can be specifically determined;16 therefore,
PHH3 has been suggested as an alternative to the Ki67 index in
PNENs.17 Furthermore, counting MAI is challenging because
apoptotic figures can be misidentified as mitotic figures.17,18
PHH3 does not stain apoptotic cells and can therefore be a
better biomarker for mitosis than MAI. Several studies have
shown good concordance between the number of mitoses and
PHH3.19,20 Accordingly, PHH3 is regarded as promising for
the assessment of grading in GEP-NENs in general.
In this study, we evaluated and compared the DIA
Ki67 with the routine procedure for the Ki67 index as-
sessment (pathology Ki67). In addition, we applied DIA
for PHH3 assessment (DIA PHH3) to explore possible
associations between PHH3 and the Ki67 index to eval-
uate the potential advantages or challenges of PHH3 as a
proliferation marker in routine practice.
MATERIALS AND METHODS
Ethical Approval
All procedures performed in studies involving human
participants were per the ethical standards of the institutional
and/or National Research Committee and the 1964 Helsinki
Declaration and its later amendments or comparable ethical
standards. This project was approved by the Regional Ethics
Committee of the Western Health Authority (REK 2016/
1622). Patients still alive have signed a written consent form to
participate.
Materials
We identified all consecutive patients diagnosed with
GEP-NENs and treated at Stavanger University Hospital
from 2003 to 2013. The hospital serves as the only hospital
for a well-defined Norwegian population of ∼380,000
people.2 Of 204 consecutive patients during that period, 35
declined to participate. In addition, 1 patient was excluded
because of the possibility of primary pulmonary neuro-
endocrine carcinoma, and 9 patients were excluded be-
cause of a lack of tissue for analysis. Thus, 159 (77.9%)
patients were included.
Archived formalin-fixed paraffin-embedded tissue from
the hospital’s diagnostic biobank was obtained. The current
WHO criteria for neuroendocrine tumors10 were used, and
pathologic tumor-node-metastasis (TNM) staging was per-
formed according to the American Joint Committee on Cancer
(AJCC) 8th edition.21 For Ki67, 500 to 2000 tumor cells were
assessed in hot spots by microscopic evaluation.21 The Ki67
index was retrieved from the original routine pathology reports,
and cases without available information were re-evaluated to
complete pertinent information on all patients, as reported in
our previous study.2
All tumors were confirmed as NENs by positive IHC
staining for synaptophysin and/or chromogranin A. Neuro-
endocrine carcinoma was included as grade 3 (high grade).
Mixed neuroendocrine–non‐neuroendocrine neoplasms were
excluded. The sample included 63 (39.6%) biopsies and 96
(60.4%) surgical specimens. MAI was not evaluated because
of the high number of biopsies with an area <10mm2.
Methods
IHC
Ki67. The MIB-1 clone (Dako, Glostrup, Denmark)
was used for routine staining at the Department of Pathol-
ogy. The method has had minor changes in processing from
2003 to 2013, but the MIB-1 clone has been the same. The
MIB-1 clone is validated for GEP-NEN grading.22,23
PHH3. Antigen retrieval and antibody dilution were
optimized before study onset. Paraffin sections adjacent to
the HE sections were cut into 2-µm-thick sections and
mounted on Superfrost Plus slides. The slides were in-
cubated at 60°C for 1 hour and stained using a Dako
Omnis immunostainer. PHH3 (nr. 06-570; Merck Group,
Darmstadt, Germany) was used at a dilution of 1:5000.
The Dako EnVision Flex+ (Dako GV80011-2) detection
system was used in line with the recommendations of the
manufacturer.
DIA
IHC staining of Ki67 was already performed, and
the available archived sections were retrieved from the
hospital’s archive. HE sections, Ki67, and PHH3 were
scanned at ×40 magnification using a Leica SCN400 slide
TABLE 1. WHO Grading of Neuroendocrine Tumors
(WHO 2019)
Grade Mitotic Activity, Per 2 mm2* Ki67%*
NET Grade 1 Low 1 < 3
NET Grade 2 Intermediate 2-20 3-20
NET Grade 3 High > 20 > 20
LCNEC High† > 20 > 20
SCNEC High† > 20 > 20
MiNEN Variable Variable Variable
*Mitotic rates are expressed as the number of mitoses/2 mm2 as determined by
counting in 50 fields of 0.2 mm2 (ie, in a total area of 10 mm2); the Ki67 pro-
liferation index value is determined by counting at least 500 cells in the regions of
highest labeling (hot spots), which are identified at scanning magnification.
†Poorly differentiated NECs are not formally graded but are considered high‐
grade by definition.
LCNEC indicates large‐cell neuroendocrine carcinoma; MiNEN, mixed
neuroendocrine–non‐neuroendocrine neoplasm; NEC, neuroendocrine carcinoma;
NET, neuroendocrine tumor; SCNEC, small‐cell neuroendocrine carcinoma;
WHO, World Health Organization.
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scanner (Leica Biosystems, Wetzlar, Germany) and up-
loaded to the image analysis software (Visiopharm,
Hoersholm, Denmark). The person responsible for the
DIA evaluation (D.L.) was blinded to the previously re-
ported routine Ki67 index results and other parameters
when DIA was performed. Patients were excluded from
the DIA if there was insufficient tumor material for
analysis (< 500 tumor cells). If a biopsy material and not a
surgical specimen was used for the original routine Ki67
evaluation, DIA was also performed on the biopsy sam-
ple, given that sufficient materials were available.
For Ki67, the percentage of positive tumor cells was
measured in the hot spot of the tumor in an area that
includes 500 to 2000 tumor cells with the Visiopharm
program (Fig. 1). The software program identified positive
nuclei (label 1) and negative nuclei (label 2) within a
manually selected area named the region of interest (ROI).
Stroma and stromal cells were excluded from the ROI by
the software program so that only the tumor cells were
evaluated, similar to our DIA Ki67 method described for
breast cancer.12 The percentage of tumor cells was
calculated. If the hot spot was ill-defined on a slide, the
measurement was repeated in different areas, and the area
with the highest positivity was counted. The program
measured the areas of positive and negative nuclei, and
based on the size of the nuclei in each tumor, an estimate
of tumor cells was calculated. A percentage was calculated
from ∼2000 tumor cells. If there were <2000 cells but
> 500 cells, a percentage was given based on the available
cells in the section. This value was compared with the
pathology Ki67 (regarded as the gold standard).
The number of PHH3-positive cells was calculated in 4
different ROIs of 2mm2 (ROI: 1 to 4) (Fig. 2). The different
ROIs were chosen subjectively from the visual identification of
areas with the highest number of PHH3-positive cells. The
number of PHH3-positive cells within each ROI was
calculated. If there was insufficient material for 4 ROIs,
fewer ROIs were chosen for measurement. For PHH3,
Visiopharm was programmed to detect IHC-stained mitotic
cells as described by others.24 Cells in all 4 substages of
mitosis, prophase, metaphase, anaphase, and telophase, were
regarded as positive.25 Objects smaller than mitotic figures
were removed by a size filter. The remaining objects were
dilated to fuse the chromatin structures of cells in anaphase or
telophase into 1 object. All remaining objects were counted,
and the number of objects per 2mm2 was calculated. The
counted objects were encircled in the original image, allowing
a visual inspection of the counted mitotic cells. Apart from the
manual selection of the 4 different ROIs, the DIA procedure
and all calculations were fully automated.
Statistics
IBM SPSS Statistics for Windows, Version 26.0 (IBM
Corporation, Armonk, NY) was used for statistical calcu-
lations. The quadratically weighted kappa was used to mea-
sure the agreement between ordinal variables.26 The interclass
correlation coefficient was used to measure the agreement
between continuous variables (single rater, absolute agree-
ment). All agreement estimates are presented with 95% con-
fidence intervals (CIs). Values <0.50, between 0.50 and 0.75,
between 0.75 and 0.90, and >0.90 indicated poor, moderate,
good, and excellent reliability, respectively.27 To plot the dif-
ference in pathology Ki67 and DIA Ki67 measurement
against average value, we used a Bland-Altman plot.28
RESULTS
The clinicopathologic characteristics of the patients are
shown in Table 2. The distribution of grading based on the
DIA Ki67, DIA PHH3, and pathology Ki67 are shown in
Figure 3. This figure shows that different methods influence
grading, with more grade 2 tumors and fewer grade 1 tumors
with the methods based on DIA than with the pathology
Ki67. The median pathology Ki67 was 2.0% (range: 1.0% to
100%). The median DIA Ki67 value was 4.1% (range: 0.0%
FIGURE 1. A, Hematoxylin and eosin staining of a grade 2
neuroendocrine tumor. B and C Immunohistochemical staining
of Ki67 with digital image analyses performed on the same
tumor. Black arrows point to some of the positive cells.
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to 99.9%). The interclass correlation coefficient of the DIA
Ki67 and pathology Ki67 showed an excellent agreement of
0.96 (95% CI: 0.94-0.98). Figure 4A shows a scatter plot of
the distribution of the DIA Ki67 and pathology Ki67. The
observed kappa between grading based on the DIA Ki67
and the pathology Ki67 was 0.86 (95% CI: 0.81-0.91).
FIGURE 2. A, Hematoxylin and eosin staining of a grade 2 neuroendocrine tumor. B, Digital image measurement of im-
munohistochemically stained phosphohistone H3 in 4 different regions of interest. C, Close-up image of hematoxylin and eosin
staining with marking of mitosis. D and E, Close-up image of the measurement of phosphohistone H3 in the regions of interest with
the highest mitotic activity.
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A Bland-Altman plot was created to visualize the difference
in agreement against average value of pathology Ki67 and
DIA Ki67 (Fig. 5).
The agreement between grading based on the DIA
Ki67 and the pathology Ki67 is shown in Table 3. None of
the grade 3 tumors was graded as grade 1 and vice versa.
Cases with less correlation between the methods
comprised mostly grade 1 and grade 2 tumors, and the
percentage was mostly measured higher (ie, > 3%) by DIA
than with the pathology Ki67. Among 26 cases with a
discrepancy between grades 1 and 2, Ki67 values of 2% to
TABLE 2. Demographics and Clinical Characteristics of the
Patients
Characteristics Value




Tumor size, median* (range), cm 1.7 (0.1-13.8)










Metastasis liver/unknown primary 7 (4.4)









N classification*, n (%)
N0 69 (44.5)
N1 86 (55.5)
M classification*, n (%)
M0 95 (61.3)
M1 60 (38.7)





*Numbers may not add up because of missing data: n= 18 for tumor size,
n= 23 for T-stage, n= 4 for N-stage and M-stage and n= 2 for AJCC stage.
AJCC indicates American Joint Committee on Cancer; WHO, World Health
Organization.
FIGURE 3. Comparison of World Health Organization (WHO)
grading based on different methods for proliferation meas-
urement. PHH3 indicates phosphohistone H3.
FIGURE 4. A, Scatter plot showing the correlation between the
Ki67 index from the pathology report and Ki67 based on
digital image analysis. B, Scatter plot showing the correlation
between the Ki67 index from the pathology report and digital
measurement of the number of phosphohistone H3 (PHH3)-
positive cells per 2mm2.
FIGURE 5. A Bland-Altman plot showing the difference Ki67
index against mean value from the pathology report and Ki67
based on digital image analysis.
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4% were found in 24 (92.3%) of the cases by either DIA
Ki67 or pathology Ki67.
PHH3 was measured in 145 (145/159=91.2%) of the
patients. Fourteen patients were excluded because of a lack
of available tumor material for analysis. A median of 3
mitoses (range: 0 to 678 cells/mm2) was observed. Figure 4B
shows a scatter plot of the distribution of DIA PHH3 and
the pathology Ki67. The observed kappa between grading
based on the DIA PHH3 and pathology Ki67 was 0.742.
(95% CI: 0.65-0.83). The agreement between grading based
on DIA PHH3 and the pathology Ki67 is shown in Table 4.
For the DIA of PHH3, there were no grade 3 tumors that
were graded as grade 1. Moreover, 35 NENs were upgraded
from grade 1 to grade 2 based on the DIA PHH3
measurement compared with pathology Ki67. In 20 (20/
35=57.1%) of these tumors, the PHH3 value was 2 or 3.
DISCUSSION
The current study explored several comparative mea-
sures for grading by the use of DIA and alternative markers
for proliferation. Grading based on the DIA Ki67 showed
good reliability compared with grading based on the path-
ology Ki67. The use of DIA PHH3 for grading did not show
similar results, with a higher number of NENs migrating
between grades, especially grade 2, as a consequence.
Whether this represents true grade migration or just artefacts
from variation in scores remains unproven.
This study confirms an excellent agreement between
the DIA Ki67 and the pathology Ki67, a finding that is
supported by other studies.13,29 DIA can improve the re-
liability and reproducibility of grading in routine
practice.30 Thus, likely the pathology departments with
this method or similar DIA available, can use DIA Ki67
as a part of their routine diagnostics. Digital pathology
has during recent years, been introduced at more pathol-
ogy departments, and the numbers are increasing.31,32
Manual counting is often difficult because of the high
cellularity commonly encountered in these tumors.30 One
of the benefits of our DIA method of Ki67 is the auto-
matic separation of stroma and stromal cells from tumor
cells. This does not apply to all DIAs, which may partly
explain the previously reported poor concordance between
the DIA and manual analysis of Ki67 found by others.33
This study included a consecutive series from a pop-
ulation-representative cohort of GEP-NEN patients in a
well-defined region of Norway. Compared with other studies
of GEP-NENs, the number of included patients with grades
2 and 3 was high, and the distribution of different grades was
more even.13,17,30,33–35 A limitation of our study is that al-
most 40% of the tumor samples were from biopsies. How-
ever, this is in line with current routine practice at many
centers since surgical specimens are not achievable for all
patients, especially patients with advanced disease.
Grading based on the DIA PHH3 agreed less well with
the WHO grade based on the pathology Ki67. This is in line
with the results of others.15,33,36 Accordingly, we believe the
DIA and use of PHH3 are not supported for routine use or as
an alternative in GEP-NEN grading. Some of the cases with
low Ki67 had high PHH3. Others have reported a specific
value for PHH3 in PNENs,14 but we could not confirm or
refute this based on the limited number of PNENs.
For both DIA Ki67 and DIA PHH3, the proportion
of grade 2 tumors was higher than the routinely reported
grading. This illustrates the difficulty in separating grade 1
and grade 2 tumors.33,37 A factor that might explain this
finding is that the DIA method makes it easier to identify a
hot spot than manual evaluation in a busy routine practice.
With DIA, measurements can be repeated or several areas
can be measured if the hot spot is difficult to identify. The
size of the hot spot (500 to 2000 cells) might also influence
the grading. A study of G1 and G2 PNENs found that DIA
overestimated the Ki67 index compared with manual eval-
uation. The difference was reduced by increasing the size of
the hot spot.38 Kroneman et al37 found that eyeball esti-
mations of Ki67 tended to downgrade more NETs to grade
1 than evaluations by DIA. These studies support our find-
ings. In many cases with a discrepancy, the value of Ki67 or
PHH3 was near the cut-off level for the grading criteria.
Discussions are ongoing regarding which method should be
regarded as the gold standard.13,34,35 For breast cancers,
there is a debate about whether the manual analysis of Ki67
should be the gold standard since several studies have shown
superior prognostic information from DIA.39,40
In conclusion, standardized DIA Ki67 scoring gave
similar results as subjective scoring but may be a time-saving
supplementary tool in surgical pathology29 that can improve
the poor intraobserver and interobserver reliability with
manual evaluation methods.41 DIA PHH3 do not agree so
well with routine grading and is not recommended as an
alternative to MAI or Ki67 in routine practice.
TABLE 3. Agreement Between Grading of Tumors Based on
Digital Image Analysis of Ki67 and Grading From Routine
Pathology Reports
Grade (DIA Ki67) n, (%)
1 2 3 Total, n (%)
Grade (routine)
1 63 (39.6) 22 (13.8) 0 85 (53.5)
2 4 (2.5) 33 (20.8) 1 (0.6) 38 (23.9)
3 0 1 (0.6) 35 (22.0) 36 (22.6)
Total 67 (42.1) 56 (35.2) 36 (22.6) 159
DIA indicates digital image analysis.
TABLE 4. Agreement Between Grading of Tumors Based on
Digital Image Analysis of Phosphohistone H3 and Grading from
Routine Pathology Reports
Grade (DIA PHH3) n, (%)
1 2 3 Total n, (%)
Grade (routine)
1 43 (29.7) 35 (24.1) 0 78 (53.8)
2 4 (2.8) 28 (19.3) 4 (2.8) 36 (24.8)
3 0 3 (2.1) 28 (19.3) 31 (21.4)
Total 47 (32.4) 66 (45.5) 32 (22.1) 145
DIA indicates digital image analysis; PHH3, phosphohistone H3.
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